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ABSTRACT 
 Despite over 3 decades of intense research, an estimated 35.3 million people 
today are living with HIV-1 (Human Immunodeficiency Virus 1), the etiological agent of 
AIDS (Acquired Immunodeficiency Syndrome). The good news is that deaths are 
declining, in large part to combinations of highly active antiretroviral drugs. However, all 
of the current treatment options do not amount to a cure and a vaccine to prevent future 
infections is not yet available. With nearly 2 new infections for every 1 patient beginning 
an antiretroviral treatment regimen, the need is as great as ever to explore every avenue 
for new therapeutic interventions.  
 One of these avenues is harnessing proteins endogenous to the very cells targeted 
for infection by HIV-1. Collectively referred to as host restriction factors, these innate 
immune proteins share a number of characteristics. First, they decrease virus replication. 
Second, expression of host restriction factors is often inducible and coupled to the 
immediate innate immune response to a foreign attack. Third, under the immense 
pressure of adapting to a pathogenic agent, host restriction factors often exhibit high 
degrees of rapid evolutionary change. Finally, if a restriction factor is potent enough, the 
virus will have evolved a counter-restriction mechanism. 
  My thesis research has focused on the APOBEC3 family of host restriction factors 
that constitute an important arm of innate immunity. These enzymes, armed with the 
capacity to trigger cytosine to uracil mutagenesis in single-stranded DNA, function to 
defend the genome against attacks from foreign DNA elements including the retrovirus 
HIV-1. A more comprehensive understanding of the entire APOBEC3 family, its cellular 
functions, and how HIV-1 counteracts these activities with its accessory protein Vif, will 
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all be essential before the design of therapeutic approaches incorporating endogenous 
APOBEC3 proteins in the fight against HIV/AIDS can be achieved. 
 All 7 APOBEC3 proteins have been implicated in restricting HIV-1. The overall 
objective of my thesis research, detailed in the following chapters, was to define which of 
the 7 APOBEC3 proteins are capable of restricting the replication of HIV-1 in a T cell 
and which are potentially the source of the high levels of G-to-A mutagenesis observed in 
patient-derived HIV-1 sequences. To begin to narrow down which proteins are involved 
in vivo, we solved a long-standing problem in the APOBEC3 field. Quantifying 
expression levels had been impeded by the degree of homology between APOBEC3s, 
both at the nucleic acid and protein levels. My colleagues and I developed and 
characterized specific and efficient expression assays for each APOBEC3 family 
member. Using these assays we demonstrate that multiple APOBEC3s were expressed in 
relevant cell types and tissues including the major target of HIV-1, CD4+ T lymphocytes. 
 To interrogate the contribution of individual APOBEC3s to HIV-1 restriction, we 
took a genetic approach and performed targeted deletion and knockdown experiments in 
a cell line that expresses multiple APOBEC3s. This approach allowed for a direct and 
definitive test of our hypothesis that multiple endogenous APOBEC3s restrict Vif-
deficient HIV-1 replication. Based on HIV-1 replication kinetics and the levels of viral 
genome mutation, we concluded that 4 APOBEC3s are involved in HIV-1 restriction and 
that any future strategies employing the restrictive APOBEC3s will benefit from 
liberating all four proteins from Vif counteraction rather than any single one alone. 
 Finally, to explore the consequences of genetic variation in the APOBEC3 locus 
on the HIV-1 restriction capacity of these proteins, we analyzed the expression levels and 
	   v	  
activity of the 7 haplotypes of the most genetically diverse APOBEC3, APOBEC3H. 
Through a series of primary cell experiments and HIV-1 spreading infections, we found 
that a subset of APOBEC3H haplotypes produce proteins that are stably expressed and 
capable of restricting naturally occurring HIV-1 variants that haven’t evolved or have lost 
the capacity to neutralize this APOBEC3. The ramifications of this variability in a human 
restriction factor coinciding with diversity in HIV-1 variants able to counteract it will be 
an exciting area of future research. 
 Overall, my research demonstrated that HIV-1 must contend with 4 APOBEC3 
proteins to efficiently replicate in T cells. Expression of the APOBEC3s in human cells is 
widespread and inducible, and these host restriction factors combine to mutagenize the 
viral genome in the absence of HIV-1 Vif or, in the case of APOBEC3H, with Vif-
proficient HIV-1 variants that are unable to mount an effective counter-defense. 
Consequently, unleashing all of these potent antiviral agents and allowing them to 
directly attack the virus’ genetic code may lead to the first targeted innate immune 
therapy against HIV-1. 
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CHAPTER 1 
 
 
Introduction - The APOBEC3 Family of Retroelement Restriction Factors 
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FOREWORD 
 The discovery of the anti-viral activities of the APOBEC3 proteins a little over 10 
years ago is regarded as a major breakthrough for the development of endogenous 
therapeutic approaches to treat HIV-1 infected individuals. Members of this DNA 
cytosine deaminase family are potent anti-viral proteins because they directly inhibit 
reverse transcription, both physically and through their hallmark C-to-U enzymatic 
activity of nascent viral replication intermediates that can result lethal mutagenesis. 
However, the HIV-1 counterdefense protein, Vif, limits these activities by interacting 
with APOBEC3 proteins and marking them for cellular degradation. My research details 
which of the 7 endogenous APOBEC3 proteins are relevant to HIV-1 restriction with an 
eventual goal of liberating these factors from Vif to control the HIV-1 pandemic. Here, I 
briefly describe the origins of the family of APOBEC3 innate immune proteins, their 
beneficial functions in antiviral defenses, deleterious potential, and potential approaches 
to leverage their potent activities as the next generation of antiviral therapies thereby 
harnessing an innate immune defense to combat a contemporary foe.   
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SUMMARY 
 The ability to regulate and even target mutagenesis is an extremely valuable 
cellular asset. Enzyme-catalyzed DNA cytosine deamination is a molecular strategy 
employed by vertebrates to promote antibody diversity and defend against foreign nucleic 
acids. Ten years ago, a family of cellular enzymes was first described with several 
proving capable of deaminating DNA and inhibiting HIV-1 replication. Ensuing studies 
on the apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3) 
restriction factors have uncovered a broad-spectrum innate defense network that 
suppresses the replication of numerous endogenous and exogenous DNA-based parasites. 
Although many viruses possess equally elaborate counter-defense mechanisms, the 
APOBEC3 enzymes offer a tantalizing possibility of leveraging innate immunity to fend 
off viral infection. Here we focus on mechanisms of retroelement restriction by the 
APOBEC3 family of restriction enzymes and we consider the therapeutic benefits, as 
well as the possible pathological consequences, of arming cells with active DNA 
deaminases. 
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DNA DEAMINASE EVOLUTION  
 Central to nucleic acid metabolism is the near-ubiquitous process of enzymatic 
deamination of adenine and cytosine bases, individually or in the context of larger nucleic 
acid constituents (Conticello et al., 2005; Grosjean, 2009). For instance, in most species 
the wobble base in several of the tRNA anti-codons is frequently changed by deamination 
of adenosine to inosine (A-to-I), which can then base pair with cytosine, uracil, or 
adenosine, thereby increasing the flexibility and decoding capacity of a tRNA anti-codon 
(Gerber and Keller, 1999). These enzymes belong to the adenosine deaminase acting on 
tRNA (ADAT) family. Related proteins in most metazoans from nematodes and flies to 
humans catalyze A-to-I editing of a variety of RNA targets (Kim et al., 1994; Nishikura, 
2010). These enzymes are called, appropriately, adenosine deaminases that act on RNA 
(ADAR). Editing events that occur in the coding region of an mRNA can result in amino 
acid substitutions in the resulting protein. However, the majority of editing events occur 
in non-coding regions of mRNA or in non-coding RNAs, and these A-to-I editing events 
can alter RNA secondary structure, stability, function, and/or capacity to be bound by 
regulatory RNAs such as siRNAs (Agranat et al., 2008; Levanon et al., 2004; Li et al., 
2009; Morse et al., 2002).  
 Cytosine to uracil (C-to-U) deamination is almost as ancient as A-to-I editing 
(Conticello et al., 2007b; Grosjean, 2009). The pyrimidine salvage pathways of most 
organisms use cytidine deaminase (CDA) to produce the essential RNA and DNA 
building blocks of uridine directly, and thymidine after additional enzymatic steps 
(Zrenner et al., 2006). However, at some point near the root of the vertebrate tree, 
polynucleotide cytosine deaminases emerged, with the lamprey CDA being a present day 
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example (Rogozin et al., 2007). This enzyme is thought to underpin a unique form of 
adaptive immunity in which the DNA segments that encode arrays of highly diverse 
leucine rich repeats are assembled into mature variable lymphocyte receptor genes by a 
recombination-mediated process. It is thought that an ancestor of the present day lamprey 
enzyme served as the original substrate for expansion of the polynucleotide cytosine 
deaminase gene family during vertebrate evolution (Figure 1-1a) (Conticello, 2008; 
Rogozin et al., 2007). The result in most vertebrates alive today is a much larger 
repertoire of polynucleotide C-to-U editing enzymes that execute diverse biological 
functions from lipid metabolism to adaptive and innate immunity (Figure 1-1 & 1-2). 
All vertebrate polynucleotide cytosine deaminases belong to the so-called 
‘APOBEC’ family. The defining feature of this family is a conserved His-X-Glu-X25-31-
Pro-Cys-X2-4-Cys zinc (Z)-coordinating motif, which is strictly required for deaminase 
activity (where X can be a variety of amino acids) (Conticello et al., 2005; Harris and 
Liddament, 2004; LaRue et al., 2009; Wedekind et al., 2003). As described in more detail 
below, key residues within this motif position zinc at the active site of the enzyme 
(Figure 1-1c). The protein sequences within these motifs enable phylogenetic groupings 
into three sub-families: APOBEC1, AID, and the APOBEC3s. The APOBEC3s can be 
further sub-divided into three sub-groups: Z1, Z2, and Z3 (Figure 1-1a) (Conticello, 
2008; LaRue et al., 2009). Importantly, the number and organization of the A3 Z-
domains can vary dramatically from branch to branch throughout the mammalian portion 
of the vertebrate phylogenetic tree (e.g., human versus mouse loci depicted in Figure 1-
1a).  
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Apolipoprotein B mRNA editing catalytic subunit 1 (APOBEC1) has provided the 
namesake to the larger family. It was discovered as an enzyme that catalyzes the 
deamination of a specific cytosine within the APOB mRNA (Figure 1-1b & 1-2a) (Teng 
et al., 1993). This produces a premature translation stop codon and a smaller secondary 
gene product. These two APOB proteins (APOB100 and APOB48) differentially regulate 
the secretion of lipoproteins from the liver (Chan, 1992). Many mammalian APOBEC1 
enzymes also possess DNA C-to-U deaminase activity (Harris et al., 2002; Ikeda et al., 
2011; Ikeda et al., 2008; Petit et al., 2009). Taken together with the fact that earlier 
vertebrate lineages, such as the one represented by birds and lizards, lack an APOB-like 
gene, it is probable that DNA editing function preceded involvement in RNA editing 
(Severi et al., 2011). 
The most conserved DNA cytosine deaminase in vertebrates is activation-induced 
deaminase (AID; gene name AICDA) (Figure 1-1a). AID has a central role in adaptive 
immunity by seeding somatic hypermutation, gene conversion, and class switch 
recombination with its DNA deaminase activity (Figures 1-1b & 1-2b) [(Di Noia and 
Neuberger, 2002; Muramatsu et al., 2000; Muramatsu et al., 1999; Petersen-Mahrt et al., 
2002); reviewed by (Conticello, 2008; Di Noia and Neuberger, 2007; Longerich et al., 
2006)]. Interestingly, the genes that encode APOBEC1 and AID are positioned adjacent 
to each other in the genomes of most vertebrates (an inversion has placed the human gene 
farther away on the same chromosome). This suggests that an ancestral AID gene 
duplicated and diverged to produce APOBEC1 (Figure 1-1a). It is likely that duplication 
of an ancestral AID/APOBEC1 locus produced the genetic seeds for the mammal-
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exclusive APOBEC3 sub-family (Figure 1-1a) (Harris and Liddament, 2004; Jarmuz et 
al., 2002).  
In humans, the seven APOBEC3 proteins are encoded by a tandemly arranged 
gene cluster (Figure 1-1a) (Jarmuz et al., 2002). These present day genes are the 
products of continual evolution, in which an ancestral cluster of three Z domains is 
predicted to have undergone a minimum of eight duplication events over the past 100 
million years to produce the locus found in most primates (LaRue et al., 2008; Münk et 
al., 2012). These domains are either expressed singly or one enzyme may consist of two 
Z domains (LaRue et al., 2009). In contrast, the ancestral APOBEC3 locus experienced a 
deletion in the rodent lineage of one of the ancestral Z-domains leading to the present day 
two domain locus, which encodes a single protein quite distinct from any of the primate 
enzymes (Figure 1-1a).  
One possible explanation for why some mammalian lineages, like primates, have 
many APOBEC3s, while other lineages, such as rodents have few is that these enzymes 
have overlapping innate immune functions to protect the host from a variety of parasitic 
elements (e.g., in HIV-1 restriction, Figure 1-2c; mechanism elaborated in section 3, 
below). Because multiple distinct innate immune mechanisms serve to suppress the 
spread of such parasitic elements, it is reasonable to postulate that some mammals will be 
fortified at the APOBEC3 locus and weaker at other loci, with each mammalian lineage 
being distinct. For instance, primates encode a single TRIM5α protein, whereas mice 
have the capacity to encode a total of eight TRIM5α-like proteins [(Sawyer et al., 2007; 
Tareen et al., 2009); see also Chapter 13 in (Lever et al., 2010)]. It is likely that each 
species’ present day innate immune fortifications were independently shaped by past 
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pathogenic pressures, which one can only speculate may have been the ancestors of 
present day viruses and transposable elements. 
 
 
BIOCHEMICAL AND STRUCTURAL INSIGHTS 
 Zinc-dependent deaminases, such as the APOBECs, catalyze the conversion of 
cytosine to uracil in polynucleotide substrates (Figure 1-1b). This reaction requires the 
activation of water by a zinc ion coordinated by the enzyme (Figure 1-1c). A glutamic 
acid in the active site of the enzyme protonates N3, priming the nucleophilic attack on the 
C4 position of the pyrimidine ring, followed by the removal and subsequent protonation 
of an amino group (NH2) that results in the release of ammonia (NH3) and uracil as 
products. This conversion can theoretically occur within both RNA and single-stranded 
DNA substrates. However, apart from APOBEC1, which has both RNA and DNA editing 
activities, AID and the APOBEC3s have proven specific to DNA substrates in vitro and 
in vivo. 
The extent of amino acid homology to APOBEC1 originally suggested that the 
APOBEC3 enzymes might be a family of RNA editing proteins (Jarmuz et al., 2002). 
Three lines of evidence, however, demonstrated that this view was incorrect and 
established the APOBEC3 enzymes as single-stranded DNA cytosine deaminases. First, 
APOBEC3 has a high degree of homology with AID and experiments in E. coli 
demonstrated AID, APOBEC3C, and APOBEC3G are capable of inducing high levels of 
mutation in an antibiotic resistance gene (Harris et al., 2002; Petersen-Mahrt et al., 2002). 
This was clearly due to DNA editing because mutation levels rose synergistically in a 
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bacterial strain deficient for uracil DNA glycosylase (UDG), an enzyme that initiates 
base excision repair by recognizing and removing uracil exclusively from DNA (Di Noia 
and Neuberger, 2002; Harris et al., 2002; Lindahl, 2000). Second, unambiguous evidence 
for DNA versus RNA editing comes from head-to-head biochemical studies using 
recombinant enzymes. AID and APOBEC3G, have a strong preference for single-
stranded DNA substrates, with no detectable RNA editing activity (Bransteitter et al., 
2003; Iwatani et al., 2006). Third, a strong preference for single-stranded DNA substrates 
is also evident in sequencing studies of retroviruses produced in the presence of a given 
APOBEC3 protein, such as APOBEC3G (Figure 1-2c) (Harris et al., 2003; Lecossier et 
al., 2003; Mangeat et al., 2003; Zhang et al., 2003). In this experimental system, each 
APOBEC3 protein presumably has a chance to deaminate viral genomic RNA cytosines 
before the reverse transcription process converts it to a single-stranded cDNA 
intermediate and then to the double-stranded DNA required for integration. However, the 
most common APOBEC3-dependent mutations detected in integrated viral DNA that has 
survived this process are genomic strand G-to-A mutations, entirely attributable to cDNA 
strand C-to-U deamination events. Genomic strand C-to-T editing events possibly due to 
RNA editing are rarely detected. Importantly, APOBEC3 DNA editing activity is 
required to explain previously reported G-to-A mutation biases in HIV-1 substrates in 
vivo (Janini et al., 2001; Vartanian et al., 1994). 
The solved structures of bacterial and yeast cytidine and cytosine deaminases 
were used to inform early functional and structural studies of various APOBEC3 family 
members (Betts et al., 1994; Ireton et al., 2003; Johansson et al., 2004; Ko et al., 2003; 
Xie et al., 2004). Each of these bacterial and yeast proteins, in monomeric form, is 
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globular with a hydrophobic β-stranded core and several surrounding a-helices. The most 
conserved structural feature is the active site, which is defined by a histidine and two 
cysteines in the yeast enzyme and three cysteines in the bacterial enzymes (Ireton et al., 
2003; Ko et al., 2003; Xiang et al., 1997). In both instances, these residues are positioned 
similarly by alpha helices and they serve to coordinate a zinc ion in the active site, which, 
as described above, is essential for the deamination reaction (Figure 1-1b). Although 
these conserved features have been useful for generating models of APOBEC3 structures, 
they have also been misleading because the oligomeric state of each enzyme is variable. 
For instance, the E. coli CDA is homodimeric and the yeast enzyme is homotetrameric 
(Betts et al., 1994; Johansson et al., 2002). This has fuelled (likely incorrect) speculation 
that APOBEC3 family members must also function as oligomers. 
Generating high-resolution structures of APOBEC3 family members has proved 
challenging in large part due to insolubility at higher protein concentrations [e.g., 
(Iwatani et al., 2006)]. However, several NMR and crystal structures have been achieved 
for the APOBEC3G catalytic domain (representing Z1-type deaminases) and crystal 
structures were obtained recently for APOBEC3C and the APOBEC3F catalytic domain 
(representing Z2-type deaminases) (e.g., Figure 1-1c) (Bohn, 2013; Chen et al., 2008; 
Furukawa et al., 2009; Holden et al., 2008; Kitamura et al., 2012b; Li et al., 2012; 
Shandilya et al., 2010). 
These structures have several conserved features that provide insight into how 
these enzymes may function. First, these proteins are all globular with a hydrophobic 
core consisting of five beta strands surrounded by six alpha helices and the hallmark α2-
β3-α3 zinc-coordinating motif that defines the larger cytosine deaminase superfamily. 
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Second, β-strands 3, 4, and 5 are arranged in parallel, similar to the RNA editing enzyme 
TadA (an ADAT) but different from the antiparallel arrangement found in bacterial and 
yeast CDAs. This parallel β3-β4-β5 organization may be a key feature that distinguishes 
polynucleotide from non-polynucleotide deaminases. Third, although many potential 
oligomeric interfaces have been captured in the crystal lattices, none have proven critical 
for enzymatic activity and no common themes have emerged (Bohn, 2013; Furukawa et 
al., 2009; Kitamura et al., 2012b; Shandilya et al., 2010). This is consistent a number of 
other studies indicating that oligomerization may not be essential for binding and 
deaminating single-stranded DNA substrates (Nowarski et al., 2008; Opi et al., 2006; 
Shlyakhtenko et al., 2011; Shlyakhtenko et al., 2012). However, more work on this topic 
is clearly needed to define the role of oligomerization in vivo, because several of the 
family members, including APOBEC3G, elicit such a property in living cells 
(Bransteitter et al., 2003; Chiu et al., 2006; Li et al., 2014; Soros et al., 2007). Finally, it 
is notable that the majority of structural and amino acid differences between APOBEC3 
structures are confined to non-catalytic loop regions. Such differences likely relate to 
substrate targeting and possible co-factor binding, ultimately reflecting physiological 
function. 
A significant remaining question in our understanding of APOBEC3 function is 
how these enzymes bind single-stranded DNA substrates. A current working model 
proposes a positively charged brim in the region surrounding the active site consisting of 
R213, R215, R313, and R320 in APOBEC3G (Chen et al., 2008; Shindo et al., 2012). 
These residues are predicted to position single-stranded DNA substrates in a manner that 
allows the target cytosine to enter the active site (Chen et al., 2008). This model also 
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predicts that in order to access to the catalytic glutamic acid, the target C will be flipped-
out with respect to the phosphodiester backbone. A base-flipping mechanism is in good 
agreement with the structure of the adenosine deaminase TadA complexed with its RNA 
substrate (Losey et al., 2006). 
Finally, the brim-domain model and TadA structures suggest an explanation for 
the different local single-stranded DNA deamination preferences among APOBEC family 
members (Chen et al., 2008; Conticello et al., 2007a). Unlike bacterial restriction 
enzymes with 4, 6, or 8 base palindromic recognition sequences, APOBEC3 family 
members have a notable preference for the base immediately 5’ of the target C (Aguiar et 
al., 2008; Bishop et al., 2004; Dang et al., 2006; Doehle et al., 2005a; Harari et al., 2009; 
Harris et al., 2003; Harris et al., 2002; Langlois et al., 2005; Liddament et al., 2004; 
Mangeat et al., 2003; Stenglein et al., 2010; Wiegand et al., 2004; Yu et al., 2004a; Yu et 
al., 2004b; Zhang et al., 2003; Zheng et al., 2004). Specifically, AID prefers a 5’ purine 
base (5’-AC or GC), APOBEC3G a 5’ cytosine (5’-CC), and all other family members a 
5’ thymine (5’-TC). Several studies have recently converged on a loop adjacent to the 
active site, positioned between β4 and α4 secondary structural elements (Chen et al., 
2008; Conticello et al., 2007b; Holden et al., 2008; Kohli et al., 2009; Kohli et al., 2010; 
Rathore et al., 2013). This is most dramatically evidenced by loop grafting experiments, 
in which this loop in AID can be replaced by the homologous loop from APOBEC3G or 
APOBEC3F resulting in a complete switch of the preferred base immediately 5’ of the 
target cytosine (Carpenter et al., 2010; Kohli et al., 2009; Kohli et al., 2010; Wang et al., 
2010). Moreover, exchanging the same loop (or even a single amino acid) between 
APOBEC3A and APOBEC3G completely swaps the dinucleotide preference of these 
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enzymes (Rathore et al., 2013). Despite this progress, the field still anxiously awaits 
high-resolution structures of enzyme-substrate complexes that will more precisely define 
the substrate binding mechanism and advance our understanding of how these enzymes 
function in vivo.  
  
 
BIOLOGICAL FUNCTIONS 
APOBEC3 Proteins in HIV Restriction 
 Pathogens including the retrovirus HIV-1 (hereafter HIV) must both engage and 
avoid numerous host factors to replicate and cause disease. Genome-wide knockdown 
and proteomic studies suggest that up to 10% of human proteins either directly or 
indirectly impact HIV replication (Brass et al., 2008; Jäger et al., 2012a; Jäger et al., 
2012b; Konig et al., 2008; Yeung et al., 2009; Zhou et al., 2008). The majority of these 
proteins are required in some capacity for virus replication (i.e., dependency factors). In 
contrast, a small number of these cellular proteins are dominant proteins that directly 
suppress virus replication (i.e., restriction factors). Restriction factor hallmarks include 
the capacity to potently inhibit virus replication, signatures of rapid evolution (positive 
selection), responsiveness to interferon, and neutralization by at least one viral counter-
restriction strategy (Harris et al., 2012; Malim and Bieniasz, 2012; Malim and Emerman, 
2008b). Here, we focus on the mechanism of HIV restriction by APOBEC3 DNA 
cytosine deaminases. 
  Original studies showed that the viral infectivity factor (Vif) protein of HIV is 
required for virus replication in primary CD4+ lymphocytes and in several common 
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laboratory T cell lines (e.g., CEM, H9, so-called non-permissive), but it was dispensable 
in several others (e.g., CEM-SS, SupT1, or permissive lines) (Fisher et al., 1987; 
Gabuzda et al., 1992; Strebel et al., 1987). This phenotypic difference led to the cloning 
of APOBEC3G as one cDNA sequence expressed differentially (of many) between CEM 
and CEM-SS (Sheehy et al., 2002). However, APOBEC3G proved remarkable as it could 
convert a permissive cell line to a non-permissive phenotype (Sheehy et al., 2002). Taken 
together with the independent and near-simultaneous discoveries of APOBEC3G as a 
putative RNA editing factor and as a DNA editing enzyme, an editing mechanism of 
restriction was predicted and shortly after demonstrated (Harris et al., 2003; Harris et al., 
2002; Jarmuz et al., 2002; Lecossier et al., 2003; Mangeat et al., 2003; Zhang et al., 
2003).  
 Over five hundred papers have now been published on APOBEC3G and the 
related APOBEC3 proteins that have culminated in a current Trojan horse-like model for 
HIV restriction as shown in Figure 1-2c. To be effective as an HIV restriction factor, 
APOBEC3G must first be expressed in the cytoplasmic compartment of an infected 
virus-producing cell (Mangeat et al., 2003). Second, cytoplasmic APOBEC3G is thought 
to interact with a Gag-ribonucleoprotein complex, and this interaction is required for 
APOBEC3G packaging (Alce and Popik, 2004; Bogerd and Cullen, 2008; Burnett and 
Spearman, 2007; Khan et al., 2005; Luo et al., 2004; Schafer et al., 2004; Svarovskaia et 
al., 2004). This interaction can be disrupted by RNase treatment and is therefore thought 
to involve a bridging RNA between APOBEC3G and the nucleocapsid region of Gag 
(Bogerd and Cullen, 2008; Cen et al., 2004; Iwatani et al., 2007; Svarovskaia et al., 
2004). The identity of the bridging RNA is still an active area of investigation; while 
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several reports indicate a role for the Alu-like 7SL RNA, a role for viral genomic RNA 
has not been excluded (Bogerd and Cullen, 2008; Khan et al., 2007; Khan et al., 2005; 
Tian et al., 2007; Wang et al., 2007). Third, by an ill-defined mechanism, packaged 
APOBEC3G must breach the nucleocapsid core of the viral particle. This is a genetically 
(but not mechanistically) defined step, as various chimeric constructs have the capacity to 
be packaged into viral particles, yet do not enter the core or restrict (Haché et al., 2005; 
Martin et al., 2011; Song et al., 2012). 
 Once an APOBEC3G-loaded viral core is deposited into a target cell, reverse 
transcription proceeds and a susceptible single-stranded cDNA intermediate is generated. 
Here, APOBEC3G deaminates C-to-U (Harris et al., 2003; Lecossier et al., 2003; 
Mangeat et al., 2003; Yu et al., 2004b; Zhang et al., 2003). The uracilated cDNA is either 
subjected to degradation, or templates the second-strand synthesis, preceding integration 
into the target cell’s genome (Kaiser and Emerman, 2006; Mbisa et al., 2007; Yang et al., 
2007). The uracils in the cDNA strand template the insertion of adenines in the nascent 
plus strand and thereby immortalize G-to-A mutations that limit subsequent rounds of 
viral replication (Harris et al., 2003; Lecossier et al., 2003; Mangeat et al., 2003; Zhang et 
al., 2003).  
Human T cell lines that express near-physiological levels of an APOBEC3G 
catalytic mutant do not suppress the replication of a Vif-deficient virus, indicating that 
the predominant mechanism of HIV restriction depends upon deaminase activity (Bishop 
et al., 2004; Browne et al., 2009; Miyagi et al., 2007; Schumacher et al., 2008). However, 
a component of APOBEC3G’s capacity to restrict HIV may be deaminase-independent 
(Bishop et al., 2006; Bishop et al., 2008; Iwatani et al., 2007; Iwatani et al., 2006; Mbisa 
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et al., 2007; Newman et al., 2005; Opi et al., 2006). The most convincing of these studies 
has shown that APOBEC3G is capable of binding viral genomic RNA and sterically 
hindering the processivity of reverse transcriptase (Bishop et al., 2006; Bishop et al., 
2008). Nevertheless, the importance of deaminase-independent mechanisms, at least for 
APOBEC3G and HIV, is questionable given the aforementioned results at physiologic 
levels. 
 Soon after the initial discovery and functional characterization of APOBEC3G, 
attention turned towards its six, highly related family members. Proviral sequences 
isolated from HIV-infected individuals exhibit two distinct patterns of G-to-A mutation 
consistent with APOBEC3-mediated deamination, both 5’-GG-to-AG and 5’-GA-to-AA 
(Caride et al., 2002; Fitzgibbon et al., 1993; Gandhi et al., 2008; Janini et al., 2001; 
Kieffer et al., 2005; Land et al., 2008; Pace et al., 2006). As mentioned previously, 
APOBEC3G has a demonstrated preference for deaminating 5’-CC dinucleotides on the 
viral minus strand resulting in 5’-GG-to-AG mutations and is therefore the most likely 
source of this mutational pattern (Harris et al., 2003; Liddament et al., 2004; Mangeat et 
al., 2003; Yu et al., 2004b; Zhang et al., 2003). However, high levels of proviral 5’-GA-
to-AA mutation in patients’ proviral sequences suggested the involvement of at least one 
additional family member. Unfortunately, all six other APOBEC3 family members prefer 
to deaminate a 5’-TC, therefore excluding the possibility of identifying an additional 
APOBEC3 source based solely on mutational preference [e.g., (Bishop et al., 2004); 
reviewed in (Albin and Harris, 2010)]. 
In cell-based model systems with forced cDNA expression, all seven APOBEC3s 
have reported activity [e.g., (Bishop et al., 2004; Dang et al., 2008; Dang et al., 2006; 
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Doehle et al., 2005a; Goila-Gaur et al., 2007; Liddament et al., 2004; OhAinle et al., 
2008; Rose et al., 2005; Wiegand et al., 2004; Yu et al., 2004a; Zheng et al., 2004); 
reviewed in (Albin and Harris, 2010)]. However, cellular expression patterns, ability to 
encapsidate into viral particles, and restriction in relevant T cell models indicate not all 
the APOBEC3s function in vivo as HIV restriction factors. For example, in primary CD4+ 
T lymphocytes, a major target of HIV in vivo, six APOBEC3s are expressed at 
appreciable levels, but APOBEC3A mRNA is undetectable (Koning et al., 2009; Refsland 
et al., 2010). In addition, only four: APOBEC3D, APOBEC3F, APOBEC3G, and 
APOBEC3H (but not APOBEC3A, APOBEC3B, and APOBEC3C), package into viral-
like particles and inhibit viral replication when stably expressed in human T cell lines 
(Hultquist et al., 2011). Finally, endogenous APOBEC3D and APOBEC3F combine to 
inflict the 5’-GA-to-AA mutation pattern observed in the non-permissive T cell line 
CEM2n (Refsland et al., 2012). Of note, CEM2n does not express appreciable levels of 
APOBEC3H mRNA; therefore the endogenous contribution of this protein could not be 
evaluated. Seven variants of APOBEC3H have been reported and cell-based studies 
indicate only a subset of these haplotypes are stable at the protein level and capable of 
HIV restriction (Dang et al., 2008; Harari et al., 2009; OhAinle et al., 2008; Wang et al., 
2011). The significance of this natural variation in human populations and the relevance 
of it to HIV restriction require further investigation. Taken together, while all of the 
APOBEC3s can be compelled to deaminate a single-stranded viral DNA in vitro or in 
heterologous cell lines by gross overexpression, only four APOBEC3s — APOBEC3D, 
APOBEC3F, APOBEC3G, and APOBEC3H — appear to have the capacity to function 
as HIV restriction factors in T lymphocytes. 
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 All successful viruses have evolved sophisticated immune suppression and/or 
evasion mechanisms to neutralize the cellular defense systems they must face. One of the 
best-studied APOBEC3 counter-restriction mechanisms is orchestrated by the HIV viral 
infectivity factor, Vif. This protein is small (23 kDa), highly basic, and strictly required 
for pathogenesis in vivo as well as for virus replication ex vivo in monocytes, 
macrophages, primary CD4+ T lymphocytes, and non-permissive T cell lines (Fisher et 
al., 1987; Gabuzda et al., 1992; Kan et al., 1986; Lee et al., 1986; Sodroski et al., 1986; 
Strebel et al., 1987; von Schwedler et al., 1993). Vif recruits a multiprotein E3 ubiquitin 
ligase complex consisting of CUL5/NEDD8, ELOB, ELOC, RBX2 and CBFb to mediate 
proteasomal degradation of the cellular APOBEC3 restriction factors (Figure 1-2c) 
(Conticello et al., 2003; Jäger et al., 2012b; Marin et al., 2003; Mehle et al., 2004; Sheehy 
et al., 2003; Yu et al., 2003). In addition to this primary role, it has been suggested that 
Vif can relieve APOBEC3G-mediated restriction by alternative mechanisms such as 
directly blocking deaminase activity, preventing encapsidation, sequestering the protein 
in catalytically inactive conformations, or impeding APOBEC3G translation (Britan-
Rosich et al., 2011; Goila-Gaur et al., 2008; Kao et al., 2004; Mariani et al., 2003b; Opi 
et al., 2007; Santa-Marta et al., 2005; Stopak et al., 2003). The extent to which these 
mechanisms function to counteract APOBEC3 during a productive infection warrants 
further investigation but is certain to be secondary to the proteasomal degradation 
mechanism. 
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APOBEC3 proteins in general innate immune defense 
Exogenous retroviruses are rare in humans, consistent with the idea that the 
multifaceted APOBEC3 defense provides robust protection against this type of pathogen. 
HIV is one exception to this rule. It is successful, at least in part, due to Vif and 
degradation of the cellular APOBEC3s. However, evidence for a long history of positive 
selection acting on the human APOBEC3 locus suggests this family has been defending 
the genomic integrity of its host’s cells long before HIV was transmitted into the human 
population (Sanville et al., 2010; Sawyer et al., 2004; Zhang and Webb, 2004). Given the 
significant presence of endogenous retroelements in the genomes of mammals (nearly 
50%), suppression of these elements may represent the sub-family’s true raison d’être 
and the primary source of the positive selection that has shaped the complex present day 
locus and the diverse functions of these innate immunity factors. 
 Endogenous retroelements, including those containing long terminal repeats 
(LTR) like endogenous retroviruses, as well as non-LTR elements like long interspersed 
nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), may have 
provided the evolutionary pressure necessary for the maintained expansion of the 
APOBEC3 locus in primates. Additionally, the differences in retrotransposition frequency 
between rodents and primates could be attributable to possessing an arsenal of seven 
APOBEC3 proteins versus only a single one (Maksakova et al., 2006; Stenglein and 
Harris, 2006). In support of this hypothesis, human APOBEC3s have demonstrated 
activity on LTR retrotransposons from mice and yeast (Bogerd et al., 2006a; Chen et al., 
2006; Dutko et al., 2005; Esnault et al., 2005; Esnault et al., 2006; Jern and Coffin, 2008; 
Lee and Bieniasz, 2007; Lee et al., 2008; Schumacher et al., 2005). Additionally, some 
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endogenous retroviruses exhibit the characteristic scars from APOBEC3F and 
APOBEC3G activity in their genomes (Anwar et al., 2013). Non-LTR elements, 
including LINE1 and Alu, are also restricted by human APOBEC3s but, in contrast to the 
HIV restriction mechanism described above, this mechanism appears entirely 
deamination-independent (Bogerd et al., 2006b; Carmi et al., 2011; Chiu et al., 2006; 
Muckenfuss et al., 2006; Stenglein and Harris, 2006).  
The generation of a single-stranded DNA intermediate in the life cycle of a 
parasitic element may render it susceptible to APOBEC3 restriction. In addition to HIV, 
other viruses including simian immunodeficiency virus, murine leukemia virus, foamy 
virus, porcine endogenous retrovirus, human T-cell leukemia virus, and hepatitis B virus 
have all been reported to be susceptible to APOBEC3-mediated editing of their genomes 
(Abudu et al., 2006; Delebecque et al., 2006; Doehle et al., 2005b; Harris et al., 2003; 
Jonsson et al., 2007; Kobayashi et al., 2004; Lochelt et al., 2005; Mangeat et al., 2003; 
Mariani et al., 2003b; Russell et al., 2005; Suspène et al., 2005a; Turelli et al., 2004; Yu 
et al., 2004a). Whether or not the APOBEC3-mediated restriction of all of these viral 
pathogens is part of a natural innate immune response or a by-product of the particular 
model systems used awaits further investigation. 
Endogenous retroelements and their mobility are believed to have played a central 
role early in shaping the human genome during speciation (Carmi et al., 2011; Kazazian, 
2004). However, this process has its associated costs. Ultimately, cells have devised 
strategies to defend and preserve genomic integrity by curbing the movement of these 
genetic elements. The evolution of the APOBEC3 family has likely played a prominent 
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role in this defense and in diversifying the retroelements to make them more useful for 
the host species [e.g., (Carmi et al., 2011)].  
 
 
PATHOLOGICAL CONSEQUENCES OF DNA DEAMINATION 
 Although DNA cytosine deamination has obvious benefits for individual cells and 
the organism as a whole, this process may have considerable pathological consequences, 
most notably cancer. For instance, overexpression of APOBEC1 in the liver of mice has 
been shown to cause hepatocellular carcinoma and liver dysplasia (Yamanaka et al., 
1995). Likewise, AID transgenesis also causes cancer, and it has been implicated in 
initiating the chromosomal translocations responsible for some lymphocyte neoplasias 
including the hallmark c-myc/IgH rearrangement in Burkitt’s lymphoma [(Okazaki et al., 
2003; Ramiro et al., 2004; Unniraman et al., 2004); reviewed by (Perez-Duran et al., 
2007)]. AID may also promote resistance to the chemotherapeutic drug imatinib (Klemm 
et al., 2009). However, the overall impact of APOBEC1 and AID on human cancer is 
questionable because their expression is largely limited to tissues associated with their 
biological functions, APOBEC1 in the enterocytes of the small intestine and AID in B 
cells (Figure 1-3a) (Muramatsu et al., 2000; Muramatsu et al., 1999; Powell et al., 1987; 
Teng et al., 1993).  
In contrast, most APOBEC3s have much broader expression ranges that span most 
tissues in the human body (Figure 1-3a) (Burns et al., 2013; Koning et al., 2009; 
Refsland et al., 2010). Broad expression profiles, potent DNA deaminase activity, and C-
to-T transition biases in tumor genome sequences strongly suggested that one or more of 
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the APOBEC3 proteins may be a source of mutation in different cancers (Burns et al., 
2013; Harris et al., 2002; Nik-Zainal et al., 2012; Roberts et al., 2012). APOBEC3B 
became a leading candidate as it uniquely and constitutively localizes to the nucleus by 
inheriting a nuclear import mechanism from AID (Bogerd et al., 2006b; Bonvin et al., 
2006; Hultquist et al., 2011; Kinomoto et al., 2007; Lackey et al., 2012; Lackey et al., 
2013; Muckenfuss et al., 2006; Pak et al., 2011; Stenglein and Harris, 2006; Stenglein et 
al., 2008). Recently, APOBEC3B was found overexpressed in some laboratory breast 
cancer cell lines, but not in available control cell lines (Figure 1-3a; e.g., compare 
HCC1569, MCF-MB-453, and MCF-MB-463 to telomerase immortalized human 
mammary epithelial cells, hTERT HMECS) (Burns et al., 2013). APOBEC3B up-
regulation was shown to be responsible for elevated genomic uracil levels and increased 
mutation rates in breast cancer cell lines (Burns et al., 2013). APOBEC3B up-regulation 
was similarly robust in the majority of human breast tumors, in contrast to barely 
detectable levels in normal breast tissue (Burns et al., 2013). Remarkably, APOBEC3B 
overexpression correlated with a doubling in the tumor genomic mutation loads, and the 
majority of C-to-T transition mutations occurred within the preferred motif of 
recombinant APOBEC3B (Burns et al., 2013).  
 Overall, a model is emerging for how APOBEC3B provides genetic fuel for 
tumorigenesis, which, coupled with selection, may help explain many hallmarks of 
cancer such as increased DNA damage, elevated proliferation, decreased apoptosis, and 
massive heterogeneity (Fig. 3b). In particular, APOBEC3B up-regulation correlates with 
inactivation of the tumor suppressor gene TP53, which strongly suggests that it may be 
an early tumor-initiating event (Burns et al., 2013). Obviously, the potential benefits to 
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encoding APOBEC3B must outweigh potential costs of carcinogenesis. An attractive 
explanation for this apparent conundrum may be that its innate immune function is 
important early in life and for the health of the species, for instance in germ cells or early 
development (Bogerd et al., 2006b; Wissing et al., 2011), whereas the toll of cancer is not 
imposed in most instances until after the reproductive years. In any event, much more 
work is now justified on APOBEC3B and its role in breast and, potentially, other human 
cancers.  
 
 
POSSIBLE AVENUES TO APOBEC3-BASED THERAPEUTICS 
Therapy by hypermutation 
 If left unimpeded by Vif, APOBEC3 proteins such as APOBEC3G can convert up 
to 10% of viral cDNA cytosines into uracils in a single-round of virus replication [e.g., 
(Harris et al., 2003; Yu et al., 2004b)]. The resulting massive levels of G-to-A mutations 
effectively ruin the genetic potential of the retrovirus in a process called lethal 
mutagenesis (Haché et al., 2006; Loeb et al., 1999). Moreover, the preferred context of 
APOBEC3G deamination events often results in the conversion of the tryptophan codon 
TGG into a premature stop codon TAG, which is more detrimental to the virus than a 
simple amino acid change. Overall, physiological levels of APOBEC3 proteins largely, if 
not fully, suppress the replication of Vif-deficient HIV.  
This remarkable potency therefore raises the prospect of developing drugs to 
leverage the APOBEC3 restriction mechanism against HIV (Figure 1-4a). Direct 
inhibition of Vif is certainly one strategy, but such an approach is destined to be 
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susceptible to problems imposed by extensive natural HIV variation and the rapid 
evolution of drug resistance. A more appealing alternative may be to develop a drug 
toward one of the more genetically stable cellular proteins recruited to the APOBEC3 
degradation complex. In particular, Vif requires at least four heterologous protein-protein 
interactions to successfully counteract the APOBEC3 proteins. The first strategy, of 
course, is targeting the direct interaction with the APOBEC3 proteins themselves, which 
may occur through conserved structural motifs (Albin et al., 2010b; Kitamura et al., 
2012a). Second is targeting the recently discovered interaction with CBFβ, which is 
essential for Vif stability and function (Jäger et al., 2012b; Zhang et al., 2012). Third and 
fourth are targeting the distinct Vif interaction motifs in ELOC (the SLQ motif) or CUL5, 
which are also essential for activity of the APOBEC3 ubiquitin ligase complex (Marin et 
al., 2003; Yu et al., 2003). Finally, it may be possible to target an upstream component of 
the proteasomal pathway involved in APOBEC3 degradation [e.g., (Kim et al., 2013)]. 
However, despite these clear opportunities for drug development, progress has 
been relatively underwhelming. Proof of concept experiments have been achieved 
through cell-based screens for preservation of APOBEC3G-GFP fluorescence in the 
presence of HIV Vif (Nathans et al., 2008). The lead molecule from these studies, RN18, 
however, has only been subject to modest additional development (Ali et al., 2012). An 
additional concern holding back development of RN18 is the major challenge of 
identifying the molecular target, which is essential for structural studies and rational 
improvements through medicinal chemistry.  
Independent lead compounds have also been identified based on predicted fit into 
the Vif-binding pocket in ELOC, which would effectively outcompete the SLQ motif of 
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Vif (Huang et al., 2013a; Huang et al., 2013b). However, the best of these indolizine type 
compounds has a modest IC50 value of 11 µM. This will likely need improvements in 
potency and solubility before efficacy can be achieved in live cell studies. In any event, 
much more work in this area is needed, including larger scale cellular screens, 
biochemical screens, and computational screens, followed by a comprehensive sets of 
secondary and tertiary screens to narrow in on the most effective drug candidates. 
 
Therapy by hypomutation 
 Vif efficiently counteracts the HIV-relevant APOBEC3 repertoire (Conticello et 
al., 2003; Hultquist et al., 2011; Kao et al., 2003; Marin et al., 2003; Sheehy et al., 2003; 
Stopak et al., 2003). Nonetheless, evidence of APOBEC3 activity is found in the proviral 
sequences derived from infected patients [e.g., (Janini et al., 2001)]. This raises the 
possibilities that either Vif cannot completely neutralize all of the cytoplasmic 
APOBEC3 before encapsidation and/or HIV regulates its high mutation rate, in part, 
through controlled degradation of the APOBEC3 proteins with Vif acting as a molecular 
rheostat optimizing the levels of cytosine deamination necessary for immune evasion and 
potentially drug resistance (Haché et al., 2006; Harris, 2008).  
 A counterintuitive but potentially more effective strategy to decrease the 
pathogenesis of HIV may be to inhibit the enzymatic activity of the APOBEC3s, thereby 
eliminating a potential source of variation for the virus (Figure 1-4b) (Harris, 2008; Li et 
al., 2012; Olson et al., 2013). Toward this end, high-throughput screens have resulted in 
proof-of-concept experiments that APOBEC3G activity can be blocked with small 
molecules (Li et al., 2012; Olson et al., 2013). However, much additional work is still 
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necessary to improve the solubility, potency, and bioavailability of APOBEC3 inhibitors, 
and efficacy will need to be demonstrated in cell-based studies before critical animal 
experiments can be done. Nevertheless, a hypomutation strategy is attractive because 
decreasing the HIV mutation rate has the potential to limit the diversity of the viral 
population and render it susceptible to normal immune clearance mechanisms (Figure 1-
4b). Indeed, the adaptive T and B cell-mediated immune responses manage to keep the 
virus in-check initially in most patients, and it is tempting to speculate that even a slight 
tip in favor of host immunity may enable complete virus clearance (i.e., analogous to 
most other viral infections). Given the fact that existing anti-retroviral drugs are 
numerous and largely effective, a big challenge facing the field is the development of a 
curative therapy. It remains possible that promoting either virus hypermutation or 
hypomutation could be part of such a cure. 
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FIGURES 
 
Fig. 1-1 Evolution and structure-function of APOBEC cytosine deaminases. (a) 
Expansion of the modern primate APOBEC3 locus encoding seven APOBEC3 genes with 
eleven zinc-coordinating (Z) domains [reprinted with permission from (Lackey et al., 
2012)]. (b) Deamination of cytosine to uracil plays a central role in innate immunity. (c) 
Three-dimensional structures of the APOBEC3G C-terminal domain and APOBEC3C. A 
zinc ion (purple) is shown coordinated in both proteins by one histidine and two cysteine 
residues in the α2-β3-α3 core. 
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Fig. 1-2 The physiological functions of the APOBEC family. (a) RNA editing by 
APOBEC1 generates a truncated APOB protein. (b) AID activity underpins the processes 
of somatic hypermutation and class switch recombination in B-cell germinal centers. (c) 
Four APOBEC3 proteins restrict HIV through cytosine deamination in the absence of Vif 
[reprinted with permission from (Hultquist et al., 2011)].  
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Fig. 1-3 APOBEC expression and model of carcinogenesis. (a) APOBEC family mRNA 
expression in the indicated cell lines and normal human tissues. Data are relative to levels 
of AID in the spleen [reprinted with permission from (Burns et al., 2013)]. (b) Model 
depicting the effect of APOBEC3B overexpression over time. 
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Fig. 1-4 Potential therapies harnessing APOBEC3 innate immunity. (a) Inhibition of the 
Vif-E3 ligase complex could result in virus restriction. (b) Inhibiting the deaminase 
activity of APOBEC3 proteins could deprive HIV of a source of variation and allow 
immune clearance. 
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CHAPTER 2 
 
 
Quantitative Profiling of the Full APOBEC3 mRNA Repertoire in Lymphocytes and 
Tissues: Implications for HIV-1 Restriction 
 
 
 
 
Reprinted with permission from: Eric W. Refsland1, Mark D. Stenglein1 Keisuke Shindo, 
John S. Albin, William L. Brown and Reuben S. Harris. (2010) Nucleic Acids Research 
38:4274-84. 
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FORWARD 
 While there is substantial evidence that multiple APOBEC3 proteins can inhibit 
HIV replication, methods for detection and quantification of the expression level of each 
individual APOBEC3 family member is challenging due to the high degree of identity 
between members. This homology often confounds interpretations of data attributing 
deaminase function of a specific APOBEC3 family member in a particular cell type or 
tissue. Before the experiments described here, very few reagents existed commercially or 
otherwise to detect the expression of the APOBEC3 family members. Here I described 
my colleagues’ and my efforts to establish the most reliable methods of APOBEC3 
detection. Since their publication in 2010, these methods have advanced the field of HIV 
restriction factors as well as opened up new directions of research in our own laboratory 
(see Chapter 5). This is supported by the greater than 100 citations this publication has 
received as of this writing. Definitively identifying the individual APOBEC3s expressed 
in a cell type or tissue is an important step towards the ultimate goal of mobilizing these 
anti-viral proteins as new options in the treatment of HIV infection.  
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SUMMARY 
 The human APOBEC3 proteins are DNA cytidine deaminases that impede the 
replication of many different transposons and viruses. The genes that encode 
APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G, and 
APOBEC3H were generated through relatively recent recombination events. The 
resulting high degree of inter-relatedness has complicated the development of specific 
quantitative PCR assays for these genes despite considerable interest in understanding 
their expression profiles. Here, we describe a set of quantitative PCR assays that 
specifically measures the mRNA levels of each APOBEC3 gene. The specificity and 
sensitivity of each assay was validated using a full matrix of APOBEC3 cDNA templates. 
The assays were used to quantify the APOBEC3 repertoire in multiple human T-cell 
lines, bulk leukocytes and leukocyte subsets, and 20 different human tissues. The data 
demonstrate that multiple APOBEC3 genes are expressed constitutively in most types of 
cells and tissues, and that distinct APOBEC3 genes are induced upon T cell activation 
and interferon treatment. These data help define the APOBEC3 repertoire relevant to 
HIV-1 restriction in T cells, and they suggest a general model in which multiple 
APOBEC3 proteins function together to provide a constitutive barrier to foreign genetic 
elements, which can be fortified by transcriptional induction.  
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INTRODUCTION 
 The APOBEC3 (A3; apolipoprotein B mRNA-editing enzyme, catalytic 
polypeptide-like 3) proteins are Zn2+-dependent DNA cytidine deaminases, which are 
capable of inhibiting the replication of an incredible range of mobile genetic elements 
[reviewed by (Chiu and Greene, 2008; Goila-Gaur and Strebel, 2008; Hultquist and 
Harris, 2009; Malim and Emerman, 2008a)]. In humans, representative A3 substrates 
include exogenous retroviruses such as HIV-1 and HTLV, endogenous retroviruses such 
as HERV, endogenous retrotransposons such as L1 and Alu, and DNA viruses such as 
HBV and HPV [e.g., (Bogerd et al., 2006b; Chiu et al., 2006; Derse et al., 2007; Lee et 
al., 2008; Mangeat et al., 2003; Muckenfuss et al., 2006; Sheehy et al., 2002; Stenglein et 
al., 2010; Suspène et al., 2005a; Vartanian et al., 2008; Zhang et al., 2003)]. Despite the 
relevance of many of these parasitic elements to human health, the A3 proteins that 
function in vivo against each particular element have yet to be defined. For instance, A3F 
and A3G have been shown to strongly restrict HIV-1 in vitro and very likely contribute to 
HIV-1 restriction in vivo, but strong arguments have also implicated several other human 
A3 proteins [reviewed by (Albin and Harris, 2010; Chiu and Greene, 2008; Goila-Gaur 
and Strebel, 2008; Hultquist and Harris, 2009; Malim and Emerman, 2008a)]. 
The seven A3 genes are positioned in tandem on human chromosome 22: A3A, 
A3B, A3C, A3D (formerly A3DE), A3F, A3G, and A3H (Jarmuz et al., 2002). A defining 
feature of each A3 gene is that it encodes a protein with one or two conserved zinc (Z)-
coordinating deaminase domains. Each Z domain belongs to one of three distinct 
phylogenetic groups: Z1 (A3A and the C-terminal halves of A3B and A3G), Z2 (A3C, 
both halves of A3D and A3F, and the N-terminal halves of A3B and A3G), and Z3 
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(A3H) (LaRue et al., 2008). Based on the relatedness of these Z domains, the human A3 
repertoire appears to be the result of a minimum of eight unequal crossing-over 
recombination events, which mostly occurred during the radiation of primates (LaRue et 
al., 2008). The net result is that the human A3 mRNAs share considerable identity, 
ranging from 30% to nearly 100% (Figure 2-1A and Table 2-S1). For example, 
nucleotides 1-473 of the A3F mRNA are 98.7% identical to A3G nucleotides 50-522. 
Similarly, A3A nucleotides 259-937 are 96.6% identical to the corresponding region of 
A3B, nucleotides 692-1370. The A3 genes are also under positive selection and 
accordingly are highly polymorphic (Kidd et al., 2007; OhAinle et al., 2008; Sawyer et 
al., 2004). These inter-domain identities and polymorphisms present considerable 
challenges to A3 expression profiling and quantification. 
 Here we report specific quantitative PCR (qPCR) assays for each of the seven 
human A3 cDNA sequences. We use these assays to profile the expressed A3 repertoire in 
common T cell lines, primary CD4+ T lymphocytes, and twenty distinct human tissues. 
We also quantify the effects of T cell stimulation and interferon (IFN) induction on A3 
expression. These expression data indicate that several A3 proteins, in addition to A3F 
and A3G, are expressed in CD4+ cells and are therefore positioned to contribute to HIV-
1 restriction. More generally, nearly every cell type and tissue expresses multiple A3s, 
consistent with a model in which parasitic elements must evolve ways to cope with a 
constitutive set of restriction factors that can be further fortified by transcriptional 
induction.  
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RESULTS 
APOBEC3 qPCR assay designs and optimization experiments 
 To determine where and when each A3 mRNA is expressed we developed a panel 
of specific qPCR assays. For each assay, several computational and manual procedures 
were used to develop specific and efficient qPCR primers. Each primer was selected to 
span two exons (Figure 2-1A and Table 2-1). The primers and probes were screened to 
avoid known single nucleotide polymorphisms and splice variations (data not shown). 
Assay specificity was tested by pitting all seven qPCR probe/primer sets against each of 
the seven A3 cDNA templates in a 49-reaction qPCR matrix. The amplification results 
demonstrated that each assay was specific to the intended target A3 (Figure 2-1B). 
The next most important parameter to test and optimize was reaction efficiency. 
Serial dilutions of linearized A3 control cDNA templates were used in qPCR reactions to 
measure efficiencies. After as many as four primer/probe redesigns for some A3s, high 
efficiencies ranging from 1.97 – 1.99 were achieved for each qPCR assay (Figure 2-1C). 
These nearly ideal efficiencies indicated that each assay would provide a robust and 
quantitative measure of the level of expression of each A3 gene. In other words, these 
data indicated that quantitative comparisons of each A3 relative to the others are possible. 
Assay standardization and normalization are crucial parameters to ensure 
quantitative data set comparisons. We therefore also designed and tested qPCR assays for 
three common housekeeping genes, TBP, RPL13A, and HPRT (Materials and Methods). 
The mRNA levels of each of these genes were consistent between cell types and tissues. 
To facilitate data normalization and comparisons, only one of these genes (TBP) was 
used as an internal standard.  
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Finally, each of the aforementioned A3 qPCR assays was evaluated on two 
independent platforms to ensure that all data could be reproduced and generalized. The 
Roche Lightcycler 480 platform, which uses fluorescent probes, was used to develop the 
assays and for all data reported here. A similar set of reaction specificities was observed 
using different instrumentation and detection methods (iCycler and SybrGreen, 
respectively; BioRad, data not shown). These data indicated that our A3 qPCR assays 
could be applied to a range of experimental questions. 
 
 
APOBEC3 expression profiles in permissive and non-permissive T cell lines 
 Three groups independently discovered A3G in 2002 (Harris et al., 2002; Jarmuz 
et al., 2002; Sheehy et al., 2002). One of these studies was based on the observation that 
there are two distinct phenotypes in human T cell lines with respect to Vif-deficient HIV-
1 infection (Gabuzda et al., 1992; Sheehy et al., 2002; Strebel et al., 1987; von Schwedler 
et al., 1993). Cell lines such as CEM and H9 are resistant to infection by Vif-deficient 
viruses and, accordingly, are termed non-permissive. On the other hand, cell lines such as 
CEM-SS (a clonal derivative of CEM) and SupT1 support HIV-1 replication in the 
presence or absence of Vif and are thus deemed permissive. A3G was originally 
identified as the dominant restriction factor whose presence accounted for the non-
permissive phenotype of CEM cells in comparison to its permissive daughter line, CEM-
SS. Since then, overexpression of several A3 family members has been shown to render 
CEM-SS non-permissive to Vif-deficient HIV replication [e.g., (Haché et al., 2008; 
Sheehy et al., 2002); reviewed by (Albin and Harris, 2010; Chiu and Greene, 2008; 
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Goila-Gaur and Strebel, 2008; Hultquist and Harris, 2009; Malim and Emerman, 2008a)]. 
Despite the elegance of this permissive and non-permissive dichotomy, the full nature of 
the Vif-deficient HIV-1 replication defect on non-permissive cells has not been 
elucidated. In other words, which A3s are required for HIV-1 restriction in non-
permissive cells: A3G or some combination of A3G and these other A3 proteins?  
To shed additional light on this important question, we profiled the expressed A3 
repertoire in the two related cell lines, non-permissive CEM and permissive CEM-SS. 
These cell lines were used to clone A3G by subtractive hybridization (Sheehy et al., 
2002) and, as expected, A3G mRNA levels were 12-fold higher in the non-permissive 
line CEM (Figure 2-2A). However, levels of A3B, A3C, A3D, and A3F were also 
significantly higher than those in CEM-SS, by 19-, 2-, 3-, and 28-fold, respectively. 
These observations suggest that other A3s, in addition to A3G, may contribute to Vif-
deficient HIV-1 restriction in CEM. However, the presence of significant A3C mRNA 
levels in CEM-SS is concordant with it alone not being sufficient to restrict the 
replication of Vif-deficient HIV-1 (Bishop et al., 2004; Yu et al., 2004a). 
Further consistent with the possibility that multiple A3s contribute to the non-
permissive phenotype, the non-permissive T cell line H9 was also found to express 
multiple A3 mRNAs at levels well beyond those in permissive cells (Figure 2-2B). A3C, 
A3D, A3F, A3G, and A3H were 2-, 8-, 16-, 19-, and 1000-fold above those in CEM-SS 
cells, respectively. In contrast to CEM cells, A3B was virtually absent, and A3H was well 
expressed (considered further below). Notably, the expression levels of all seven A3 
genes were extremely low and approaching detection limits in the permissive line 
SupT11. Thus far, SupT11 is the only T cell line that we have found that is practically 
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devoid of A3 gene expression. The molecular explanation for this is not known, but it is 
not due to deletion of the locus because specific qPCR products are still detected. 
 
APOBEC3 expression profiles in primary leukocytes 
 Next we sought to define the A3 repertoire in fresh, unstimulated peripheral blood 
mononuclear cells (PBMCs) (Figure 2-2B). Multiple A3s were expressed in PBMCs with 
the overall pattern resembling that of CEM and H9 non-permissive lines (significant 
levels of A3C, A3D, A3F, and A3G). However, some major differences were detected. 
First and most strikingly, PBMCs were found to express high A3A levels, which were 
approximately 5000-fold greater than CEM. These observations were consistent with 
recent reports indicating that A3A expression is specific to the CD14+ lineage, which 
includes macrophages and monocytes (Chen et al., 2006; Koning et al., 2009; Peng et al., 
2007; Stenglein et al., 2010). Second, PBMCs expressed virtually no A3B mRNA, which 
is approximately 100-fold less than CEM. Third, PBMCs expressed 4-fold more A3G 
than CEM, and 40-fold more than CEM-SS. Finally, PBMCs were found to express high 
levels of A3H, similar to those observed in H9, approximately 13-fold more than CEM, 
and nearly 1000-fold more than CEM-SS or SupT11. 
  
The expressed APOBEC3 repertoire in naïve and stimulated CD4+ T lymphocytes 
 CD4+ T lymphocytes are a major target of HIV-1. To define the expressed A3 
repertoire in this important T cell subset, we used negative selection to isolate CD4+ 
lymphocytes from fresh PBMCs (Figure 2-3A). These cells were stimulated with IL-2 
and PHA and shown to proliferate by CFSE staining and flow cytometry (Figure 2-3B). 
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T-cell stimulation caused the induction of every A3 with the exception of A3A (Figure 2-
3C). Mitogen activation had been shown previously to induce A3G expression in CD4+ 
T cells (Koning et al., 2009; Stopak et al., 2007). The increase in A3H expression levels 
is particularly remarkable, rising 22-fold over naïve levels.  
 
Several APOBEC3s are interferon-responsive 
 In response to viral infection, cytokines such as type I interferons (IFN) are 
induced, and these in turn activate the expression of hundreds of genes. Several A3s have 
been shown to be IFN-responsive, but only two reports have considered the entire A3 
repertoire and procedures have varied considerably [(Argyris et al., 2007; Bonvin et al., 
2006; Chen et al., 2006; Koning et al., 2009; Peng et al., 2007; Stenglein et al., 2010; 
Tanaka et al., 2006; Vetter et al., 2009; Wang et al., 2008); see Discussion]. To extend 
this work, fresh PBMCs were treated with leukocyte IFN and the resulting A3 mRNA 
levels were quantified by qPCR (Figure 2-4A). In bulk PBMCs, A3A was clearly 
induced, in agreement with prior reports (Koning et al., 2009; Peng et al., 2006; Stenglein 
et al., 2010; Taylor et al., 2004). The other A3s were also found to be upregulated but to 
lesser extents.  
We next examined the effects of IL-2, PHA, and IFN on A3 expression in naïve 
and stimulated CD4+ T cells (Figure 2-4B). As shown above, the T cell mitogens IL-2 
and PHA induced the mRNA levels of all of the A3s except A3A (compare Figure 2-3C 
and Figure 2-4B). In contrast, IFN treatment did little to alter these expression profiles. 
Thus, the A3s in CD4+ T lymphocytes are not IFN inducible, whereas the A3s in at least 
one other PBMC cell type are IFN-responsive. Based on recent reports, CD14+ 
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phagocytic cells such as monocytes and macrophages are likely to be the only leukocyte 
subset in which A3 expression is IFN-inducible [(Koning et al., 2009; Peng et al., 2006; 
Stenglein et al., 2010; Taylor et al., 2004) and data not shown]. 
 
APOBEC3 expression profile in human tissues 
 An important question with respect to A3 expression is whether or not it is 
confined to immune cell compartments. To help address this issue, we quantified the 
expressed A3 repertoire of twenty normal human tissues. Two cell lines, CEM and 
SupT11, and fresh PBMCs were assayed in parallel to facilitate comparisons with our 
other data sets. Several interesting observations emerged from these studies (Figure 2-5). 
First, consistent with central roles in innate immunity, A3 expression levels were 
high in lymphoid organs such as the thymus and spleen. The thymus, which is rich in T 
lymphocytes, has an expressed A3 repertoire similar to that of primary CD4+ T cells: low 
A3A and A3B, high A3C, A3D, A3F, A3G, and A3H  (compare Figure 2-5 and Figure 2-
3C). The spleen is rich in both B and T lymphocytes, but it is also a major reservoir for 
undifferentiated monocytes (Swirski et al., 2009). This helped reconcile observations 
showing that the spleen has relatively high levels of all seven A3s, consistent with 
previous observations indicating that A3A is restricted to CD14+ cells including 
monocytes (Koning et al., 2009; Peng et al., 2006; Stenglein et al., 2010). 
 Second, many A3s were clearly expressed outside of the blood compartment or 
common immune tissues. For example, five of seven A3s showed peak expression levels 
in lung tissue: A3A, A3B, A3C, A3D, and A3H. The most remarkable was A3A, which was 
detected at levels 70-fold higher in the lung than the median value from all 20 tissues. 
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This observation is consistent with large numbers of CD14+ macrophages residing in 
lung alveoli. A bronchoalveolar lavage cell preparation from a non-smoking individual 
yields 1 x 107 cells, of which 90-95% are macrophages (Daniele et al., 1977). In addition, 
A3A was expressed in adipose tissue at levels 5-fold higher than the median value. This 
level is compatible with the finding that adipose from an obese individual is 40% 
macrophages by weight (Weisberg et al., 2003). Also of note is A3 expression in the 
ovary. Levels of A3C, A3F, and A3G were 3-, 5-, and nearly 3-fold higher, respectively 
than median values from the other tissues. This may indicate a requirement for viral and 
transposable element restriction in female germ cells [e.g., (Stenglein and Harris, 2006)]. 
 Finally, some tissues expressed virtually no A3s. The brain and the testes, for 
instance, had low A3 levels comparable to those of SupT11 (compare Figure 2-5 and 
Figure 2-2B). These are largely immune privileged organs that are physically separated 
from other tissues and from potential pathogen infections by the blood-brain barrier and 
the blood-tubular barrier, respectively. The apparent A3 expression deficiency in these 
tissues may also be due in part to the absence of appropriate gene expression activators 
such as interferons, cytokines, and/or growth factors. 
 
Strong correlations between APOBEC3 mRNA and protein expression levels 
 To ask whether the observed APOBEC3 mRNA levels correlate with protein 
levels, we separated cell extracts by SDS-PAGE and probed the resulting blots with 
antibodies raised against A3F and A3G (Figure 2-6). The A3F polyclonal antibody is 
specific to the best of our knowledge [(Haché et al., 2008; Holmes et al., 2007) and 
unpublished observations]. The A3G polyclonal antibody is semi-specific as it reacts with 
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both A3A and A3G, but these proteins are distinguishable by size (Koning et al., 2009; 
Newman et al., 2005; Stenglein et al., 2010).  
 In strong agreement with our qPCR data and many prior studies, A3F and A3G 
protein levels are considerably lower in CEM-SS than they are in the non-permissive 
lines CEM [e.g., Figure 2-6A; (Hache and Harris, 2009; Haché et al., 2008)]. The low 
but still measurable levels of A3G in the CEM-SS population also enabled quantification 
by densitometry, revealing a 5- to 10-fold difference at the protein level between these 
two lines. This value closely resembles the 10-fold difference in A3G mRNA levels 
between CEM and CEM-SS (Figure 2). In further agreement with our qPCR data, A3G 
protein was too low to detect by immunoblotting in SupT11 and approximately 1.6-fold 
higher in H9 than CEM. As for A3F, nearly equivalent protein levels were observed in 
H9 and CEM, and it was undetectable in SupT11 and CEM-SS (Figure 2-2 and Figure 
2-6A). Finally, we compared the protein expression of A3F and A3G in primary CD4+ T 
lymphocytes under naïve and stimulated conditions. Consistent with our qPCR data, A3F 
was induced slightly and A3G levels increased approximately 2-fold upon T cell 
stimulation (Figure 2-3C and Figure 2-6B). Overall, we conclude that strong 
correlations are evident between the qPCR results and the immunoblot data. 
 
 
DISCUSSION 
 Despite remarkable progress identifying A3 restriction substrates such as HIV-1, 
transposons, and foreign DNA, the overarching biological functions of the A3 repertoire 
are still being elucidated [(Esnault et al., 2005; Sheehy et al., 2002; Stenglein et al., 
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2010); reviewed by (Chiu and Greene, 2008; Goila-Gaur and Strebel, 2008; Hultquist and 
Harris, 2009; Malim and Emerman, 2008a)]. What events drove the rapid expansion of 
the A3 locus to encode seven A3 proteins, and a total of eleven zinc-coordinating 
domains? Does each A3 protein serve some unique, divergent function or do they serve 
the same function only in different places and/or at different times? How much 
redundancy exists? How much specificity? How much of this is governed by 
transcriptional programs? To begin to address the latter question, in particular, here we 
report qPCR assays that enable the specific and quantitative detection of the entire seven 
gene human A3 repertoire. We have improved on previous commercial methods by 
reporting the identity, specificity and efficiency of each A3 primer/probe set, by 
demonstrating the assay’s functionality and usefulness across detection platforms and, 
most importantly, by quantifying A3 expression in multiple human tissues and cell types. 
During the course of completing our experiments, an independent study on A3 expression 
in hematopoietic cells and tissues was published by Koning et al. (Koning et al., 2009). 
These two studies are largely complementary, but some differences merit discussion. 
 The first point is technical. We developed our own qPCR assays and, as such, 
were able to ensure target specificity and near identical reaction efficiencies (Figure 2-1). 
We also report the nucleotide sequences of the primers and probes so the assays are fully 
compatible with many different qPCR methods and instruments (Table 2-1). In contrast, 
Koning et al. used proprietary primers and probes from Applied Biosystems, which are 
optimized for specific reagents and instrumentation and less readily adaptable to other 
platforms. Knowledge of the primer binding sites is also crucial for detecting and 
ultimately ascertaining the function of alternatively spliced A3 variants. 
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 Second, our study uniquely focuses on the question of which A3s are expressed in 
such a manner that they may contribute to HIV-1 restriction in vivo. The observation that 
the non-permissive T cell lines CEM and H9 express significantly higher levels of A3G 
and A3F is not surprising (Figure 2-2). However, what is notable is that six A3s (i.e., all 
but A3A) are expressed at higher levels in these non-permissive cell lines. The 
constitutive A3 repertoire in H9 appears remarkably similar to the induced repertoire in 
stimulated, primary CD4+ T lymphocytes (Figures 2-2B and 2-3C). A3H levels, in 
particular, increase over 20-fold upon T cell stimulation with IL-2 and PHA. Together 
with prior cell culture overexpression studies indicating that A3H can restrict HIV-1 in a 
Vif susceptible manner (Dang et al., 2008; Harari et al., 2009; Li et al., 2010; OhAinle et 
al., 2008; OhAinle et al., 2006; Tan et al., 2009), our expression data strengthen the case 
that A3H may contribute to HIV-1 restriction in vivo. In contrast, a role for A3A in HIV-
1 restriction in CD4+ T cells is unlikely, because it is not expressed in this cell type and it 
does not restrict Vif-deficient HIV-1 in overexpression experiments [this study and 
(Bishop et al., 2004; Chen et al., 2006; Koning et al., 2009; Stenglein et al., 2010)]. 
Unambiguously testing the involvement of other A3s in HIV-1 restriction, in addition to 
A3F and A3G, will require much further work. 
 Third, based on an extensive survey of A3 expression in 20 tissues, we conclude 
that the A3 mRNAs are expressed broadly and not confined to cells of the immune 
compartment (although there is clearly some bias to immune cell types; Figure 2-5). For 
example, adipose, colon, cervix, bladder, and the heart all express at least two A3s at 
levels 2-fold above the median among all tissues. In partial contrast, Koning et al. 
concluded that, apart from germ cell tissues, A3 expression is confined to the 
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hematopoietic compartment and that their detection in many tissues is simply due to 
infiltrating leukocytes (Koning et al., 2009). This is likely the case for some tissues such 
as lung and adipose where significant numbers of A3A-expressing macrophages are 
found. Although the true breadth of A3 expression in human tissues (and a different 
developmental stages) will not be fully appreciated until suitably specific 
immunohistochemistry antibodies are developed, at least two additional lines of evidence 
support the likelihood that A3s are expressed broadly. First, as noted by Koning et al and 
as is also evident in our data sets, the A3G mRNA levels typically exceed those of A3F in 
PBMCs and in specific leukocyte types [Figures 2-3C, 2-4 and 2-5 and (Koning et al., 
2009)]. This ratio is inverted in some tissues such as the cervix, colon and ovary, strongly 
suggesting that immune cell infiltration is not the whole story [Figure 2-5 and (Koning et 
al., 2009)]. Second, many clonally derived cancer cell lines of non-immune cell origins 
have been shown to express multiple human A3s, such as colorectal hepatocarcinoma, 
adenocarcinoma, melanoma, and lung carcinoma lines [(Bonvin et al., 2006; Harris et al., 
2002; Henry et al., 2009; Jarmuz et al., 2002; Jost et al., 2007; Kock and Blum, 2008; 
Liddament et al., 2004) and www.oncomine.org]. It is possible that A3 expression 
switches on at some stage during oncogenesis, but given the abundance of A3s in cancer 
cell lines it is likely that part of this reflects the normal gene expression program that 
existed prior to immortalization. Thus, the broad and apparently constitutive A3 
expression profile of many human tissues is consistent with a general role for A3 proteins 
in innate immunity. Substrates may not only include endogenous and exogenous 
retroelements, but also DNA viruses and even naked, foreign double-stranded DNA [e.g., 
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(Narvaiza et al., 2009; Stenglein et al., 2010; Suspène et al., 2005a; Vartanian et al., 
2008)].  
Fourth, our data and those of Koning et al. are somewhat discordant on the 
relative difference between A3G and A3F expression levels. They concluded that the 
A3G mRNA levels are 10-fold higher than those of A3F (Koning et al., 2009). In 
contrast, we did not observe such a large expression bias. In some tissues such as lung we 
observed a modest bias in favor of A3G. Conversely, in other tissues such as the colon 
and ovary, we observed a slight bias toward A3F. However, in general, we observed that 
A3F and A3G levels are fairly similar and that these mRNAs are invariably expressed 
together. Our data are consistent with prior A3F and A3G multi-tissue northern blot 
results and the fact that the promoter regions of A3F and A3G are 96% identical over a 
5kb region including exons 1 and 2 (Liddament et al., 2004). We favor a model in which 
A3F and A3G are coordinately expressed [proposed originally by (Liddament et al., 
2004)]. A greater understanding of the promoters and their associated transcription 
factors will help provide future tests of this model. It is possible that differences between 
the results reported here and the literature are due to protocol differences such as random 
primed versus oligo-dT mediated cDNA synthesis, the latter being much less efficient 
and susceptible to repetitive elements in 3’ UTRs, and/or to imperfect PCR reaction 
efficiencies (e.g., Figure 2-S2).  
 On a strong complementary note, a major point detailed here and in the study by 
Koning and coworkers is the inducibility of A3 mRNA expression. Several prior studies 
have examined the IFN-responsiveness of the A3s and particularly A3G and the 
conclusions have been variable (Argyris et al., 2007; Bonvin et al., 2006; Chen et al., 
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2006; Koning et al., 2009; Peng et al., 2006; Stenglein et al., 2010; Tanaka et al., 2006; 
Wang et al., 2008). However, in agreement with Koning and coworkers, our data indicate 
that none of the A3s are induced by IFN in primary CD4+ T lymphocytes (Figure 2-4B). 
Small increases in A3 expression, such as for A3A, can be attributed readily to a few 
contaminating CD14+ cells in the T lymphocyte preparations. Rather, the strong IFN 
responsiveness of the A3s, highlighted by A3A, may be a property of other blood cell 
lineages such as CD14+ monocytes and macrophages (Chen et al., 2006; Koning et al., 
2009; Stenglein et al., 2010). We also found that T cell activation with IL-2 and PHA 
causes the induction of 6/7 A3s [i.e., all but A3A; Figure 2-4B and (Koning et al., 2009; 
Stopak et al., 2007)]. These studies combine to indicate that cells have multiple 
mechanisms to regulate A3 expression. Thus, in addition to constitutive expression of 
most of the A3 repertoire in many cell types and tissues, transcriptional regulation is 
likely to have a major role in ultimately determining the efficacy and potency of A3-
dependent defenses against viral and non-viral challenges. 
Overall, turning back to the question of HIV-1 restriction, our studies are 
consistent with A3F, A3G, and potentially several other A3s being important in CD4+ T 
lymphocytes. A3H is the most likely additional restriction factor because (i) it is 
expressed in the non-permissive T cell line H9 (Figure 2-2), (ii) it is expressed in naïve 
CD4+ cells (Figure 2-3), (iii) it is induced 20-fold by T cell activation (Figure 2-3), and 
(iv) it is capable of HIV-1 restriction in a Vif-susceptible manner (Dang et al., 2008; 
Harari et al., 2009; Li et al., 2010; OhAinle et al., 2008; OhAinle et al., 2006; Tan et al., 
2009). Although the literature overwhelmingly favors a role for A3G in HIV-1 
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restriction, with A3F a distant second, A3H and several of the other A3s warrant 
substantive additional investigation.  
 
 
MATERIALS AND METHODS 
Cell lines 
Human T cell lines were cultured in RPMI (Thermo-Fisher) supplemented with 10% fetal 
bovine serum (Denville). SupT1 and H9 were obtained from the AIDS Research and 
Reference Reagent Program. SupT11 is a sub-clone of SupT1 obtained by limiting 
dilution. CEM and CEM-SS were described (Haché et al., 2008).  
 
Enrichment and culture of primary cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from blood (Memorial Blood 
Center, St. Paul, MN) by Ficoll-Paque gradient centrifugation (GE Healthcare). The 
resulting buffy coat was subjected to negative selection to enrich for naïve primary CD4+ 
T cells (Miltenyi Biotech). Primary cells were cultured in RPMI supplemented with 10% 
FBS and stimulated to proliferate with 50 U ml-1 recombinant interleukin-2 (IL-2; 
Sigma), and 10 µg ml-1 phytohemagglutinin (PHA; Fisher Healthcare). To confirm 
proliferation, 106 cells were stained with 10 µM carboxyfluorescein diacetate, 
succinimidyl ester (CFSE) according to the manufacturer (Invitrogen) and analyzed by 
flow cytometry. PBMCs and CD4+ T cells were treated with 2 ng ml-1 universal type I 
interferon (R&D Systems).  
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RNA preparation 
PBS-washed cells were prepared for RNA isolation by lysis in ice-cold buffer RLT 
(Roche) supplemented with 10 µl ml-1 2-mercaptoethanol (Sigma). RNA was isolated 
using the RNeasy kit (Qiagen). Two optional components of the kit, QiaShredder and on-
column DNase digestion, were used to homogenize lysates and remove genomic DNA. 
RNA concentrations were determined spectroscopically and RNA quality was assessed 
by gel analysis (Figure 2-S1). Total RNA from 20 distinct tissues, each from a minimum 
of 3 donors, was purchased from Ambion. The control qPCRs for housekeeping genes 
(below) were similarly efficient for all RNA preparations, indicating equally high 
qualities and integrities. 
 
cDNA synthesis  
1 µg of total RNA was used to synthesize cDNA using avian myeloblastosis virus reverse 
transcriptase (AMV RT; Roche) and random hexameric primers. We found that random 
hexamer mRNA priming was preferable to oligo-dT priming, which resulted in 
inefficient synthesis of some A3 cDNAs, particularly A3D and A3F, most likely because 
of their long, repeat-rich 3’ untranslated regions (UTRs) (Figure 2-1A and Figure 2-S2). 
cDNA synthesis reactions were performed by mixing 3 µl of 333 µM random hexamer 
primer (50 µM final concentration) with 1 µg of total RNA diluted in 10 µl of RNase-free 
water. This mixture was heated for 10 minutes at 65˚C to remove RNA secondary 
structure and then cooled briefly on ice. 7 µl of master mix containing 0.5 µl Protector 
RNase inhibitor (Roche), 0.4 µl AMV RT, 4 µl 5x AMV RT reaction buffer, and 2.1 µl 
dNTPs (Roche, 10 mM each; ~1 mM each final concentration) were then added to these 
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reactions, which were subsequently incubated at 25˚C for 10 min, 42˚C for 1 hour, then 
95˚C for 5 min. Reactions were then diluted by addition of 80 µl RNase-free H2O, and 
used in qPCR reactions.  
 
Quantitative PCR 
cDNAs levels were quantified by PCR using a Roche Lightcycler 480 instrument 
according to the manufacturer’s protocols. Reactions were performed in 96 well plates 
with each containing 7.5 µl 2x probe master mix (Roche), 1.25 µl H2O, 1.05 µl primers 
(5 µm each), 0.2 µl UPL probe (Roche), and 5 µl cDNA (prepared as above). Reactions 
were incubated at 95˚C for 10 min, then 40 cycles of 95˚C for 10 sec, 58˚C for 15 sec, 
then 72˚C for 2 sec. Table 2-1 lists the full sequences of all primers and probes used in 
this study; the design rationale and validation experiments are described below. The PCR 
cycle at which amplification was detectable above a background threshold (threshold 
cycle, or Ct) was calculated with the maximum second derivative method using the 
Lightcycler 480 software (Roche, version 1.5.0). cDNA was synthesized and qPCR 
performed in triplicate for each sample, and the mean values and standard deviations for 
each triplicate are reported. 
 
Primer Design 
Primer pairs were designed to avoid inter-A3 identity and only amplify the intended A3 
target (Figure 2-1A, Figure 2-S2, Table 2-1, and Table 2-S1). Primer pair specificity 
was verified by manually inspecting alignments of primers and A3 cDNA sequences, by 
using BLAST (version 2.2.20; http://blast.ncbi.nlm.nih.gov/) and Primer-BLAST 
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software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/; default parameters except E 
set to 1) and, experimentally, by attempting to amplify 104 copies of every A3 control 
template with each set of A3 qPCR primers (Figure 2-1B). Primers were additionally 
designed to have similar melting temperatures (Table 2-1) and were confirmed to have 
similar reaction efficiencies (Figure 2-1C and see below). Furthermore, primers were 
designed such that they would amplify all described variants of each A3 mRNA (i.e., 
splice variants and SNPs; data not shown). Design was assisted by the Roche 
ProbeFinder software (version 2.43; http://qpcr.probefinder.com/roche3.html) and by 
Primer3 software (version 0.4.0; (http://primer3.sourceforge.net/). 
 
Data Analysis 
Expression level normalization: A3 expression data were normalized to the expression of 
TATA-box binding protein (TBP; see below). Essentially identical normalized results 
were obtained using ribosomal protein 13A (RPL13A), or hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) (data not shown). None of these controls showed 
altered expression levels upon treatment of cells with IL-2, PMA and/or IFN. 
Determination of reaction efficiencies: For all assays, the primer efficiency was 
determined using serial dilutions of control templates (e.g., Figure 2-1C). The control 
templates consisted of portions of the 5’ UTRs and coding regions of the A3 cDNAs 
amplified by PCR and cloned into pCR2.1-TOPO (Invitrogen). The same templates were 
used to validate assay specificity (Figure 2-1B). These plasmids were linearized by 
digestion with XmnI or BglII, phenol-chloroform extracted, ethanol precipitated, and the 
DNA concentration was determined spectroscopically. Ten-fold serial dilutions of these 
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plasmids were prepared with 101-108 plasmid molecules per 5 µl. These dilutions were 
used as templates in qPCR reactions. Ct values were plotted against the log10 number of 
template molecules in each reaction (Figure 2-1C), and the slope of this line determines 
the reaction efficiency according to the equation: efficiency = 10(-1/slope) (Pfaffl, 2001). 
Reaction efficiencies were also calculated from the actual amplification curves from 
several experiments (Peirson et al., 2003). Reaction efficiencies calculated by these two 
methods agreed closely (data not shown). 
The reaction efficiencies (E) determined in this manner were then used to 
calculate relative expression levels between two samples (S1 and S2), normalized to a 
reference gene (ref, TBP), according to published methods (Pfaffl, 2001): 
∆Ct(A3) = CtA3,S1 - CtA3,S2 
∆Ct(ref) = Ctref,S1 - Ctref,S2 
Relative Expression = (EA3)-∆Ct(A3) / (Eref)-∆Ct(ref) 
 
Immunoblotting 
Cells were cultured and/or isolated as described above, washed in PBS and lysed in 0.2% 
NP40 buffer with 1x EDTA-free protease inhibitor mixture (Roche). Proteins were 
subjected to ice-cold acetone precipitation prior to quantification (Bio-Rad). An equal 
amount of protein was fractionated on a 10% SDS-polyacrylamide gel and transferred to 
a PVDF membrane (Millipore). Membranes were blotted with antibodies specific to A3F, 
A3G, or tubulin (Covance). The A3F and A3G polyclonal antibodies were obtained from 
the AIDS Research and Reference Reagent Program courtesy of M. Malim (Kings 
College London) and J. Lingappa (University of Washington), respectively (Holmes et 
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al., 2007; Newman et al., 2005). Band intensities were quantified using Image J software 
(NIH). 
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FIGURES 
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Figure 2-1. A panel of quantitative PCR assays to monitor APOBEC3 mRNA levels. (A) 
Overview of A3 mRNA features. Each A3 mRNA is depicted to scale except 2100 
nucleotides of the A3F 3’ UTR are not shown. Inter-A3 regions of 90% or greater identity 
over >18 nucleotides are highlighted in color.  
(B) A histogram depicting the results of running each A3 qPCR assay against each of the 
seven A3 cDNA control templates.  
(C) A graph showing the A3 qPCR assay amplification ranges and efficiencies. The mean 
and standard deviation of two independent experiments each consisting of three replica 
reactions is shown (in most instances the error is smaller than the symbol). 
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Table 1.  APOBEC3 qPCR primers and probes. 
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Figure 2-2. APOBEC3 expression in human T cell lines and naïve PBMCs. (A) A3 
expression in the permissive T cell line CEM-SS and the non-permissive line CEM. 
Mean values and standard deviations of three independent qPCR reactions are shown for 
each condition. Expression is normalized to the reference gene TBP and the level of 
CEM-SS A3G is set to 1 to facilitate comparison (denoted by the asterisk).  
(B) A3 expression in the permissive T cell lines SupT11 and CEM-SS in comparison to 
non-permissive lines CEM and H9. The expressed A3 repertoire in PBMCs is shown for 
comparison (data from an independent experiment in which CEM and CEM-SS yielded 
results similar to those shown here). The experimental parameters are identical to those 
used in panel A.  
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Figure 2-3. APOBEC3 expression in naïve and stimulated CD4+ lymphocytes. (A) Flow 
cytometry histograms depicting the results of CD4+ lymphocyte purification by negative 
selection.  
(B) Flow cytometry histograms of CFSE-labeled cells 4 days after mock or IL-2/PHA 
treatment, naïve and stimulated, respectively.  
(C) A3 expression in naïve and 3 day stimulated CD4+ lymphocytes. Data from CEM are 
shown for comparison. Expression is normalized to TBP and the level of A3H in CEM is 
set to 1 (denoted by the asterisk). Mean values and standard deviations of three 
independent qPCR reactions are shown for each condition. 
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Figure 2-4. IFN induces APOBEC3 expression in PBMCs but not CD4+ T cells. The 
relative A3 mRNA levels in (A) PBMCs and (B) CD4+ T lymphocytes treated for 48 
hours with IL-2/PHA and/or IFN. Expression is normalized to TBP and the naïve A3H 
level is set to 1 (denoted by the asterisk). Mean values and standard deviations of three 
independent qPCR reactions are shown for each condition. 
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Figure 2-5. APOBEC3 expression in human tissues. A summary of qPCR data showing 
the relative A3 mRNA levels in the indicated cells and tissues. The color scheme provides 
qualitative information, as the full range of blue (low expression) to red (high expression) 
color is used for each row of data. The inset numbers represent the relative levels of each 
A3 mRNA across the panel with the median value in each row set to 1. Since the assay 
efficiencies are almost identical (Figure 1C), these quantitative data can be used to 
compare any of the values within the table. Three replicas were done for each condition 
and the average values were used to construct the table (the errors were less than 10% 
and are not shown for simplicity). 
 
  
	  
	   67	  
 
Figure 2-6. APOBEC3 immunoblots. (A) T cell line or (B) primary CD4+ lymphocyte 
(IL-2/PHA or mock treated) protein extracts were examined by immunoblotting with 
antibodies specific to A3F or A3G. The blots were stripped and re-probed with anti-
tubulin to control for protein loading. 
 
 
 
 
 
  
	  
	   68	  
 
Figure 2-S1. Formamide agarose gel analysis of representative total RNA preparations 
from the indicated cell lines (10 µg/lane). The large and small ribosomal RNAs are 
indicated. 
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Figure 2-S2. A comparison of qPCR results using cDNA templates primed by poly-dT or 
random hexamers. See the main text and methods for details.  
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Table 2-S1. APOBEC3 qPCR primer specificities  
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CHAPTER 3 
 
 
Endogenous Origins of HIV-1 G-to-A Hypermutation and Restriction in the 
Nonpermissive T Cell Line CEM2n 
 
 
 
 
Reprinted with permission from: Eric W. Refsland, Judd F. Hultquist, and Reuben S. 
Harris. (2012) PLoS Pathogens 8:e1002800. 
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FOREWORD 
 HIV uses its accessory protein Vif to shield itself from lethal mutagenesis by 
cellular APOBEC3 proteins. The APOBEC3-Vif interaction is therefore a promising 
target for drug development, and a clear definition of all proteins involved on both sides 
of this critical host-pathogen conflict is crucial. However, apart from APOBEC3G, 
conflicting over-expression studies have been published on the six other human 
APOBEC3s, some supporting and some refuting each protein’s involvement in HIV 
restriction. Here, we use a combination of gene targeting and RNA interference to define 
the endogenous sources of Vif-deficient HIV restriction and G-to-A hypermutation in a 
nonpermissive T cell line. As anticipated, APOBEC3G contributed partially to restriction 
and proved to be the source of hypermutations at 5’GG dinucleotides. However, a major 
and unexpected role for APOBEC3D became evident in the APOBEC3F-null 
background, with both proteins combining to suppress viral infectivity and form 
hypermutations at 5’GA dinucleotides. We conclude that endogenous levels of 
APOBEC3D, APOBEC3F, and APOBEC3G act redundantly to restrict Vif-deficient HIV 
and produce the two hallmark dinucleotide hypermutation patterns observed in patient-
derived viral sequences. Therapeutic strategies that unleash this full ‘swarm’ of restrictive 
APOBEC3 proteins are likely to be more effective than those that focus on enabling a 
single enzyme. 
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SUMMARY 
 The DNA deaminase APOBEC3G converts cytosines to uracils in retroviral 
cDNA, which are immortalized as genomic strand G-to-A hypermutations by reverse 
transcription. A single round of APOBEC3G-dependent mutagenesis can be catastrophic, 
but evidence suggests that sublethal levels contribute to viral genetic diversity and the 
associated problems of drug resistance and immune escape. APOBEC3G exhibits an 
intrinsic preference for the second cytosine in a 5’CC dinucleotide motif leading to 
5’GG-to-AG mutations. However, an additional hypermutation signature is commonly 
observed in proviral sequences from HIV-1 infected patients, 5’GA-to-AA, and it has 
been attributed controversially to one or more of the six other APOBEC3 deaminases. An 
unambiguous resolution of this problem has been difficult to achieve, in part due to 
dominant effects of protein over-expression. Here, we employ gene targeting to dissect 
the endogenous APOBEC3 contribution to Vif-deficient HIV-1 restriction and 
hypermutation in a nonpermissive T cell line CEM2n. We report that APOBEC3G-null 
cells, as predicted from previous studies, lose the capacity to inflict 5’GG-to-AG 
mutations. In contrast, APOBEC3F-null cells produced viruses with near-normal 
mutational patterns. Systematic knockdown of other APOBEC3 genes in an APOBEC3F-
null background revealed a significant contribution from APOBEC3D in promoting 
5’GA-to-AA hypermutations. Furthermore, Vif-deficient HIV-1 restriction was strong in 
parental CEM2n and APOBEC3D-knockdown cells, partially alleviated in APOBEC3G- 
or APOBEC3F-null cells, further alleviated in APOBEC3F-null/APOBEC3D-knockdown 
cells, and alleviated to the greatest extent in APOBEC3F-null/APOBEC3G-knockdown 
cells revealing clear redundancy in the HIV-1 restriction mechanism. We conclude that 
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endogenous levels of APOBEC3D, APOBEC3F, and APOBEC3G combine to restrict 
Vif-deficient HIV-1 and cause the hallmark dinucleotide hypermutation patterns in 
CEM2n. Primary T lymphocytes express a similar set of APOBEC3 genes suggesting that 
the same repertoire may be important in vivo. 
 
 
INTRODUCTION 
 Human cells can express up to seven APOBEC3 (A3) proteins: A3A, A3B, A3C, 
A3D, A3F, A3G, and A3H (Koning et al., 2009; Refsland et al., 2010). A3G is the 
archetypal restriction factor, capable of restricting Vif-deficient HIV-1 (hereafter HIV) 
by packaging into viral cores and then suppressing reverse transcription and deaminating 
viral cDNA cytosines to uracils (C-to-U) (reviewed by (Albin and Harris, 2010; Malim 
and Emerman, 2008a)). The hallmark of A3G activity is viral genomic plus-strand G-to-
A mutations within 5’GG-to-AG dinucleotide motifs, which reflects its minus-strand 
5’CC-to-CU preference (Harris et al., 2003; Yu et al., 2004a). However, HIV single-cycle 
and spreading infection experiments have yet to provide an overall consensus to explain 
the additional 5’GA-to-AA dinucleotide bias that is also commonly found in patient-
derived viral sequences (Caride et al., 2002; Fitzgibbon et al., 1993; Gandhi et al., 2008; 
Janini et al., 2001; Wood et al., 2009). In fact, over-expression studies have implicated all 
six of the other A3 proteins in generating this mutation pattern, with multiple studies for 
and against each enzyme (reviewed by (Albin and Harris, 2010)). For example, despite 
several early studies strongly implicating A3F as a major source of the 5’GA-to-AA 
mutations ((Bishop et al., 2004; Liddament et al., 2004; Wiegand et al., 2004; Zheng et 
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al., 2004) and nearly twenty more thereafter), two recent papers have questioned its 
relevance to HIV restriction and hypermutation (Miyagi et al., 2010; Mulder et al., 2010). 
The data are even murkier and more conflicting for the other five human APOBEC3 
proteins (reviewed by (Albin and Harris, 2010); summarized in Discussion). 
Three major problems have made it difficult to address which endogenous A3 
proteins cause HIV restriction and hypermutation. First, most prior studies have relied on 
transient or stable over-expression of a single A3 coupled to assays for viral infectivity 
and hypermutation. Although powerful for answering some questions, over-expression of 
a dominant and active DNA deaminase may overwhelm regulatory mechanisms and 
adversely affect the cell, result in nonspecific packaging into the virus, and create 
sequence artifacts by gratuitous deamination of non-productive viral replication 
intermediates. Most over-expression approaches are complicated further by being done in 
HEK293 (kidney) or HeLa (cervical) cells, which may not recapitulate as many aspects 
of restriction and/or viral replication as CD4+ T cell lines. Even best attempts to stably 
express physiological levels of APOBEC3 proteins in permissive CD4+ T cell lines are 
imperfect, because each A3 is expressed without other family members (i.e., out of 
normal endogenous context) and the expression of each protein is driven by heterologous 
promoters with foreign 5’ and 3’ untranslated sequences that are unlikely to be 
responsive to cellular signaling pathways triggered by viral infection and/or interferon 
signaling (Albin et al., 2010a; Haché et al., 2008; Hultquist et al., 2011; Mariani et al., 
2003b; Miyagi et al., 2010; Miyagi et al., 2007; Schumacher et al., 2008). Second, the 
seven human A3 genes share high levels of nucleotide identity, which has hindered the 
development of gene-specific quantitative real-time (Q)-PCR assays and knockdown 
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reagents. This problem is in the midst of being overcome with the development of robust 
Q-PCR assays (Koning et al., 2009; Refsland et al., 2010) and the creation of gene-
specific knockdown constructs (this study and (Berger et al., 2011; Kamata et al., 2009; 
Wissing et al., 2011)). Finally, the field has yet to benefit from a robust genetic system, 
because HIV does not replicate in mouse models and the vast majority of human somatic 
cell lines are polyploid and/or difficult to engineer.  
In this study, we use gene targeting and knockdown experiments to systematically 
interrogate the impact of the endogenous A3 repertoire on Vif-deficient HIV replication 
in the near-diploid T cell line CEM2n. Null clones demonstrated that A3G is solely 
responsible for HIV 5’GG-to-AG hypermutations. A3F-null clones inflicted near-normal 
hypermutation patterns in Vif-deficient HIV, demonstrating that this enzyme alone is not 
responsible for 5’GA-to-AA hypermutations. Systematic depletion of other expressed A3 
mRNAs in the A3F-null background revealed an unanticipated, major role for A3D in 
generating 5’GA-to-AA hypermutations and restricting Vif-deficient HIV replication. We 
conclude that endogenous A3D and A3F combine to generate hallmark 5’GA-to-AA 
hypermutations and A3G generates the 5’GG-to-AG hypermutations. All three enzymes 
work together to suppress Vif-deficient HIV replication and generate the classical non-
permissive phenotype. 
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RESULTS 
A New Model System for T Cell Genetics 
 The human T cell line CEM was originally isolated from a 3 year-old female with 
acute leukemia (Foley et al., 1965). It is a model T cell system for HIV research that, 
along with its derivative CEM-SS, enabled the identification of A3G as a dominant HIV 
restriction factor (Sheehy et al., 2002). However, our CEM laboratory stock proved sub-
ideal for gene targeting because it tested near tetraploid (Figure 3-S1). We noticed 
however that the original cytogenetic analyses of CEM had 47 chromosomes and a range 
of 41-95 (Foley et al., 1965). We therefore obtained an early stock of CEM (CCRF-
CEM), generated subclones by limiting dilution, and measured DNA content by flow 
cytometry. In comparison to our original CEM line, several of these subclones had half 
the DNA content and were most likely diploid (Figure 3-1A).  
 One representative subclone, hereafter called CEM2n, was selected for further 
characterization. Flow cytometry showed that CEM2n expresses high levels of CD4 and 
the HIV co-receptor CXCR4 (Figure 3-1B). CEM2n still manifests the classic non-
permissive phenotype by supporting wildtype HIV replication while restricting Vif-
deficient HIV, similar to our tetraploid non-permissive line CEM (Figure 3-1C), as 
described originally (Gabuzda et al., 1992; Sheehy et al., 2002). As anticipated by this 
phenotype, Q-PCR demonstrated expression of multiple A3 mRNAs (Figure 3-S2 & 
below). Finally, karyotype analysis showed that CEM2n is near-diploid, with a total of 47 
chromosomes, including three copies of chromosome 20 and a common T cell leukemia 
reciprocal translocation (Figure 3-1D). These characteristics indicated that CEM2n 
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would be an appropriate model system to delineate the endogenous A3s involved in HIV 
restriction. 
 
Targeted Deletion of APOBEC3G in CEM2n 
 Over 100 reports support a role for A3G in Vif-deficient HIV restriction 
(reviewed by (Albin and Harris, 2010)). A3G shows a strong bias for 5’GG-to-AG 
hypermutation, but it also has a secondary preference for 5’GA-to-AA invoking the 
formal possibility that it alone could be responsible for both dinucleotide signatures (e.g., 
(Harris et al., 2003; Yu et al., 2004b)). To address this possibility, we used two rounds of 
rAAV-mediated gene targeting to generate A3G-null derivatives. The A3G targeting 
construct replaces exon 3, which encodes the N-terminal zinc-coordinating deaminase 
domain, with a promoterless drug resistance cassette (Figure 3-2A). A correctly targeted 
A3G gene is expected to be null because transcripts originating at the A3G promoter will 
splice to an acceptor sequence within the 5’ end of the cassette and then terminate with a 
polyA sequence at the 3’ end of the cassette (i.e., the C-terminal two-thirds of the mRNA 
and protein should never be expressed). CEM2n was transduced with rAAV-A3G::Neo 
and drug resistant clones were selected with G418. PCR showed that 6/103 (5.8%) clones 
were targeted (Figure 3-S3 & Table 3-1). 
 To delete the remaining A3G allele, the drug resistance cassette was removed by 
transducing a representative clone with a Cre expressing adenovirus, and then subclones 
with a loxP-to-loxP recombination event were identified by PCR screening (Figure 3-
S3). Next, the original rAAV-A3G::Neo construct was used for a second round of gene 
targeting. 2/86 drug resistant clones were null and 4/86 were retargeted, yielding a second 
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round targeting frequency of 7.0% (Table 3-1). The A3G-null clones had undetectable 
levels of A3G mRNA and protein and, importantly, the mRNA levels of all of the 
flanking A3 genes and the A3F protein levels were largely unperturbed (Figure 3-2B & 
C). The parental CEM2n line and its A3G-null derivatives had similar morphologies and 
growth rates.  
To explore the functional consequences of deleting the endogenous A3G gene, we 
performed single-cycle infectivity assays with VSV-G pseudotyped Vif-deficient HIVIIIB. 
After one full round of replication, new viruses produced from A3G-null cells were used 
to infect CEM-GFP reporter cells and GFP fluorescence was measured 2 days later by 
flow cytometry to quantify infectivity. In comparison to the fully non-permissive parental 
line CEM2n, the A3G-null derivative lines produced viruses with approximately 10-fold 
improved infectivity (Figure 3-2D). However, these viruses were still 2-fold less 
infectious than Vif-deficient HIV produced in parallel using the related permissive T cell 
line, CEM-SS. We note that although CEM-SS is commonly accepted as permissive for 
Vif-deficient HIV replication, our recent work revealed that it expresses multiple A3s 
including low levels of A3G (Refsland et al., 2010). Thus, it is quite possible that a fully 
null derivative of CEM2n could produce even higher levels of infectious Vif-deficient 
HIV (further supported by experiments described below). Regardless, these data 
demonstrate that endogenous A3G is not the only factor contributing to Vif-deficient HIV 
restriction in CEM2n. 
 To gauge the gross level of G-to-A hypermutation in proviral DNA embedded in 
the genomes of the CEM-GFP reporter cells used above, we performed a series of 
differential DNA denaturation (3D-PCR) experiments (Hultquist et al., 2011; Suspène et 
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al., 2005b). A 511 bp region of the HIV gag-pol gene was amplified over a range of PCR 
denaturation temperatures from 77.2 to 85.5 o C and subjected to gel electrophoresis. As 
anticipated, Vif-deficient HIV proviruses derived from non-permissive T cell lines H9 
and CEM2n yielded PCR products at low denaturation temperatures, down to 78.4 and 
79.4o C, respectively, indicative of high levels of G-to-A hypermutation (Figure 3-2E). 
Vif-deficient HIV proviruses derived from CEM-SS only amplified at high denaturation 
temperatures, also as expected. In contrast, Vif-deficient proviruses derived from A3G-
null cells yielded PCR amplicons at temperatures as low as 80.4oC, suggesting major 
levels of residual hypermutation but lower than those inflicted by the full A3 repertoire in 
CEM2n.  
To examine mutational spectra, high temperature (unbiased) PCR amplicons were 
cloned and sequenced. As expected, Vif-deficient proviruses derived from the parental 
cell line CEM2n harbored extensive G-to-A hypermutations in two distinct dinucleotide 
contexts: 70% 5’GG and 30% 5’GA. This contrasted starkly to proviral sequences 
derived from A3G-null cells, in which the 5’GG-to-AG hypermutations nearly disappear 
(6%) (Figure 3-2F, Table 3-2, and Figure 3-S4). These results establish A3G as the 
major source of 5’GG-to-AG hypermutations, consistent with prior over-expression 
studies indicating that A3G is the only DNA deaminase that prefers minus strand 5’CC 
target sites (e.g., (Harris et al., 2003; Mangeat et al., 2003; Yu et al., 2004b; Zhang et al., 
2003). These mutation spectra also implicate at least one other DNA cytosine deaminase 
in restricting HIV and generating 5’GA-to-AA hypermutations. 
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Targeted Deletion of APOBEC3F in CEM2n 
 Q-PCR revealed that CEM2n cells express six of seven A3 genes, A3B, A3C, 
A3D, A3F, A3G, and A3H, all of which have been implicated in catalyzing the 5’GA-to-
AA hypermutation patterns (Figure 3-S2, Discussion, and examples (Bishop et al., 2004; 
Liddament et al., 2004; Wiegand et al., 2004; Zheng et al., 2004)). A3F was our top 
candidate because (i) A3F expression tracks with A3G in non-permissive T cell lines, 
primary lymphocytes, and secondary immune tissues (Hultquist et al., 2011; Liddament 
et al., 2004; Refsland et al., 2010), (ii) A3F is encapsidated into budding viruses and 
restricts Vif-deficient HIV when over-expressed in permissive T cell lines (Albin et al., 
2010a), (iii) Vif targets A3F for degradation (Albin et al., 2010a; Wiegand et al., 2004; 
Zheng et al., 2004), (iv) A3F restriction capability and Vif counteraction activity is 
conserved with rhesus macaque A3F and SIV Vif (Hultquist et al., 2011; Virgen and 
Hatziioannou, 2007), and (v) Vif-deficient HIV isolates that regain the capacity to 
replicate on A3F expressing cells invariably restore Vif function (Albin et al., 2010a). 
However, despite this strong evidence favoring a role for A3F in HIV restriction and 
hypermutation, recent studies have questioned its importance (Miyagi et al., 2010; 
Mulder et al., 2010). 
To determine the involvement of endogenous A3F in Vif-deficient HIV restriction 
and hypermutation, we generated A3F-null cell lines using two rounds of rAAV-mediated 
gene targeting as described above (Figure 3-3A and Figure 3-S5). A3F-null clones 
showed no detectable mRNA or protein, and the mRNA levels of all of the flanking A3 
genes and the A3G protein levels were largely unaffected (Figure 3-3B & C). Similar to 
the loss of A3G, the deletion of A3F resulted in cells semi-permissive for Vif-deficient 
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HIV (Figure 3-3D) as well as in a modest decrease in the overall level of mutation as 
gauged by 3D-PCR (Figure 3-3E). However, we were surprised to find that the 
hypermutation spectrum of Vif-deficient HIV produced in A3F-null cells was 
indistinguishable from that of the same virus produced in the CEM2n parent, retaining a 
large percentage of 5’GA-to-AA mutations (Figure 3-3F, Table 3-2, and Figure 3-S4). 
Thus, the infectivity data showed that endogenous A3F does contribute to Vif-deficient 
HIV restriction, but the hypermutation data clearly implicate at least one other 
endogenous 5’TC deaminating A3. 
 
APOBEC3D and APOBEC3F Combine to Cause 5’GA-to-AA Hypermutations 
 To identify the remaining source of the 5’GA-to-AA hypermutations, we 
developed a panel of short hairpin (sh)RNA reagents to systematically knockdown the 
expression of A3B, A3C, A3D, A3G, and A3H in the A3F-null background (Figure 3-4A). 
Knockdown efficiencies ranged from 50-80% and were specific to each intended A3 
mRNA target. These efficiencies may be even higher at the protein level due to the 
known effects of shRNA in triggering mRNA cleavage/degradation and in suppressing 
translation (Fabian et al., 2010), but this could only be confirmed for A3G due a lack of 
specific antibodies for the other A3s (Figure 3-4B). The parental CEM2n and A3F-null 
lines were transduced with non-silencing (shNS) and each of the aforementioned shA3 
constructs. Pools of shRNA expressing cells were selected with puromycin (co-expressed 
from the same transducing virus), subjected to knockdown verification by Q-PCR, and 
infected as above with VSV-G pseudotyped Vif-deficient HIV to determine infectivity 
levels and hypermutation patterns. 
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 Each individual A3 knockdown had little impact on the infectivity or the 3D-PCR 
profile of Vif-deficient HIV produced in the CEM2n parental line (Figure 3-4C, 3-4D). 
A3F-null cells expressing the non-silencing shRNA yielded a significant 7-fold increase 
in the infectivity of Vif-deficient HIV over parental CEM2n as above (Figure 3-4C). 
Similarly, A3F-null cells transduced with shA3B or shA3C knockdown constructs 
produced Vif-deficient viruses with 8- and 9-fold infectivity increases, indicating no 
further contribution to restriction from these A3 proteins (Figure 3-4C). However, in 
contrast, A3F-null cells transduced with shA3D, shA3G, and shA3H constructs yielded 
Vif-deficient viruses that were 16-, 36-, and 14-fold more infectious, respectively (Figure 
3-4C). Remarkably, the A3F-null/A3G-knockdown cells produced higher levels of 
infectious Vif-deficient HIV than CEM-SS cells (Figure 3-4C). 
 Proviral DNA sequencing of Vif-deficient viruses produced in A3F-null cells in 
combination with non-specific shRNA (shNS), shA3B, shA3C, or shA3H showed no 
significant alteration in the fraction of hypermutations that occurred within 5’GA or 
5’GG dinucleotides (Figure 3-4E, and Table 3-2). Over 15 G-to-A mutations were found 
for all experimental conditions, with one exception being viral DNA originally produced 
in A3F-null/A3G knockdown cells, which yielded only 8 mutations (4 GG-to-AG and 4 
GA-to-AA). In contrast, A3F-null/A3D knockdown cells produced almost no 
hypermutations in the 5’GA-to-AA dinucleotide context: 3% 5’GA, 93% 5’GG, and 4% 
other (Figure 3-4E, Table 3-2, and Figure 3-S4). This major contribution from A3D was 
only observed in the absence of A3F and it was rather surprising because most other 
reports have ascribed modest or no antiretroviral activity to this enzyme ((Bishop et al., 
2004; Dang et al., 2011; Dang et al., 2006; Haché et al., 2008); reviewed recently (Albin 
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and Harris, 2010)). We conclude that, in CEM2n cells, endogenous A3D and A3F 
combine to restrict Vif-deficient HIV (with A3G) and, importantly, work together 
(mostly without A3G) to inflict 5’GA-to-AA hypermutations. 
 
Knockout and Knockdown Subclone Analyses  
 An unavoidable consequence of gene targeting is the clonal nature of the 
procedure required to generate biallelic knockout derivatives of a parental cell line. 
Additionally, the previously described single-cycle assays on A3G-null and A3F-null cell 
lines were done several months apart with virus stocks produced at different times. To 
minimize these potential effects, two independently derived subclones of each of the 
knockout lines, A3G-null and A3F-null, as well as two independent subclones from the 
A3D and A3G shRNA knockdown pools were generated and assayed in parallel. Q-PCR 
and immunoblotting was used to confirm knockdown efficiencies, 60-85% for A3D and 
60-70% for A3G (Figure 3-5A & B). These cell lines were infected with VSV-G 
pseudotyped Vif-deficient HIV to determine infectivity levels after approximately one 
round of replication (Figure 3-5C). As above, deletion of either A3G or A3F increased 
viral infectivity an average of 38- or 20-fold, respectively. Knockdown of either A3D or 
A3G in the CEM2n background had little effect. In contrast, knockdown of A3D or A3G 
in the A3F-null background resulted in additional increases in Vif-deficient virus 
infectivity, averaging 27- and 49-fold higher than the baseline level in fully restrictive 
CEM2n cells expressing non-specific shRNA.  
 To assess the impact of A3 deletion and knockdown on HIV replication over time, 
a series of parallel spreading infections were initiated on the same panel of cell lines 
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(Figure 3-5A & B). Cells were infected at a multiplicity of infection of 1% with either 
Vif-proficient or Vif-deficient HIVIIIB. Every 2-3 days supernatants were removed to 
infect the reporter line CEM-GFP to assay live virus and, in parallel, to measure p24 
levels (Figure 3-5D and Figure 3-S6). Vif-proficient virus replicated on every cell line 
tested with peaks of infection occurring on days 7 to 13. The precise reason(s) for this 
kinetic variation is unclear but it does not seem to correlate with A3 genotype (compare 
with Figure 3-S6). As expected, Vif-deficient HIV replication was fully restricted in 
CEM2n cells but peaked readily in CEM-SS. A3G-null and A3F-null cells failed to 
produce detectable levels of infectious Vif-deficient virus, as monitored by the CEM-
GFP (live virus) reporter system (although modest increases in p24 levels were detected 
in cell-free supernatants). In addition, knockdown of A3D or A3G in either the CEM2n 
background, or somewhat surprisingly, in the A3F-null background was unable to render 
cells fully permissive for Vif-deficient virus replication. Taken together, even though 
strong infectivity recoveries were evident in single round infections of cells completely 
lacking A3G or A3F or cells lacking A3F plus knocked-down A3D or A3G, the remaining 
endogenous A3s were still sufficient to restrict the spread of Vif-deficient virus (i.e., 
those A3s that were not manipulated by knockout or knockdown). These data combined 
to suggest that the simultaneous elimination of A3D, A3F, and A3G (and possibly also 
A3H) would ultimately be necessary to render CEM2n fully permissive for Vif-deficient 
HIV replication. 
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DISCUSSION 
 Null mutations are a gold standard of genetics as they enable a definitive 
assessment of a given gene’s function by comparing the phenotype of the wildtype 
parental state with that of an isogenic null derivative. Here, we report the identification of 
a new T cell line, CEM2n, derived from the common parental line CCRF-CEM. CEM2n 
is near-diploid, expresses CD4 and CXCR4, supports Vif-proficient but not Vif-deficient 
HIV replication, expresses a complex A3 gene repertoire (similar to primary CD4+ T 
lymphocytes; Figure 3-S2 & (Refsland et al., 2010)), and is amendable to genetic 
manipulation by multiple methods including RNAi and gene targeting. We defined the 
HIV-restrictive A3 repertoire in this cell line by constructing A3G- and A3F-null 
derivatives, systematically depleting each expressed A3 with specific shRNA constructs, 
and performing a series of Vif-deficient HIV infectivity and proviral DNA hypermutation 
experiments. These data enable the conclusions that endogenous levels of A3D, A3F, and 
A3G combine to limit the infectivity of Vif-deficient HIV, that A3G acts alone to inflict 
5’GG-to-AG hypermutations, and that A3D and A3F work together to elicit 5’GA-to-AA 
hypermutations. Since both 5’GG and 5’GA mutational patterns are common in patient-
derived HIV proviral DNA sequences and a CEM2n-like A3 repertoire is expressed in 
primary CD4+ T lymphocytes, we hypothesize that these three A3s will also be 
responsible for HIV restriction and hypermutation in vivo  (e.g., (Janini et al., 2001; 
Kieffer et al., 2005; Kijak et al., 2008; Land et al., 2008; Piantadosi et al., 2009)).  
However, despite considerable efforts from our group and others, A3H remains a 
debatable factor in HIV restriction. This is due partly to the fact that some A3H 
haplotypes are more stable at the protein level (haplotypes II, V, VII >> I, III, IV, VI 
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(OhAinle et al., 2008; Ooms et al.; Wang et al.)). Over-expression studies are mostly 
consistent showing that A3H-hapII can restrict Vif-deficient HIV, that Vif can counteract 
this activity, and that these interactions are conserved between the A3H orthologs of 
other species and their cognate lentiviral Vif proteins (Hultquist et al., 2011; LaRue et al., 
2010; Li et al., 2010; OhAinle et al., 2008; Ooms et al., 2010; Zhen et al., 2010). A3H is 
also expressed in primary CD4+ lymphocytes and induced upon HIV infection (Hultquist 
et al., 2011; LaRue et al., 2010). However, our present studies were not able to 
unambiguously address whether this enzyme contributes to HIV restriction because 
endogenous A3H mRNA levels in CEM2n are ~20-fold lower than those in primary 
CD4+ lymphocytes (Refsland et al., 2010) (Figure 3-S2). Even so, we observed a 
significant increase in Vif-deficient HIV infectivity in A3F-null/A3H-knockdown cells in 
comparison to the A3F-null line suggesting that even sub-physiological levels of 
endogenous A3H may be restrictive. This observation is additionally interesting in light 
of sequencing data showing that CEM2n is homozygous for the haplotype II genotype. 
  Our present studies will also help resolve literature conflicts on the topic of Vif-
deficient HIV restriction by A3A, A3B, and A3C (e.g., A3A: (Aguiar et al., 2008; Berger 
et al., 2011; Bishop et al., 2004; Bogerd et al., 2006a; Goila-Gaur et al., 2007; Marin et 
al., 2008; Wiegand et al., 2004); A3B: (Bishop et al., 2004; Doehle et al., 2005a; Haché 
et al., 2008; Hultquist et al., 2011; Yu et al., 2004a); A3C: (Bishop et al., 2004; Bogerd et 
al., 2006b; Langlois et al., 2005; Wiegand et al., 2004; Yu et al., 2004a; Zheng et al., 
2004)). A3A is not expressed in CD4+ T lymphocytes or cell lines and is therefore 
unlikely to have a role (Aguiar et al., 2008; Koning et al., 2009; Refsland et al., 2010; 
Stenglein et al., 2010). It is also Vif-resistant, suggesting that it is of little threat to the 
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virus, and incapable of restricting Vif-deficient HIV even upon stable over-expression in 
permissive T cell lines (e.g., (Hultquist et al., 2011)). A3B is expressed at low levels in 
CD4+ T lymphocytes and some T cell lines such as CEM, and its over-expression 
potently restricts HIV in the HEK293T model system (Bishop et al., 2004; Doehle et al., 
2005a; Hultquist et al., 2011; Koning et al., 2009; Refsland et al., 2010; Yu et al., 2004a). 
However, A3B is also insensitive to HIV Vif and does not restrict Vif-deficient HIV or 
inflict hypermutations when stably over-expressed in permissive T cell lines (Bishop et 
al., 2004; Doehle et al., 2005a; Haché et al., 2008; Hultquist et al., 2011; OhAinle et al., 
2008; Rose et al., 2005; Yu et al., 2004a). Taken together with data shown here that A3B 
knockdown in parental CEM2n or the A3F-null background has no impact on virus 
infectivity or hypermutation profiles, we conclude that endogenous A3B also does not 
contribute to HIV restriction. A3C is highly expressed in primary CD4+ T cells and T 
cell lines, exhibits a 5’GA-to-AA hypermutation preference (especially with SIV-based 
viral substrates), and is susceptible to HIV Vif (Langlois et al., 2005; Refsland et al., 
2010; Yu et al., 2004a). However, when over-expressed in permissive T cell lines 
SupT11 or CEM-SS, A3C does not encapsidate or restrict Vif-deficient HIV replication 
(Hultquist et al., 2011). Moreover, since A3C knockdown in the parental CEM2n or the 
A3F-null background had no impact on virus infectivity in our present studies, we 
conclude that endogenous A3C is also unlikely to contribute to Vif-deficient HIV 
restriction.  
As elaborated in the Introduction, many prior published reports have been 
susceptible to a major weakness by being dependent upon enforced cDNA over-
expression. Here, we overcome this drawback by identifying a new genetic system for 
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host factor studies and systematically deleting and/or depleting endogenous A3 genes. 
Our studies demonstrate that A3G is the sole source of 5’GG-to-AG hypermutations and, 
formally, that it is a minor (at best) contributor to 5’GA-to-AA hypermutations. Our 
studies are also consistent with the phenotypes of the molecular clones engineered to be 
preferentially susceptible to A3F or A3G (Russell and Pathak, 2007; Simon et al., 2005). 
However, our studies are additionally unique by providing an unanticipated 
demonstration of a major role for endogenous A3D in inflicting 5’GA-to-AA 
hypermutations. Thus, virtually all 5’GA-to-AA hypermutations can now be explained by 
overlapping A3D and A3F activities. Such an unambiguous assignment of function 
would not have been possible by simple over-expression studies because A3D and A3F 
have a similar 5’TC deamination preferences. Altogether, we conclude that endogenous 
levels of three enzymes – A3D, A3F, and A3G – combine to inflict signature G-to-A 
hypermutations and mediate HIV restriction. 
 
 
MATERIALS AND METHODS 
Cell Lines 
All T cell lines were maintained in RPMI supplemented with 10% fetal bovine serum 
(FBS) and 0.5% penicillin/streptomycin (P/S). Our original CEM (4n) line was obtained 
from Michael Malim (Sheehy et al., 2002). The initial CCRF-CEM line used here was 
obtained from the ATCC (cat #CCL119), and it was subcloned by limiting dilution to 
obtain multiple daughter clones including CEM2n. The HIV infectivity indicator cell line 
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CEM-GFP was obtained from the AIDS Research and Reference Reagent Program. 
HEK293T cells were cultured in DMEM supplemented with 10% FBS and 0.5% P/S. 
 
Karyotype Analyses 
Giemsa banding and karyotype determination were performed at the University of 
Minnesota’s Cytogenetics Laboratory. 
 
rAAV Targeting Constructs 
Generation of rAAV targeting vectors was performed as described (Rago et al., 2007). 
Homology arms were selected to avoid identity with other A3 genes and repetitive 
sequences. CEM2n genomic DNA was prepared using Gentra Puregene Cell Kit (Qiagen) 
and 1 kb homology arms were amplified using high fidelity PCR (Platinum Taq HiFi, 
Invitrogen). Primer sequences and genomic location of arms are listed in Table 3-S1. 
Arms were cloned into pJet1.2 using CloneJet PCR cloning kit (Fermentas) and sequence 
verified. Left arms were digested with SpeI and NotI and right arms were digested with 
SalI and NotI. pSEPT (Rago et al., 2007) plasmid was digested with SpeI and SalI and 
pAAV-MCS containing the viral ITR was digested using NotI. rAAV vectors were then 
constructed via four-way ligation and purified using standard phenol:chloroform 
extraction followed by ethanol precipitation. 20 µl of each ligation mixture was used to 
transform 10 µl electro-competent DH10B cells. Plasmid DNA was harvested from 
ampicillin resistant colonies and verified by restriction digest and DNA sequencing. 
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AAV Virus Production, Infection of Target Cells  
AAV-2 viral stocks were prepared by co-transfecting HEK293T cells at 50% confluency 
with sequence verified rAAV targeting vector, pHelper and pAAV-RC (Stratagene) 
(Trans-IT, Mirus). Three days after transfection, media and cells were collected and 
subjected to 3 cycles of freeze-thaw-vortex (30 min at -80oC, 10 min thaw at 37oC, 30 s 
vortex). Cellular debris was removed by centrifuging for 30 min at 12,000 rpm in a table-
top centrifuge. rAAV was further purified and concentrated using an AAV Purification 
ViraKit (Virapur) per manufacturer’s instructions. One million CEM2n recipient cells 
were infected with a range of volumes (2-100 µl) of virus. Three days after infection, 
cells were seeded into 96-well plates at a density of 1000 cells/well in G418 containing 
media (1 mg/ml). G418 resistant clones were expanded and harvested for genomic DNA. 
Clones were screened for homologous recombination events at the desired locus with 
PCR primers specific to upstream (5’), downstream (3’) regions of the targeted allele, and 
the targeting vector. To recycle the targeting construct for the second allele, clones were 
infected with a Cre-expressing adenovirus (Ad-Cre-GFP, Vector Biolabs). Cells were 
cloned by limiting dilution and tested for drug sensitivity. 
 
RNA Isolation, cDNA Synthesis, and Q-PCR 
mRNA isolation, reverse transcription and Q-PCR were performed as described 
(Refsland et al., 2010). RNA from 5 x 106 cells was isolated using the RNeasy kit 
(Qiagen). 1 µg total RNA was used to synthesize cDNA with random hexameric primers 
(AMV RT; Roche). cDNA levels were quantified using established procedures, primers, 
and probes (Refsland et al., 2010) using a Roche LightCycler 480. All reactions were 
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done in triplicate and A3 levels were normalized to the housekeeping gene TBP and 
presented relative to values for the parental CEM2n line. 
 
Viral Constructs  
Vif-proficient (Genbank EU541617) and Vif-deficient (X26, X27) HIVIIIB A200C 
proviral constructs have been described (Albin et al., 2010a; Haché et al., 2008). 
 
Spreading Infections 
Vif-proficient and Vif-deficient HIV spreading infections were performed as previously 
described (Albin et al., 2010a). For p24 ELISA, anti-p24 mAb (183-H12-5C, NIH 
ARRRP) coated 96-well plates (maxisorp, Nunc) were incubated with supernatants from 
infected cultures for 1 hr. Following 3 washes with PBS 0.1% Tween 20 (PBS-T), a 
second 1 hr incubation with a different anti-p24 mAb (9725, N. Somia) was used to 
‘sandwich’ the p24 antigen. After an additional 3 PBS-T wash steps, p24 was quantified 
by 0.5 hr incubation with an enzyme-linked secondary goat anti-mouse IgG-2A/HRP 
followed by 3 PBS-T wash steps and incubation with 3,3’,5,5’ tetramethybenzidine 
(TMB) for 6 min. The reaction was stopped upon addition of 1 M H2SO4 and absorbance 
at 450 nm was quantified on a microplate reader (Synergy MX, Biotek). 
 
Single Cycle Infections  
HEK293T cells were co-transfected at 50% confluence with a Vif-deficient HIV proviral 
expression construct and a VSV-G expression construct. Viral containing supernatants 
were harvested, titered on CEM-GFP, and used to infect CEM2n and A3-null derivatives 
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at a 25% initial infection. 12 h post-infection cells were washed to remove remaining 
VSV-G virus and resuspended in RPMI growth media. 36 h later, viral containing 
supernatants were used to infect CEM-GFP reporter cells and cell and viral particle 
lysates were prepared. 
 
Immunoblotting 
Cell pellets were washed and directly lysed in 2.5x Laemmli sample buffer. Viral 
particles were isolated from filtered supernatants by centrifugation and then resuspended 
in 2.5x Laemmli sample buffer. SDS-PAGE and immobilization of protein to PVDF was 
carried out using the Criterion system (Bio-Rad). 
 
Flow cytometry 
Immunostaining with CD4-PC7 and CXCR4-PE (Beckman Coulter) was carried out per 
the manufacturer’s instructions. CEM and CEM2n stained negative for CCR5 (data not 
shown). Infected CEM-GFP cells were fixed with 4% paraformaldehyde in 1X PBS. 
Fluorescence was measured on a FACS Canto II instrument (BD), and data were 
analyzed with FlowJo Flow Cytometry Analysis Software (Version 8.8.6). 
 
shRNA Knockdown Vectors 
pLKO.1 lentiviral vectors expressing short-hairpin RNA (shRNA) to A3B 
(TRCN00001420546), A3C (TRCN0000052102), A3D (TRCN0000154811), A3G 
(TRCN0000052191), and A3H (TRCN0000051799) were obtained from Open 
Biosystems. Lentivirus was produced by co-transfecting 50% confluent 293T cells with 
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an shRNA expression construct, an HIV gag-pol helper plasmid, a VSV-G expression 
construct and Trans-IT (Mirus). Two days after transfection, supernatant was collected 
and replaced with fresh media. The following day, media was pooled and virus was 
clarified by passing supernatants through a 0.45 µM PVDF filter. To concentrate the 
virus, clarified supernatants were centrifuged at 22,000 x g for 2 h. Virus containing 
pellets were resuspended in 1X PBS. One million CEM2n and A3F-null cells were 
infected with 50 µl of virus and two days post-infection, media was replaced with 
puromycin containing media (1µg/ml). Subclones were generated by limiting dilution in 
96-well plates. Knockdown efficiency and specificity on transduced pools and subclones 
was assessed with Q-PCR (Refsland et al., 2010).  
 
3D-PCR 
3D-PCR was carried out as described (Hultquist et al., 2011). A 511 bp amplicon from 
the gag-pol genes of integrated proviruses was amplified with degenerate primers and 
quantified (Roche, LightCycler 480). Normalized amounts of integrated provirus were 
used for a second round of PCR over a range of denaturation temperatures using a 
gradient thermocycler (Eppendorf). 
 
Mutational Spectra Analysis 
48 h after infection of CEM-GFP cells with Vif-deficient HIV, genomic DNA was 
prepared and PCR was used to generate a 511 bp amplicon over the gag-pol region. 
Primer sequences are listed in Table 3-S1. This amplicon was cloned into pJet1.2 using 
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CloneJet PCR cloning kit (Fermentas) and sequenced. Duplicate sequences were 
discarded. Sequences were analyzed using Sequencher 4.6 (Gene Codes Corp).  
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FIGURES 
 
Figure 3-1. CEM2n is a Near-Diploid, Non-Permissive T Cell Line.  
(A) Flow cytometric analysis of fixed CEM2n (red) and CEM4n (gray) cells stained with 
propidium iodide.  
(B) Contour plot of CD4 and CXCR4 levels in CEM2n.  
(C) HIV spreading infection profiles in CEM2n as monitored by periodic infection of an 
LTR-GFP reporter cell line, CEM-GFP.  
(D) Giemsa-banding karyotype of a representative CEM2n metaphase spread. Red arrows 
indicate typical lesions in lymphoblastic leukemia. 
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Figure 3-2. Construction and Characterization of A3G-Null CEM2n Cells. 
(A) A3G exon 3 targeting strategy. LA, left homology arm; SA, splice acceptor; IRES, 
internal ribosomal entry site; Neo, G418 resistance gene; pA, poly adenylation signal; 
RA, right homology arm; yellow triangles, loxP sites.  
(B) A3 mRNA expression profiles of the indicated cells relative to parental CEM2n 
(mean and s.d. shown for triplicate experiments). 
(C) Immunoblots of A3G, A3F, and tubulin (TUB) in the indicated cells. 
(D) Infectivity of Vif-deficient HIV produced using the indicated cell lines following a 
single replicative cycle (mean and s.d. shown for p24-normalized triplicate experiments).  
(E) 3D-PCR profiles of HIV gag-pol and cellular MDM2 targets within genomic DNA of 
infected CEM-GFP reporter cells. 
(F) HIV G-to-A mutation profiles of proviruses originating in the indicated cell types. 
The mutation frequency at each dinucleotide is illustrated as a pie chart wedge (n > 15 kb 
per condition). 
 
  
	   99	  
Gene Allele 1 Allele 2 Allele 1 
retargeted 
Total clones 
analyzed 
Overall targeting 
frequency (%) 
APOBEC3G 6 2 4 189 6.3 
APOBEC3F 7 3 2 170 7.1 
Totals:                          24 359 6.7 
 
Table 3-1. Gene targeting statistics in CEM2n. 
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Cell line 
 
Expt. 
no. 
Number of 
511bp  
gag-pol 
amplicons 
Total kb 
sequenced 
Total 
GG-to-AG 
mutations 
Total 
GA-to-AA 
mutations 
Total 
GY-to-AY 
mutations 
Total 
other 
mutations 
CEM2n 1 30 15.3 40 17 0 8 
CEM2n 2 30 15.3 21 30 0 3 
∆G 1 30 15.3 3 42 3 2 
∆F 2 30 15.3 18 21 0 6 
∆F shNS 3 30 15.3 31 30 1 5 
∆F shA3B 3 30 15.3 24 39 2 10 
∆F shA3C 3 30 15.3 10 7 1 9 
∆F shA3D 3 30 15.3 81 3 3 9 
∆F shA3G 3 30 15.3 4 4 0 19 
∆F shA3H 3 30 15.3 17 18 1 6 
 
Table 3-2. Mutation Summary. 
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Figure 3-3. Construction and Characterization of A3F-Null CEM2n Cells.  
(A) A3F exon 3-4 targeting strategy. LA, left homology arm; SA, splice acceptor; IRES, 
internal ribosomal entry site; Neo, G418 resistance gene; pA, poly adenylation signal; 
RA, right homology arm; yellow triangles, loxP sites.  
(B) A3 mRNA expression profiles of the indicated cells relative to parental CEM2n 
(mean and s.d. shown for triplicate experiments). 
(C) Immunoblots of A3F, A3G, and tubulin (TUB) in the indicated cells. 
(D) Infectivity of Vif-deficient HIV produced using the indicated cell lines following a 
single replicative cycle (mean and s.d. shown for p24-normalized triplicate experiments).  
(E) 3D-PCR profiles of HIV gag-pol and cellular MDM2 targets within genomic DNA of 
infected CEM-GFP reporter cells. 
(F) HIV G-to-A mutation profiles of proviruses originating in the indicated cell types. 
The mutation frequency at each dinucleotide is illustrated as a pie chart wedge (n > 15 kb 
per condition). 
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Figure 3-4. Construction and Characterization of A3F-Null/A3-Knockdown CEM2n 
Cells. 
(A) Levels of each indicated A3 mRNA in CEM2n or A3F-null cells transduced with 
shNS, shA3B, shA3C, shA3D, shA3G, or shA3H constructs (mean and s.d. shown for 
triplicate experiments). 
(B) Immunoblots of A3G and tubulin (TUB) in CEM2n or A3F-null cells stably 
transduced with the indicated shRNA-expressing lentivirus. 
(C) Infectivity of Vif-deficient HIV produced using the indicated transduced cell pool 
and reported using the CEM-GFP system (mean and s.d. shown for p24-normalized 
triplicate experiments; in some instances, the error is nearly indistinguishable from the 
histogram bar outline).  
(D) 3D-PCR profiles of HIV gag-pol and cellular MDM2 targets within genomic DNA of 
infected CEM-GFP reporter cells. 
(E) HIV G-to-A mutation profiles of proviruses originating in the indicated cell types. 
The mutation frequency at each dinucleotide is illustrated as a pie chart wedge (n > 15 kb 
per condition). Pie charts were generated for those conditions with > 1 mutation per kb 
analyzed. Mutation numbers for all conditions can be found in Table 2 and Table S1. 
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Figure 3-5. Characterization of Independent Knockout and Knockdown Clones. 
(A) Levels of each indicated A3 mRNA in CEM2n, A3G- and A3F-null derivatives, and 
CEM-SS (relative to TBP; mean and s.d. shown for triplicate experiments). 
(B) Levels of each indicated A3 mRNA in CEM2n or A3F-null cells transduced with 
shNS, shA3D, or shA3G constructs (relative to TBP; mean and s.d. shown for triplicate 
experiments). 
(C) Single-cycle infectivity of Vif-deficient HIV produced in parallel in the indicated cell 
lines (mean and s.d. shown for p24-normalized triplicate experiments).  
(D) The kinetics of Vif-proficient (blue diamonds) and Vif-deficient (red squares) HIV 
spreading infection in the indicated cell lines. Numbers distinguish independent clones. 
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Table 3-S1. Primer Sequences. 
 
Figure 3-S1. CEM is a Near-Tetraploid T Cell Line.  
Giemsa-banding karyotype of a representative CEM metaphase spread. Red arrows 
indicate typical lesions in lymphoblastic leukemia. 
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Figure 3-S2. A Comparison of A3 mRNA Levels in CEM2n, CEM(4n), and Primary 
CD4+ Lymphocytes. 
Total RNA was produced from the indicated sources, 1 µg was converted to cDNA, and 
one-twentieth of each cDNA was used to prime the indicated Q-PCR reactions. Levels of 
A3G in CEM2n are set to 1 to facilitate comparison. See methods for additional details. 
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Figure 3-S3. PCR Reactions to Detect A3G Targeting Events. 
(A) Schematic of a correctly targeted A3G locus. Diagnostic PCR reactions enable 
detection of the IRES-Neo cassette adjacent to the left targeting arm (PCR A = 1.8 kb) 
and adjacent to the right targeting arm (PCR B = 1.8 kb). An internal primer set enables 
detection of any drug resistant clone (PCR C = 1.9 kb). The flanking primers also enable 
detection of the loxP-to-loxP deletion product following Cre-mediated recombination 
(PCR D = 2.9 kb). 
(B) Agarose gel image of PCR products produced from the genomic DNA of CEM2n 
(WT), an A3G heterozygote, and an A3G-null clone. 
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Figure 3-S4. G-to-A Mutation Loads for Vif-deficient HIV Produced in CEM2n and 
Key Derivatives. 
The G-to-A mutation number per independent amplicon is shown in histogram format for 
Vif-deficient HIV recovered from single-round viral infections of the indicated cell lines. 
(A) CEM2n experiments 1 and 2 are combined into a single histogram.  
(B) A3G-null CEM2n.  
(C) A3F-null CEM2n.  
(D) A3F-null/A3D-knockdown CEM2n. The corresponding dinucleotide preferences are 
shown in pie format in Figures 3-2F, 3-3F, and 3-4E. The G-to-A mutations for all 
experimental conditions are summarized in Table 3-2. A trend toward higher G-to-A 
mutation loads and a bimodal mutation distribution was observed in viruses produced in 
parental CEM2n and in the A3F-null/A3D-knockdown derivative, suggesting that 
endogenous A3G may be more processive (not necessarily more anti-viral) than A3F or 
A3D. 
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Figure 3-S5. PCR Reactions to Detect A3F Targeting Events. 
(A) Schematic of a correctly targeted A3F locus. Diagnostic PCR reactions enable 
detection of the IRES-Neo cassette adjacent to the left targeting arm (PCR A = 2.1 kb) 
and adjacent to the right targeting arm (PCR B = 1.7 kb). An internal primer set enables 
detection of any drug resistant clone (PCR C = 1.9 kb). The flanking primers also enable 
detection of the loxP-to-loxP deletion product following Cre-mediated recombination 
(PCR D = 2.8 kb). 
(B) Agarose gel image of PCR products produced from the genomic DNA of CEM2n 
(WT), an A3F heterozygote, and an A3F-null clone. 
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Figure 3-S6. Vif-Proficient and Vif-Deficient HIV Replication Kinetics. 
Quantification of supernatant p24 levels at the indicated time points in (A) CEM2n and 
the indicated A3F- or A3G- null derivatives,  
(B) CEM2n subclones expressing the indicated shRNA constructs, and  
(C) CEM2n A3F-null subclones expressing the indicated shRNA constructs. The 
spreading infections in panels A, B, and C were done in parallel, and they are therefore 
directly comparable. Vif-proficient and Vif-deficient viral replication was done in 
parallel in CEM-SS (the only non-isogenic condition) and presented in panel A for 
comparison.  
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CHAPTER 4 
 
 
Stable APOBEC3H Inhibits HIV-1 Replication in Primary T Lymphocytes 
 
 
 
 
This chapter is adapted from a manuscript submitted for publication that is awaiting peer 
review: Eric W. Refsland, Judd F. Hultquist, Elizabeth M. Luengas, Terumasa Ikeda, 
Nadine M. Shaban, Emily K. Law, William L. Brown, Michael Emerman, and Reuben S. 
Harris. In review, PLOS Genetics.  
 
 
 
 
Authors’ Contributions 
EWR performed all of the experiments, wrote and revised the manuscript, and designed 
all of the figures except as follows. JFH aided in the experimental design, primary cell 
isolations, HIV infection experiments and revised the manuscript. EML aided in the 
primary cell isolations, monoclonal APOBEC3H antibody characterization, and 
APOBEC3H genotyping. TI performed the APOBEC3H adaptation experiment. NMS 
aided in the HIV Vif surface modeling. EKL and WLB aided in the APOBEC3H 
monoclonal antibody characterization. ME provided the APOBEC3H monoclonal 
hybridomas and revised the manuscript. RSH aided in the design of the experiments and 
in manuscript preparation/revision. 
	   117	  
 
FOREWORD 
 The APOBEC3 enzymes protect cells by inhibiting the spread of retroelements, 
including HIV-1, by blocking reverse transcription and mutating cytosines in single-
stranded DNA replication intermediates. HIV-1 Vif counteracts restriction by marking 
APOBEC3 proteins for proteasomal degradation. APOBEC3H is the most diverse 
member of this protein family. Humans have seven distinct APOBEC3H haplotypes with 
three producing stable and four producing unstable proteins upon forced overexpression. 
Here, we examine the stability phenotype of endogenous APOBEC3H in donors with 
different haplotypes and address how these stability differences, as well as natural viral 
diversity, combine to determine HIV-1 infectivity. We found that endogenous 
APOBEC3H haplotypes yield stable or unstable proteins and that stable APOBEC3H is 
induced during viral infection and restricts the replication of isolates with naturally 
occurring hypo-functional but not hyper-functional Vif alleles. We also found that the 
global distribution of stable APOBEC3H alleles correlates with the prevalence of HIV-1 
Vif alleles capable of mediating its degradation, strongly suggesting that the viral Vif 
protein is capable of adapting to the APOBEC3H restriction potential of an infected 
individual. Thus, the combination of human APOBEC3H haplotypes and virus Vif alleles 
may help account for some of the observed disparities in disease progression and virus 
transmission.  
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SUMMARY  
The Vif protein of HIV-1 allows virus replication by degrading several members of the 
host-encoded APOBEC3 family of DNA cytosine deaminases. Polymorphisms in both 
host APOBEC3 genes and the viral vif gene have the potential to impact the extent of 
virus replication among individuals. The most genetically diverse of the seven human 
APOBEC3 genes is APOBEC3H with seven known haplotypes. Overexpression studies 
have shown that a subset of these variants express stable and active proteins whereas the 
others encode proteins with a short half-life and little, if any, antiviral activity. We 
demonstrate that these stable/unstable phenotypes are an intrinsic property of endogenous 
APOBEC3H proteins in primary CD4+ T lymphocytes and confer differential resistance 
to HIV-1 infection in a manner that depends on natural variation in the Vif protein of the 
infecting virus. HIV-1 with a Vif protein hypo-functional for APOBEC3H degradation, 
yet fully able to counteract APOBEC3D, APOBEC3F, and APOBEC3G, was susceptible 
to restriction and hypermutation in stable APOBEC3H expressing lymphocytes, but not 
in unstable APOBEC3H expressing lymphocytes. In contrast, HIV-1 with hyper-
functional Vif counteracted stable APOBEC3H proteins as well as all other endogenous 
APOBEC3s and replicated to high levels. We also found that APOBEC3H protein levels 
are induced over 10-fold by infection. Finally, we found that the global distribution of 
stable APOBEC3H haplotypes correlates with the distribution a critical hyper-functional 
Vif amino acid residue. These data combine to strongly suggest that stable APOBEC3H 
haplotypes present as in vivo barriers to HIV-1 replication, that Vif is capable of adapting 
to these restrictive pressures, and that an evolutionary equilibrium has yet to be reached. 
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INTRODUCTION 
The human APOBEC3 (A3) family of DNA cytosine deaminases is encoded by 
seven genes arranged in tandem on chromosome 22 (reviewed by (Conticello, 2008; 
Refsland and Harris, 2013)). These proteins inhibit the replication of a broad number of 
parasitic elements, including many retroviruses, some DNA viruses, and several 
endogenous retroelements and retrotransposons by both deaminase-dependent and -
independent mechanisms (reviewed by (Desimmie et al., 2014; Malim and Bieniasz, 
2012; Refsland and Harris, 2013)). Several lines of evidence indicate that A3D, A3F, 
A3G, and A3H contribute to HIV-1 restriction by packaging into assembling virus 
particles and, upon virus entry into new target cells, deaminating viral cDNA cytosines to 
uracils and impeding the progression of reverse transcription (reviewed by (Desimmie et 
al., 2014; Malim and Bieniasz, 2012; Refsland and Harris, 2013)). The cDNA uracil 
lesions template the insertion of genomic strand adenines during second strand reverse 
transcription and ultimately manifest as G-to-A mutations which destroy virus infectivity 
by the introduction of deleterious missense and nonsense mutations within viral open 
reading frames.  
Mammalian A3 proteins pose such a threat to lentivirus replication that an 
ancestor of present day HIV-1 evolved an accessory protein called Vif (virion infectivity 
factor) to inhibit these restriction factors. HIV-1 Vif assembles an E3 ligase complex 
comprised of CBFβ, ELOB, ELOC, CUL5, and RBX2 to mediate the poly-ubiquitination 
and proteasomal degradation of restrictive A3s ((Jäger et al., 2012b; Zhang et al., 2012) 
and references therein). This process enables HIV-1 to replicate in its main target cell, 
CD4+ T lymphocytes, which express multiple A3s and would otherwise be non-
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permissive for viral replication (Hultquist et al., 2011; Koning et al., 2009; Refsland et 
al., 2010). However, this process is less than 100% effective, as G-to-A mutations are 
commonly observed in viral sequences from clinical specimens and, depending on the 
patient, may be biased toward a GG-to-AG dinucleotide context indicative of A3G or a 
GA-to-AA characteristic of A3D, A3F, and/or A3H (Albin and Harris, 2010; Caride et 
al., 2002; Fitzgibbon et al., 1993; Gandhi et al., 2008; Hultquist et al., 2011; Janini et al., 
2001; Kieffer et al., 2005; Kijak et al., 2008; Koning et al., 2009; Land et al., 2008; Pace 
et al., 2006; Piantadosi et al., 2009; Refsland et al., 2010; Suspène et al., 2006; Ulenga et 
al., 2008; Vartanian et al., 1994; Wood et al., 2009). 
The present day human A3 locus is a result of multiple gene duplication events 
during evolution from an ancestral mammalian locus (LaRue et al., 2008). Unlike the Z1 
domain (e.g. A3A) or Z2 domain (e.g. A3C) deaminase genes, which show considerable 
copy number variation between mammalian phylogenetic tree branches, the Z3 domain 
gene (e.g. A3H) exists in only one copy in all mammalian genomes sequenced to date 
(LaRue et al., 2010). Overexpression studies have shown that A3H and the orthologous 
Z3 domain deaminases from several mammalian species have a conserved capacity to 
restrict retrovirus replication, and likewise are neutralized by the Vif proteins of each 
species’ lentivirus (Bogerd et al., 2004; LaRue et al., 2010; Mangeat et al., 2004; Mariani 
et al., 2003a; Schröfelbauer et al., 2004; Virgen and Hatziioannou, 2007; Xu et al., 2004; 
Zielonka et al., 2009; Zielonka et al., 2010). However, a role for A3H in vivo has not yet 
been elucidated since endogenous expression of the protein has been difficult to detect 
(Li et al., 2010).  
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A3H is the most polymorphic of the human A3 genes due to circulation of at least 
7 distinct A3H haplotypes (OhAinle et al., 2008; Wang et al., 2011). These haplotypes are 
comprised of various combinations of 5 single nucleotide polymorphisms located in 
exons 2, 3 and 4 that range in allele frequencies globally from 6 to 87% (Duggal et al., 
2013). Previous overexpression and pulse-chase experiments have shown that 3 A3H 
haplotypes yield proteins with relatively long half-lives (stable), 1 produces a protein 
with weak stability, and another 3 make completely unstable proteins (Dang et al., 2008; 
OhAinle et al., 2008; Wang et al., 2011). For example, transient transfection of cells with 
A3H haplotype II cDNA with SNPs at residues 15, 18, 105, 121, and 178 (NRRDD) 
yields a protein readily detectable by immunoblotting, whereas A3H haplotypes I 
(NRGKE) and III (∆RRDD) produce weakly expressed or undetectable proteins, 
respectively (OhAinle et al., 2008; Wang et al., 2011). However, it is not yet known 
whether these dramatic haplotype-associated stability/instability phenotypes also 
manifest for endogenous A3H proteins expressed in primary immune cells. This 
distinction is important because only stably expressed haplotypes would be predicted to 
exert selective pressure on HIV-1 replication and potentially contribute to virus 
restriction and diversification in vivo. Indeed, a recent paper linked putatively stable A3H 
haplotype II to enhanced restriction, higher frequencies of G-to-A mutation, and more 
favorable clinical phenotypes (lower viral loads and higher patient CD4+ T cell numbers) 
(Ooms et al., 2013a). 
 Here, we test the hypothesis that HIV-1 infectivity will be influenced by both host 
A3H haplotype as well as viral vif genotype. We detect the expression and induction of 
endogenous A3H protein from stable A3H alleles following HIV-1 infection. By 
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constructing a set of molecular clones encoding Vif proteins of varying abilities to 
antagonize stable A3H, we showed that expression of one allele of stable A3H is 
sufficient to inhibit hypo-functional Vif virus replication and promote G-to-A 
mutagenesis in the expected GA-to-AA dinucleotide context. In contrast, a hyper-
functional Vif variant effectively counteracted stable A3H activity. Virus adaptation to 
stable A3H may be occurring on a global scale because the geographic distribution of a 
key hyper-Vif amino acid correlates with the distribution of stable A3H haplotypes. 
Taken together, these data demonstrate that stable A3H haplotypes affect HIV-1 
replication in the primary target cells of the virus, and further suggest that viral evolution 
requires the Vif protein to adapt to counteract the restrictive pressure imposed by these 
enzymes. Therefore, the combination of A3H haplotype and viral vif variation may be 
critical and linked factors in HIV-1 adaptation to human populations. 
 
RESULTS 
At least two A3H haplotypes encode stable proteins in primary T lymphocytes 
 To address whether the dramatic protein stability phenotypes observed previously 
in overexpression studies ((Dang et al., 2008; OhAinle et al., 2006; Wang et al., 2011); 
Figure 1A) extend to endogenous A3H haplotypes in primary T cells, we used our 
recently developed anti-A3H monoclonal antibodies (Li et al., 2010) as well as a new 
commercial anti-A3H polyclonal antibody to probe protein expression in CD4+ T 
lymphocytes from healthy donors with different haplotypes (Materials and Methods, 
Figure 1B & Figure S1). Primary CD4+ lymphocytes were isolated by negative 
selection, stimulated with IL2 and PHA for 72 hrs, and subjected to immunoblotting. 
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Three of 24 donors were heterozygous for a predicted stable A3H haplotype and none 
were homozygous (6% allele frequency; Table S1). Anti-A3H immunoblots 
demonstrated clear differences in steady-state protein levels, with robust detection of 
haplotypes II and V, weaker detection of haplotype I, and no detection of haplotypes III 
and IV (Figure 1B). In comparison, A3G and HSP90 protein levels were expressed 
similarly between donors.  
 To confirm the prediction from previous overexpression studies that the observed 
difference in A3H protein levels is really at the protein and not the RNA level, RT-qPCR 
(Refsland et al., 2010) was used to quantify A3 mRNA levels in primary CD4+ T 
lymphocytes. Similar A3H mRNA levels were observed regardless of haplotype (Figure 
1C). The mRNA levels of the other A3 genes were also unrelated to A3H haplotype, with 
some minor variation observed between donors (typically less than 2-fold, as reported 
(Koning et al., 2009; Refsland et al., 2010)). Thus, consistent with prior overexpression 
and pulse-chase experiments to measure protein half-life (Dang et al., 2008; OhAinle et 
al., 2008; Wang et al., 2011), the large difference between the various A3H haplotypes in 
primary CD4+ cells occurs at the protein level.  
 
Identification of Vif residues that interact with stable A3H and still antagonize the 
other A3 proteins expressed in primary T cells 
Primary CD4+ T lymphocytes express 6 A3 family members (Koning et al., 2009; 
Refsland et al., 2010). We asked whether or not the ability of Vif to antagonize A3H 
could be separated from its ability to antagonize the other A3 proteins expressed in 
primary CD4+ T cells. Previous work indicated that Vif proteins of different HIV-1 
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isolates show varying capacities to counteract stable A3H (NL4-3/IIIB and LAI (Binka et 
al., 2012; Hultquist et al., 2011; LaRue et al., 2010; Li et al., 2010; Ooms et al., 2013b)), 
but these studies did not address spreading infections in T cells where A3D, A3F, and 
especially A3G selective pressures might influence Vif function. To help inform this 
construction, we performed a series of HIV-1 IIIB N48H adaptation experiments in 
which this lab-derived strain was subjected by stepwise passage to increasing ratios and 
levels of stable A3H haplotype II expressed in SupT11 cells (Figure 2A & B). An N48H 
variant was used to initiate these experiments because prior work had already 
demonstrated that this natural variation improved the A3H counteraction capacity of the 
Vif protein of IIIB/NL4-3 (Ooms et al., 2013b). These experiments were initiated by 
infecting (MOI 0.05) uniform pools of stable A3H-low expressing cells (weakly 
selective) and, after an 8 day incubation, viral supernatants were transferred to the next 
highest selective condition, and this process was repeated until 100% stable A3H-high 
conditions were reached (Materials and Methods).  
In comparison to the starting virus, HIV-1 IIIB N48H, which could only replicate 
in SupT11 control vector and A3H-low expressing cells, one of the adapted viruses 
showed rapid and nearly indistinguishable replication kinetics in SupT11 cells expressing 
low, intermediate, and high levels of stable A3H (Figure 2C). The majority (5/9) of Vif 
sequences from this adapted population had a K63E amino acid substitution. 
Furthermore, we noticed that the K63E substitution recovered in these adaptation 
experiments is part of a cluster of 4 amino acids that distinguishes the IIIB lab strain from 
an isolate recovered from a homozygous stable A3H haplotype II patient (Li et al., 2010). 
The Vif protein from this particular isolate is even better than LAI Vif at counteracting 
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stable A3H haplotype II (Li et al., 2010). We therefore predicted that the combination of 
N48H (to be more LAI Vif-like (Ooms et al., 2013b)) and GDAK60-63 to EKGE60-63 
(to be more haplotype II patient Vif-like (Li et al., 2010)) would result in a hyper-
functional Vif protein capable of fully antagonizing stable A3H haplotype II (hyper-Vif; 
Figure 3A). In addition, the separation-of-function approach required the generation of a 
Vif variant even more sensitive than lab-Vif to restriction by stable A3H haplotype II. 
This was done by introducing F39V into the HIV-1 IIIB lab strain, which is a substitution 
that confers sensitivity to stable A3H haplotype II (Binka et al., 2012) (Figure 3A). 
The A3 neutralization activities of the hyper-, lab-, and hypo-Vif HIV-1 IIIB 
variants were assessed by comparing spreading infection kinetics in SupT11 cell lines 
stably expressing a control vector, A3D-HA, A3F-HA, A3G-HA, and low, intermediate, 
and high levels of untagged A3H haplotype II (Figure 3B & C). The A3 expression level 
in each SupT11 clone was sufficient to delay (A3D) or fully suppress (A3F, A3G, A3H 
haplotype II) replication of a Vif-null HIV-1 IIIB control virus, consistent with our 
original studies using these stable cell lines (Hultquist et al., 2011). Importantly, the 
hyper-, lab-, and hypo-Vif HIV-1 IIIB variants spread with nearly identical efficiencies in 
the SupT11 cell lines expressing the control vector, A3D-HA, A3F-HA, and A3G-HA, 
demonstrating fully intact capacities to neutralize these restriction factors. In contrast, 
each isolate exhibited differential replication kinetics on the SupT11 lines expressing 
low, intermediate, and high levels of stable A3H haplotype II. The hyper-Vif isolate 
replicated with strong kinetics under all conditions including the highest stable A3H 
haplotype II expression levels, the lab-Vif isolate was delayed under intermediate and 
high A3H expression conditions, and the hypo-Vif isolate showed restricted replication 
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phenotypes almost indistinguishable from the Vif-deficient control. These data 
demonstrate that naturally occurring amino acid residues that positively or negatively 
influence Vif-mediated neutralization of A3H can do so without impacting Vif activity 
against A3D, A3F, and A3G and therefore allow for a direct interrogation of endogenous 
A3H function in primary T lymphocytes. 
 
HIV-1 restriction by stable A3H in primary T lymphocytes 
 In order to determine the relative importance of the polymorphisms of A3H and 
Vif on HIV-1 replication in primary cells, a series of spreading infection experiments was 
initiated in CD4+ cells from individuals who encode different haplotypes of A3H with 
viruses encoding the hyper-, lab-, and hypo-Vif alleles that differentially antagonize 
A3H. We found that all 3 viruses replicated with similar kinetics in primary CD4+ T cells 
from donors homozygous for unstable A3H haplotype I or heterozygous for unstable 
A3H haplotypes III and IV. Indicating that hyper-, lab-, and hypo-Vif viruses are all 
capable of neutralizing the restrictive levels of A3D, A3F, and A3G expression in 
primary cells (Figure 4A & S2). In contrast, only the hyper-Vif virus replicated with 
robust kinetics in CD4+ T cells from donors heterozygous for stable A3H haplotypes II 
or V (Figure 4B & S2). The lab-Vif and hypo-Vif viruses showed delayed and strongly 
inhibited replication kinetics, respectively, in CD4+ T cells from donors heterozygous for 
stable A3H haplotypes (Figure 4B & S2). All of the heterozygous stable A3H haplotype 
II donors also had a copy of unstable A3H haplotype I, so these large differences in 
replication kinetics are due to only a single stable A3H allele. Thus, these experiments 
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demonstrate that even a single allele of endogenous stable A3H constitutes a formidable 
barrier to replication of susceptible HIV-1 isolates.  
 The APOBEC3 proteins must be packaged into viral particles to restrict HIV-1 
replication. To confirm that stable, endogenous A3H acts by this mechanism, aliquots of 
cells and virus-containing supernatants were taken on days 3, 5, 7 and 9 post-infection for 
each donor/virus condition and analyzed by immunoblotting (Figure 4C). First, we 
observed that A3H is induced at the protein level over the course of infection. This is 
most evident in cells infected with the hypo-Vif virus, most likely because this Vif 
variant fails to bind endogenous A3H and trigger its degradation. The level of A3H 
induction observed here at the protein level corresponds roughly to the level of induction 
observed previously at the mRNA level (>10-fold (Hultquist et al., 2011)). Second, there 
is a strong correlation between cellular Vif, cellular A3H, and packaged A3H levels. This 
is most evident upon direct comparison of the hyper-Vif and hypo-Vif infections. Vif 
disappears, cellular A3H is induced weakly, and very little viral A3H is observed in 
particles from hyper-Vif infection of stable haplotype II cells. In contrast, Vif decreases 
modestly, cellular A3H is induced strongly, and large amounts of A3H are observed in 
particles from the hypo-Vif infection of stable haplotype II cells. As expected from the 
SupT11 experiments described above, the lab-Vif spreading infection elicited 
intermediate phenotypes. Most importantly, levels of A3H in viral particles correlated 
with virus replication kinetics, with the hyper-Vif virus spreading robustly and the hypo-
Vif virus being restricted almost completely. Thus, HIV-1 replication, as well as the 
induction and encapsidation of A3H, are influenced by both host A3H haplotype and the 
viral vif genotype. 
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G-to-A mutation spectra of Vif separation-of-function isolates subjected to different 
endogenous A3H haplotypes 
 The hallmark activity of HIV-1-restrictive A3 family members is viral cDNA 
deamination of C-to-U, with the uracil lesions ultimately immortalizing as genomic 
strand G-to-A mutations (reviewed by (Desimmie et al., 2014; Duggal and Emerman, 
2012; Harris et al., 2012; Malim and Bieniasz, 2012)). To determine the correlation 
between mutagenesis and the relative restriction incurred by each of the separation-of-
function Vif variants in combination with different A3H haplotypes, the viruses from 
each stable and unstable A3H experimental condition were subjected to analysis by 
differential DNA denaturation (3D)-PCR (Hultquist et al., 2011; Refsland et al., 2012; 
Suspène et al., 2005b). This technique depends on the fact that every PCR amplicon has a 
characteristic denaturation temperature that must be reached in order to yield visible PCR 
product, and G-to-A mutations within the amplicon will result in the appearance of 
product at significantly lower temperatures. After 15 days of spreading infection, viral 
supernatants were removed and used to infect CEM-GFP reporter cells. After allowing 2 
days for infection and integration, total cellular DNA was prepared, quantified, and 
subjected to 3D-PCR analysis of a 564 bp HIV-1 pol region (Figure 4D). All viruses 
from unstable A3H haplotype III/IV expressing cells showed no evidence for G-to-A 
hypermutation, as the lowest denaturation temperature with visible PCR product was the 
same as that of the original molecular clone. The level of G-to-A mutation in hypo-Vif 
viruses from stable A3H haplotype II/I cells was clearly the highest, but levels for lab-Vif 
and hyper-Vif viruses were also significantly above the background level established by 
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the amplification cut-off for the original molecular clone. Interestingly, a significant level 
of G-to-A mutation was also evident in hypo-Vif and lab-Vif viruses (but not in hyper-
Vif virus) from unstable haplotype I/I cells, indicating that A3H haplotype I protein is 
capable of lower levels of viral cDNA deamination and may contribute to HIV-1 
mutagenesis, though not to obvious infectivity decreases.  
 To analyze the mutation spectrum and local dinucleotide mutation contexts, we 
used normal high-fidelity PCR (98°C denaturation temperature) and Sanger sequencing 
to analyze the pol region of proviral DNA from an independent experiment (i.e., viruses 
from day 15 of the experiment shown in Figure 4A-C). Consistent with the 3D-PCR 
experiment discussed above, the highest level of G-to-A mutation occurred in hypo-Vif 
viruses from cells expressing stable A3H haplotype II, and the lowest level of G-to-A 
mutation occurred in hyper-Vif viruses from cells expressing unstable A3H haplotype I 
(5.0 G-to-A mutations per kb versus 0.2 G-to-A mutations per kb; Figure 4E). Most 
(76%) of the hypo-Vif viruses’ G-to-A mutations occurred in a GA-to-AA context, 
consistent with the 5’TC deamination preference of A3H shown previously (Harari et al., 
2009; Hultquist et al., 2011; Ooms et al., 2013a). In contrast, few G-to-A mutations were 
observed in a GG-to-AG context characteristic of A3G, further supporting the SupT11 
experiments shown above that demonstrate that each of the Vif separation-of-function 
variants retains equivalent and strong A3G antagonism (Figure 4E & S3). 
 
Global correlations between HIV-1 Vif genotypes and human A3H haplotypes 
If A3H exerts selective pressure on HIV-1, then Vif variants most capable of 
neutralizing its activity should predominate in areas where stable A3H haplotypes also 
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predominate. A geographic breakdown of 9713 HIV-1 isolates represented in the Los 
Alamos database revealed that F39 (an A3H resistance residue) predominates in Africa, 
whereas V39 (an A3H susceptibility residue) predominates in Asia (Figure 5A). In 
addition, the N48 residue in Vif that confers sensitivity to high levels of stable A3H 
haplotype II (Binka et al., 2012; Hultquist et al., 2011; Ooms et al., 2013b) in HIV-1 IIIB 
and NL4-3, is present in only 9% of African isolates but in 30% of isolates from Asia. 
Interestingly, these Vif allelic distributions correspond to the worldwide estimates for 
A3H haplotypes from the 1000 genomes project previously reported (Genomes Project et 
al., 2012; OhAinle et al., 2008), with stable haplotypes predominating in Africa and 
unstable haplotypes in Asia (Figure 5B). Thus, HIV-1 Vif appears to have the capacity to 
adapt to the A3H haplotype of a population. A major prediction is therefore that stable 
A3H may be a protective factor in HIV-1 acquisition, especially in instances in which a 
stable A3H haplotype individual is exposed to a hypo-Vif inoculum from an unstable 
A3H haplotype patient (Figure 5C). 
 
A3H-altering Vif residues define an interaction surface 
 All current evidence indicates that Vif heterodimerizes with CBFβ, directly binds 
restrictive A3s, and recruits an E3-ligase ubiquitin complex to target them for 
proteasomal degradation (Desimmie et al., 2014; Duggal and Emerman, 2012; Harris et 
al., 2012; Malim and Bieniasz, 2012). Recently, a crystal structure of the Vif-CBFβ-
ELOB-ELOC-CUL5 complex was determined, providing long-awaited details of the 
molecular architecture of Vif (Guo et al., 2014). The separation-of-function Vif variants 
described here provide an opportunity to define the A3H interaction surface. 
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Interestingly, all of the amino acids that comprise these variants map to the same solvent-
exposed surface of Vif (Figure 6A). The critical hypo- and hyper-Vif residues, F39 and 
GDAK60-63, are particularly close together. Moreover, the delayed and differential 
spreading infection phenotypes of HIV-1 isolates with each of these single amino acid 
substitutions in SupT11 T cells expressing high levels of stable A3H haplotype II 
indicates that each of these residues makes partial contribution to the overall hyper-Vif 
phenotype (Figure 6B). 
 Analogous but physically distinct separation-of-function Vif mutants have been 
described for A3F and A3G. For instance, the DRMR14-17 motif is required for A3F 
degradation, but does not affect A3G neutralization (Russell and Pathak, 2007; 
Schröfelbauer et al., 2006). Furthermore, another motif, YRHHY40-44, specifically 
compromises the A3G interaction (Russell and Pathak, 2007). The fact that the A3H 
interaction surface defined above and these A3F- and A3G-specific motifs map to distinct 
solvent exposed surfaces strongly indicates that Vif may use different binding modes in 
order to neutralize each of these restriction factors.  
 
 
DISCUSSION 
A3H is the most polymorphic A3 family member in the human population, and 
here we provide the first protein-level demonstration that the differential stability and 
inducibility of endogenous A3H haplotypes in primary T cells impacts HIV-1 replication 
in its normal target cells. We also report that natural variation in HIV-1 Vif results in the 
differentially neutralization of stable A3H haplotype II and influences virus replication 
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and hypermutation activities in primary CD4+ lymphocytes. The hyper-Vif virus showed 
strong replication kinetics and low levels of G-to-A mutation under all conditions tested, 
whereas the hypo-Vif virus was only restricted and hypermutated in primary CD4+ T 
lymphocytes expressing endogenous levels of stable A3H haplotype II. Because the 
separation-of-function variants were based on naturally occurring HIV-1 amino acid 
residues, our data combine to indicate that stable haplotypes of endogenous A3H may 
constitute a replication barrier to a significant subset of circulating HIV-1 strains. This 
conclusion is further supported by strong correlations between A3H haplotype stability 
and predicted Vif functionality in worldwide human and HIV-1 genotype information 
(Figure 5A & B). 
Homology to other A3s with high-resolution structural information indicates that 
N15 is a highly conserved residue near the end of α-helix 1 and therefore most likely 
required for A3H structural integrity. NMR and mutagenesis studies with the catalytic 
domain of A3G have shown that this helix is essential for the stability and integrity of the 
entire deaminase domain, as it makes several essential contacts with internal residues 
(Chen et al., 2008; Harjes et al., 2009). For instance, an alanine substitution of the 
homologous A3G residue N208 renders the enzyme catalytically dead (Chen et al., 
2008). In contrast, the glycine at position 105 is predicted to be in the middle of β-strand 
4, located far from N15 and on the backside of the enzyme relative to the catalytic zinc-
coordinating active site. This location and the observed intermediate stability of A3H 
haplotype I protein combine to suggest a different mechanism, possibly by altering an 
interaction with a cellular binding partner (Li et al., 2010). Consistent with these 
predictions, all evidence indicates that A3H haplotypes III and IV (∆N15) encode 
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complete loss-of-function proteins, whereas haplotype I (G105) encodes a hypofunctional 
variant because higher-than-background levels of G-to-A mutations are observed in the 
hypo-Vif virus in haplotype I expressing T cells.  
Our data agree with the main conclusion of a study published recently by the 
Simon group (Ooms et al., 2013a). They concluded that A3H haplotype II is a relevant 
HIV-1 restriction factor by showing more G-to-A mutations accumulating in viruses 
replicating in A3H haplotype II donor PBMC, in comparison to the same viruses 
replicating in haplotype I donor PMBC (Ooms et al., 2013a). Our studies help explain 
their results by showing that stable A3H haplotypes are indeed expressed at the protein 
level in primary HIV-1 target cells and that, depending upon the functionality of the 
infecting viruses Vif protein, the outcomes can range from aphenotypic (hyper-Vif) to 
strong infectivity restriction and hypermutation (hypo-Vif). Importantly, the wide 
variation in G-to-A hypermutation levels observed in these controlled experiments may 
help explain the similarly wide variation reported in patient derived HIV-1 sequences 
(Albin and Harris, 2010; Caride et al., 2002; Fitzgibbon et al., 1993; Gandhi et al., 2008; 
Hultquist et al., 2011; Janini et al., 2001; Kieffer et al., 2005; Kijak et al., 2008; Koning 
et al., 2009; Land et al., 2008; Pace et al., 2006; Piantadosi et al., 2009; Refsland et al., 
2010; Suspène et al., 2006; Ulenga et al., 2008; Vartanian et al., 1994; Wood et al., 
2009). Variation occurs for both overall G-to-A mutation frequency and for local 
dinucleotide preferences with, in many instances, GA-to-AA mutations predominating 
(e.g. (Janini et al., 2001; Land et al., 2008)). These in vivo biases could be due to the 
combination of stable A3H haplotypes and infection by hypo-functional Vif isolates. 
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The results presented here, together with recent data from the Simon group (Ooms 
et al., 2013a), combine to strongly suggest that stable A3H haplotypes may be 
functioning as contemporary HIV-1 restriction factors. Stable A3H haplotypes may 
contribute to disease progression by limiting HIV-1 replication within an infected 
individual, as indicated by statistically lower viral loads and higher CD4+ T cell counts in 
haplotype II patients in comparison to haplotype I patients (Ooms et al., 2013a). 
However, stable A3H haplotypes may also affect rates of transmission. In particular, our 
studies predict lower rates of virus acquisition when an infected patient has an unstable 
haplotype and their uninfected partner has a stable A3H haplotype (Figure 5C). 
Moreover, in instances where HIV-1 breaches this transmission barrier, our studies 
predict that the Vif protein will have to adapt in order to effectively counteract stable 
A3H. Thus, HIV-1 may need to adapt differently to the A3 repertoire in different 
humans, supported by correlations between worldwide Vif and A3H genotypes (Figure 
5A & B). Overall, polymorphisms in human A3H and HIV-1 Vif appear to be combining 
to actively limit HIV-1 pathogenesis. 
 
 
MATERIALS AND METHODS 
Virus constructs 
Vif-proficient (GenBank EU541617) and Vif-deficient (X26, X27) HIVIIIB A200C 
proviral constructs have been described (Albin et al., 2010a; Haché et al., 2008). 
Substitutions to construct the hypo-Vif and hyper-Vif variants were introduced with site-
directed mutagenesis using primers RSH6951 5’TCA-AGG-AAA-GCT-AAG-GAC-
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TGG-GTT-TAT-AGA-CAT-CAC-TAT-GAA-AG & RSH6952 5’CTT-TCA-TAG-
TGA-TGT-CTA-TAA-ACC-CAG-TCC-TTA-GCT-TTC-CTT-GA for the F39V 
substitution, RSH6949 5’TTT-ATA-GAC-ATC-ACT-ATG-AAA-GTA-CTC-ATC-
CAA-AAA-TAA-GTT-CAG-AAG-TAC-AC & RSH6950 5’GTG-TAC-TTC-TGA-
ACT-TAT-TTT-TGG-ATG-AGT-ACT-TTC-ATA-GTG-ATG-TCT-ATA-AA for the 
N48H substitution, and RSH6965 5’TCC-AAA-AAT-AAG-TTC-AGA-AGT-ACA-
CAT-CCC-ACT-AGA-GAA-GGG-CGA-GTT-AGT-AAT-AAC-AAC-ATA-TTG-
GGG-TCT-GCA-TAC-AGG & RSH6966 5’CCT-GTA-TGC-AGA-CCC-CAA-TAT-
GTT-GTT-ATT-ACT-AAC-TCG-CCC-TTC-TCT-AGT-GGG-ATG-TGT-ACT-TCT-
GAA-CTT-ATT-TTT-GGA for the GDAK60-63EKGE substitutions. 
 
Cell lines  
SupT11 and CEM-GFP T cells were maintained in RPMI supplemented with 10% fetal 
bovine serum (FBS) and 0.5% penicillin/streptomycin (P/S). 293T cells were cultured in 
DMEM supplemented with 10% FBS and 0.5% P/S. The generation and characterization 
of the SupT11 panel stably expressing vector, A3D-HA, A3F-HA, A3G-HA, and 
untagged A3H haplotype II have been described (Hultquist et al., 2011). 
 
APOBEC3H antibodies and immunoblotting  
APOBEC3H monoclonal antibodies P1H6-1, P1D8-1, P3A1-1, and P3A3-A10 were 
generated previously (Li et al., 2010) and purified by ammonium sulfate precipitation. 
We presume that the increased sensitivity of these antibodies over the original description 
(Li et al., 2010) is due to purification and increased concentration relative to the 
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unpurified culture supernatants used previously. Aliquots of two of these monoclonal 
antibodies have been made available through the NIH AIDS Reagent Program as #12155 
(P3A3-A10) and 12156 (P1H6-1). Specificity was demonstrated by immunoblotting 
lysates from 293T cells transiently transfected with HA-tagged A3A, A3B, A3C, A3D, 
A3F, A3G, and A3H haplotype II (Figure S1A). Epitopes were mapped by 
immunoblotting lysates from 293T cells transiently transfected with a panel of chimeric 
human/cow A3H/A3Z3 constructs (Figure S1C). A polyclonal antibody raised against 
APOBEC3H residues 45-183 was used according to the manufacturer’s instructions 
(NBP1-91682, Novus Biologicals). Cells were pelleted, washed, and then directly lysed 
in 2.5X Laemmli sample buffer. Virus containing supernatants were filtered and virus-
like particles isolated by centrifugation through a 20% sucrose cushion and resuspended 
in 2.5X Laemmli sample buffer. Lysates were subjected to SDS-PAGE and protein 
transfer to PVDF using the Criterion system (Bio-Rad).  
 
RT-qPCR 
Isolation of total RNA, reverse transcription, and qPCR were performed as described 
(Refsland et al., 2010). Briefly, total RNA was isolated from cells using the RNeasy kit 
(Qiagen). 1 µg of RNA was used to generate cDNA with Transcriptor reverse 
transcriptase (Roche) according to the manufacturer’s instructions using random 
hexameric primers. Quantitative PCR was performed using a LightCycler480 instrument 
(Roche). All reactions were done in triplicate and A3 levels were normalized to the 
housekeeping gene Tata Binding Protein (TBP). 
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Selection of APOBEC3H adapted viruses 
The procedures to adapt viruses in culture to an APOBEC3 challenge are based on prior 
reports (Albin et al., 2010a; Haché et al., 2008). HIV-1 IIIB Vif N48H was generated as 
described above. The selection experiments were initiated at a MOI of 0.05 by infecting 
150,000 cells, 100% of which were SupT11 expressing low levels of A3H haplotype II in 
a total volume of 1 ml in one well of a 24 well plate. Infections were monitored by 
removing supernatants and infecting the reporter cell line CEM-GFP every 3-4 days. The 
infected cells were split and the media was replenished at 4 days post-infection to prevent 
overgrowth of the culture. On day 8 of the infection, 250 µl of the virus containing 
supernatant from the infected wells was passaged to 150,000 SupT11 cells expressing 
higher levels of A3H haplotype II (50% low/50% intermediate). The virus supernatants 
were passaged in a stepwise manner 4 additional times into cultures with increasing 
levels of A3H haplotype II expression: 1:2:1 low:intermediate:high; 1:1 int:high; 1:3 
int:high; 100% high. To purify emerging adapted viruses, a culture of 100% SupT11 
expressing high levels of A3H haplotype II was infected at a MOI of 0.05 an additional 3 
times. Finally, viruses were used to infect CEM-GFP and genomic DNA was isolated 
using the Puregene reagents (Qiagen). Proviral DNA encoding a 1287-bp fragment of 
pol-vif-vpr amplified with primers RSH1438 5’CCC-TAC-AAT-CCC-CAA-AGT-CA 
and RSH1454 5’ CAA-ACT-TGG-CAA-TGA-AAG-CA. Amplicons were cloned into 
CloneJet (ThermoScientific) and Sanger sequenced using flanking plasmid-specific 
primers. 
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HIV-1 spreading infections 
Vif-proficient and Vif-deficient HIV-1 spreading infections were performed as 
previously described (Albin et al., 2010a). Viruses were generated by transfecting 10 µg 
of proviral expression construct into 293T cells. Titers of the viruses were assessed using 
the CEM-GFP reporter cell line. SupT11 spreading infections were initiated at a 0.01 
MOI and the infection was monitored every 2-3 days using the CEM-GFP reporter line 
(Gervaix et al., 1997). Primary CD4+ T cells were infected at a 0.02 MOI and culture 
supernatants were collected every 2-3 days and analyzed using an in-house p24 ELISA. 
Supernatants from infected cultures were incubated with for 1 hr on anti-p24 mAb (183-
H12-5C, NIH ARRRP) coated 96-well plates (Nunc). Following 4 washes with PBS 
0.1% Tween 20 (PBS-T), a second 1 hr incubation anti-p24 mAb (9725) was used to 
‘sandwich’ the p24 antigen. Wells were again washed 4 times, p24 was quantified by 0.5 
hr incubation with an enzyme-linked secondary goat anti-mouse IgG-2A/HRP followed 
by 4 PBS-T wash steps and incubation with 3,3’,5,5’ tetramethybenzidine (TMB) for 6 
min. The reaction was stopped upon addition of 1 M H2SO4 and absorbance at 450 nm 
was quantified on a microplate reader (Synergy MX, Biotek). 
 
Primary cells 
Peripheral blood mononuclear cells were isolated from whole blood (Memorial Blood 
Center, St. Paul, MN) by ficoll gradient centrifugation as previously described (Hultquist 
et al., 2011; Refsland et al., 2010). Naïve CD4+ T lymphocytes were purified by negative 
selection according to the manufacturer’s instructions (Miltenyi Biotech). Cells were 
stimulated and maintained in RPMI with 20 U/mL human interleukin-2 (Miltenyi 
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Biotech) and 10 µg/ml phytohemagglutinin (Thermo Scientific). Cells were stimulated 
for 72 hours prior to infection or harvesting for total RNA and protein lysate. Purity (> 
95%) and activation were confirmed by staining with an anti-CD4 antibody or anti-CD25 
antibody respectively (Miltenyi Biotech).  
 
Ethics Statement 
This study has been reviewed and exempted by the University of Minnesota Institutional 
Review Board (#0503E68687). All PBMCs were isolated from healthy and de-identified 
individuals. 
 
APOBEC3H genotyping 
Primers and PCR conditions for polymorphisms (N15/∆N15A3H, rs140936762; 
R18/L18, rs139293; G105/R105, rs139297; D121/K121, rs139299 & rs139298; 
E178/D178, rs139302) genotyping have been described (Wang et al., 2011). Amplicons 
were cloned into CloneJet (ThermoScientific) and Sanger sequenced. When possible, 
linkage of heterozygous polymorphic sites was established by Sanger sequencing of 
amplicons from cDNA following reverse transcription of total RNA. Healthy donors 
were assessed for A3H haplotype by preliminary screening of PBMCs by immunoblot for 
A3H protein expression and a diagnostic PCR for the N15/∆N15 polymorphism. CD4+ T 
cells were isolated from the selected donors (Table S1) as described above.  
 
3D-PCR 
To assess global hypermutation semi-quantitatively, 3D-PCR was performed as described 
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(Hultquist et al., 2011). 15 days postinfection virus containing supernatants were used to 
infect 25,000 CEM-GFP cells. 48 hours later, genomic DNA was isolated (Qiagen) and 
an 876 bp region of pol was amplified from proviral DNA. The relative amount of this 
amplicon in each sample was assessed with qPCR (Roche). Normalized amounts of 
proviral DNA was then used to generate a smaller 564 bp inner amplicon over a range of 
denaturation temperatures (77.0-86.2° C). The resulting PCR products were fractionated 
using agarose gels and visualized following ethidium bromide staining.  
 
Proviral sequencing 
Hypermutation spectra analysis was performed as described (Hultquist et al., 2011; 
Refsland et al., 2012). The 876 bp outer amplicon generated from proviral pol DNA was 
used to seed a second, inner PCR reaction with a uniform denaturation temperature of 
98°C. The resulting 564 bp amplicon was cloned into CloneJet (ThermoScientific). A 
total of 10 independent clones (>5 kb) were Sanger sequenced for each condition. Clones 
with identical mutations were eliminated. 
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FIGURES 
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Figure 4-1. Endogenous APOBEC3H stability/instability occurs at the protein level. 
A) A schematic of the 7 gene A3 locus and the 5 polymorphisms in A3H exons 2, 3, and 4 
that combine to produce 7 different haplotypes. On the right, a summary of the 7 different 
A3H haplotypes based on observed protein stability or instability in overexpression 
studies (OhAinle et al., 2008; Wang et al., 2011) and as defined here, in primary CD4+ T 
lymphocytes. The two residues that underlie the stable/unstable phenotypes are 
highlighted in red (N15/∆15 and R105/G105). 
B) Immunoblots showing endogenous A3H, A3G, and HSP90 protein levels in 
stimulated primary T lymphocytes from 4 donors with the indicated A3H haplotypes 
(donors 10, 11, 12, and 18). In this experiment endogenous A3H is detected with a 
polyclonal rabbit antibody. 
C) A3 mRNA levels in primary T lymphocytes from 4 donors with the indicated A3H 
haplotypes (donors 4, 10, 12, and 18). Expression levels are shown relative to the 
housekeeping gene TBP. 
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Figure 4-2. APOBEC3H adaptation studies. 
A) Immunoblots of A3H and tubulin in SupT11 cell lines stably expressing low, 
intermediate (int), and high levels of stable haplotype II protein. In this experiment A3H 
is detected with the mouse monoclonal antibody P3A3-A10. 
B) Schematic of the stepwise A3H adaptation procedure (see text and Materials and 
Methods for details).  
C) Spreading infection kinetics of the parental and adapted viruses on the A3H-
expressing SupT11 lines shown in A. The parental virus is completely inhibited in cells 
expressing high A3H levels, whereas adapted virus replication is robust. 
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Figure 4-3. Generation and validation of HIV-1 Vif separation-of-function 
molecular/viral probes. 
A) A schematic of the Vif protein encoded by each HIV-1 molecular clone showing 
amino acid differences responsible for the hyper- and hypo-Vif functionality relative to 
lab-Vif (HIV-1 IIIB/NL4-3) against stable A3H haplotype II. 
B) Immunoblots showing the expression levels of the indicated A3 proteins stably 
expressed in SupT11 cells. In this experiment untagged A3H is detected with the mouse 
monoclonal antibody P3A3-A10. 
C) HIV-1 spreading infection kinetics for the indicated viruses on A3-expressing SupT11 
cells lines described in panel B. The hyper-, lab-, and hypo-Vif isolates spread with 
similar kinetics on cells expressing a control vector, A3D, A3F, or A3G, but showed 
clear phenotypic differences on cells expressing low, intermediate (int), and high levels 
of stable A3H haplotype II. 
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Figure 4-4. Stable APOBEC3H inhibits HIV-1 replication in primary T lymphocytes 
and inflicts GA-to-AA hypermutations.  
A) HIV-1 replication kinetics of the hyper-, lab-, and hypo-Vif variants in CD4+ T 
lymphocytes from a representative healthy donor encoding unstable A3H haplotype I/I 
(donor 2).  
B) HIV-1 replication kinetics of the hyper-, lab-, and hypo-Vif variants in CD4+ T 
lymphocytes from a representative healthy donor encoding one allele of stable A3H 
haplotype II and one allele of unstable A3H haplotype I (donor 4). 
C) Immunoblots of the indicated proteins in virus-like particles (VLPs) and in cells from 
days 3, 5, 7, and 9 of the spreading experiments shown in panels A & B.  
D) 3D-PCR amplicons generated from proviral DNA of the indicated viruses isolated on 
day 15 of a spreading infection of unstable A3H (haplotypes I/I and III/IV) or stable A3H 
(haplotype I/II) donor cells (donors 2, 4, 12). This experiment is representative and 
performed independently of those shown in panels A-C. 
E) Histograms depicting the frequencies of GA-to-AA and GG-to-AG mutations under 
the indicated spreading infection conditions (complementary to the experiment shown in 
panel D with all sequences derived from independent 98°C high-fidelity PCR 
amplifications). A minimum of 10 clones were sequenced for each condition (≥5 kb). 
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Figure 4-5. Correlations between the global distributions of HIV-1 hyper-Vif alleles 
and human A3H haplotypes.   
A) The left histogram depicts the frequency of HIV-1 isolates encoding a phenylalanine 
or valine at Vif residue 39 from the indicated geographic regions (n=9713; 
www.hiv.lanl.gov). The right histogram shows the frequency of stable versus unstable 
A3H alleles from the same geographic regions (n=1092; www.1000Genomes.org).  
B) A model depicting the anticipated relative transmission efficiencies between infected 
patients and uninfected individuals with equivalent or different A3H haplotypes. 
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Figure 4-6. Vif separation-of-function substitutions define the likely APOBEC3H 
interaction surface. 
A) A surface representation of Vif and CBFβ (pdb 4N9F). The side-chains of the amino 
acid residues conferring hypo-Vif (residue 39) and hyper-Vif phenotypes (residues 48 
and 60-63) are shaded green and located on a common solvent-exposed surface. A 90° 
rotation reveals distinct Vif separation-of-function residues implicated in the interactions 
with A3F (yellow) and A3G (orange). See main text for details. 
B) Spreading infection kinetics of the indicated HIV-1 Vif variants on SupT11 cells 
stably expressing a vector control (left) or high levels of A3H haplotype II (right). Figure 
4C data for hyper-, lab-, and hypo-Vif are shown again here to facilitate comparisons. 
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  A3H Polymorphisms 
Donor 15 18 105 121 178 A3H Haplotype Expression 
1 N/∆ R/L G/R K/D E/E I/IV Unstable 
2 N/N R/R G/G K/K E/E I/I Unstable 
4 N/N R/R G/R K/D E/D I/II Stable 
5 N/N R/R G/G K/K E/E I/I Unstable 
8 N/N R/R G/G K/K E/E I/I Unstable 
10 N/N R/R G/R K/D E/D I/II Stable 
11 N/N R/R G/R K/D E/E I/V Stable 
12 ∆/∆ R/L R/R D/D E/E III/IV Unstable 
18 N/N R/R G/G K/K E/E I/I Unstable 
 
Table 4-S1. Selected donor genotyping results. 
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Figure 4-S1. Characterization of mouse monoclonal antibodies specific to human  
APOBEC3H. 
A) Immunoblots demonstrating the specificity of the A3H monoclonal antibodies P1D8-1 
and P3A3-A10 in 293T cells transiently expressing the indicated A3-HA protein. 
B) Immunoblots of A3H and tubulin expression levels in primary T lymphocytes 9 days 
after infection with Vif proficient or deficient viruses. A3D-HA expressed poorly in this 
experiment (donor 25). 
C) Schematics of human A3H hap II (open box), cow A3Z3 (black box), and A3H/A3Z3 
chimeric derivatives. The epitopes for mouse monoclonal antibodies P1D8-1 and P3A3-
A10 are shown. Immunoblots of 293T cells transiently transfected with the indicated 
human/cow chimeric A3H/A3Z3 constructs. Monoclonal antibodies P1D8-1 and P3A3-
A10 recognize distinct N- and C-terminal epitopes, respectively. 	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Figure 4-S2. Stable APOBEC3H inhibits HIV-1 replication in primary T 
lymphocytes.  
A) HIV-1 replication kinetics of the hyper-, lab-, and hypo-Vif variants in CD4+ T 
lymphocytes from 5 healthy donors encoding the unstable A3H haplotype indicated 
(donors 1, 5, 8, 12, and 18). 
B) HIV-1 replication kinetics of the hyper-, lab-, and hypo-Vif variants in CD4+ T 
lymphocytes from 2 healthy donors heterozygous for the indicated allele of stable A3H 
(donors 10 and 11). 
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Figure 4-S3. Stable APOBEC3H alleles inflict GA-to-AA hypermutations  
in viruses encoding hypo-Vif variants. 
HIV-1 G-to-A mutation profiles of the hyper-, lab-, and hypo-Vif proviruses originating 
from primary T lymphocytes with the indicated A3H haplotype (donors 2, 4, and 12). 
GA-to-AA mutations characteristic of A3H activity are shown in red. 
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CHAPTER 5 
 
 
CONCLUSIONS AND DISCUSSION – APOBEC3 Expression and the HIV-
Restrictive APOBEC3 Repertoire 
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FOREWORD 
 HIV pathogenesis requires the hijacking or neutralization of a significant portion 
of human proteins. These proteins are collectively referred to as either dependency or 
restriction factors. While the current treatments for HIV infection include drugs that 
target the enzymes encoded by the HIV genome, an attractive alternative target is the 
interaction between other viral proteins and these dependency or restriction factors. 
Especially appealing are the HIV restriction factors of the APOBEC3 family of DNA 
cytosine deaminases. These enzymes directly inhibit viral replication by inflicting lethal 
levels of mutagenesis following the first round of reverse transcription. These potent 
innate immune factors are neutralized by HIV Vif, which nucleates the formation of an 
ubiquitin ligase complex and binds the APOBEC3 proteins to initiate their degradation. 
Successfully disrupting this interaction, either the APOBEC3/Vif interaction, or Vif with 
one of its essential cellular co-factors, necessitates the identification of all the relevant 
participants. 
 To determine which APOBEC3 genes are expressed in CD4+ T cells and 
positioned to restrict HIV replication, my colleagues and I developed first-in-their class 
qPCR assays specific for each of the 7 APOBEC3 genes. These assays where used to 
compare APOBEC3 expression in human T cell lines, primary T lymphocytes, and 22 
normal human tissues. These data demonstrated that multiple APOBEC3 genes are 
expressed in most types of cells, positioned together to impede attacks from 
retroelements, and that this expression can be induced by transcriptional activation. 
  To begin to address which individual APOBEC3 proteins restrict HIV replication 
in vivo, we generated isogenic human cell lines lacking only APOBEC3F or APOBEC3G 
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expression. We concluded from Vif deficient HIV single-cycle and spreading infection 
experiments that APOBEC3D, APOBEC3F, and APOBEC3G combine to restrict HIV 
and are responsible for nearly all of the G-to-A hypermutation observed in the human cell 
line CEM2n. 
 A fourth APOBEC3, APOBEC3H has been implicated in HIV restriction but its 
contribution remains somewhat ambiguous partly due to a high degree of genetic 
diversity. To gain an appreciation for how this genetic variation impacts the expression 
and HIV restriction activity of APOBEC3H, we used a series of primary cell experiments 
and HIV spreading infections to probe the 7 distinct haplotypes encoded by the human 
genome. Three of these haplotypes encode a protein that expresses well and is able to 
restrict circulating HIV variants that encode hypofunctional Vif proteins unable to mount 
a counter-defense against this subset of APOBEC3H alleles. We conclude from these data 
that APOBEC3H constitutes a natural barrier to HIV replication of isolates that may have 
lost or never developed the ability to antagonize this APOBEC3. 
 Taken together, my research demonstrates that multiple APOBEC3 are expressed 
constitutively in HIV target cells. This expression increases upon cellular activation and 
further increases upon HIV infection. By inflicting catastrophic levels of mutation in the 
genetic information of the virus, 4 of these proteins, APOBEC3D, APOBEC3F, 
APOBEC3G and stable APOBEC3H haplotypes restrict virus replication. These insights 
will forward the pursuit of targeted innate immune therapies that can free the swarm of 
HIV-restrictive APOBEC3s and extinguish viral replication.
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 APOBEC3 Expression 
 The APOBEC3 (A3; A3A-H) proteins inhibit a variety of retroelements including 
endogenous retroviruses, retrotransposons, DNA viruses, and exogenous retroviruses 
including HIV [reviewed in (Chiu and Greene, 2008; Goila-Gaur and Strebel, 2008; 
Hultquist and Harris, 2009)]. However, the individual A3 proteins that function in vivo 
against each of these substrates is poorly defined. For example, both A3F and A3G 
strongly restrict HIV in vitro and likely contribute to HIV restriction in vivo, but all other 
human A3 proteins have also been implicated [reviewed by (Albin and Harris, 2010)].  
 The APOBEC3 locus in primates is the result of multiple gene duplication events 
during evolution from an ancestral mammalian locus (LaRue et al., 2008). As a result, all 
of the APOBEC3 genes and gene products share extensive homology including long 
stretches of hundreds of nucleotides with >96% sequence identity (Figure 2-1A). To no 
surprise then, the development of specific reagents to detect and quantify expression 
levels has been hindered. To overcome this, we have generated and characterized a full 
panel of qPCR primers and probes specific to each of the 7 A3s. We used these assays to 
interrogate A3 mRNA expression in multiple T cell lines, primary T lymphocytes, and a 
panel of 20 normal human tissues. Human T cell lines express multiple A3s and primary 
T lymphocytes express 6 of the 7. This is consistent with our hypothesis that multiple 
A3s target HIV. A3A was not expressed in any T cell we examined and we concluded that 
it does not contribute to restriction in this cell type. A3 expression was widespread and 
not confined to the immune compartments analyzed or tissues with high numbers of 
infiltrating immune cells (e.g. the spleen, thymus, adipose, and lung) suggesting a 
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possible functional role for these enzymes in tissues including colon, cervix, bladder, and 
heart, a matter deserving of further investigation. 
 In addition to constitutive expression, we analyzed the A3 expression following 
transcriptional activation. Multiple prior studies have examined the changes in A3 (most 
often A3G) expression following type I interferon (IFN) treatment with little consensus 
emerging (Argyris et al., 2007; Bonvin et al., 2006; Chen et al., 2006; Koning et al., 
2009; Peng et al., 2006; Stenglein et al., 2010; Tanaka et al., 2006; Wang et al., 2008). 
Using our qPCR assays we did not detect any transcriptional increase of any A3 in 
primary CD4+ lymphocytes upon IFN treatment. This may indicate that IFN stimulation 
of A3 expression is confined to other blood cell lineages (e.g. monocytes and 
macrophages (Chen et al., 2006; Koning et al., 2009; Stenglein et al., 2010). In contrast, 6 
of 7 A3s were induced upon addition of T cell activators IL-2 and PHA demonstrating the 
induciblity of A3 expression in T cells and the likelihood of multiple mechanisms of 
regulation. Consistent with this idea is an experiment I performed with another graduate 
student measuring A3 mRNA expression in primary CD4+ T lymphocytes during the 
course of an HIV spreading infection (Hultquist et al., 2011). The expression of three A3s 
– A3C, A3G, and A3H dramatically increased over 9 days post-infection indicating an as 
yet unknown mechanism of transcriptional control imparted by an HIV infection. 
  It is also important to note that these qPCR assays have added benefits beyond 
defining the HIV-restrictive repertoire in T cells. Recently they have been applied to 
cancer cell lines and primary tumor samples (Burns et al., 2013; Leonard et al., 2013). 
These papers detail the overexpression of A3B in both breast and ovarian cancers and its 
potential role in mutagenizing the genome and initiating tumorigenesis or in the 
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development of drug resistance. These studies highlight the importance of our qPCR 
assays in attributing expression of a specific A3 in any cell type or tissue. 
  
The HIV-Restrictive APOBEC3 Repertoire  
 In addition to multiple A3s being expressed in the relevant cell types and 
positioned to target HIV, another clue supporting the role of multiple A3s in HIV 
restriction is the mutation pattern observed in proviral DNA from infected patients. Two 
distinct dinucleotide patterns of G-to-A hypermutation emerge, 5’GG-to-AG and 5’GA-
to-AA (Janini et al., 2001; Kieffer et al., 2005; Land et al., 2008; Piantadosi et al., 2009). 
These mutations in the viral coding strand are complementary to the two intrinsic 
dinucleotide preferences (5’CC and 5’TC) of the A3s on the non-coding strand [reviewed 
in (Albin and Harris, 2010)]. While our qPCR assays were informative for the reasons I 
just highlighted above, they were unable to sufficiently narrow the list of A3s potentially 
relevant to HIV restriction to less than 6 of 7. Of these, A3G has a unique preference for 
the 5’CC dinucleotide and all of the remaining 5 have a reported preference for 5’TC 
(Albin and Harris, 2010). 
 To examine the individual contribution of an A3 on HIV restriction, prior studies 
have relied on forced transient overexpression in heterologous cell types to define 
whether or not an A3 can restrict HIV replication. Taking an alternative genetic 
approach, we systematically deleted all copies of a target A3 gene in a near-diploid 
human CD4+ T cell line. This generation of an A3-null cell lines had four distinct 
advantages. One, the cell type we manipulated was a relevant target of HIV. Two, the 
transgene expression was driven by a different promoter, often viral, outside its normal 
	   163	  
genomic context. Three, the expression levels were difficult to correlate with endogenous 
levels. Finally, genetic ablation of an A3 and creation of an isogenic set of cell lines 
allowed for a definitive determination of whether or not the A3 does restrict HIV 
replication in that cell type. 
 A3G is the most studied and best-described A3 family member with potent 
activity against Vif-deficient HIV (Albin and Harris, 2010; Chiu and Greene, 2008; 
Harris et al., 2012; Malim, 2009). Using an rAAV-mediated gene targeting approach, we 
deleted the two copies of A3G from the genome of the human T cell line CEM2n. 
Consistent with prior reports, single-cycle infectivity experiments and proviral DNA 
sequencing analysis demonstrated that while A3G is the major source for the 5’GG-to-
AG hypermutations, it is not the only factor contributing to Vif-deficient HIV restriction. 
A3F is perhaps the next most potent on the list of A3 restriction candidates (Albin and 
Harris, 2010). Using a similar approach we deleted both copies of A3F from CEM2n. 
Like A3G, deletion of A3F did not result in a complete restoration of Vif-deficient HIV 
replication, presumably due to the presence of A3G in the cells. We expected to see a 
similar reduction in the levels of 5’GA-to-AA mutations (the dinucleotide preference of 
A3F) in proviral DNA from viruses spread on A3F-null cells. However, the levels of 
5’GA-to-AA mutation were virtually unchanged, strongly suggesting another A3 in the 
generation of this mutation type. Only upon addition of an shRNA directed against A3D 
did the 5’GA-to-AA mutations vanish. We concluded from these experiments that in 
CEM2n T cells, 3 A3s – A3D, A3F, and A3G combine to restrict Vif-deficient HIV. In 
addition, these 3 A3s likely contribute to the 2 major G-to-A mutation patterns observed 
in vivo. 
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 In a set of complimentary experiments performed in parallel, another graduate 
student and I performed a series of single-cycle and spreading infections on the T cell 
line SupT11 stably expressing each of the 7 A3s from humans and rhesus macaques 
(Hultquist et al., 2011). The results of these experiments were consistent with our 
deletion studies, demonstrating a conserved ability of A3D, A3F, A3G, and A3H to 
encapsidate into viral particles, to restrict the replication of Vif-deficient HIV and 
mutagenize proviral DNA sequences. Taken together, these two studies utilizing two 
different but complimentary approaches arrived at the same conclusion, that T cells are 
armed with multiple A3s that form an imposing barrier to HIV lacking Vif by inflicting 
catastrophic levels of mutation of the virus’ genome.  
 An unfortunate difference between the deletion and stable expression experiments 
discussed above was the former’s inability to adequately interrogate A3H. CEM2n cells 
do not express levels of A3H mRNA above background making a definitive assessment 
of its role in HIV restriction in this system challenging (Refsland et al., 2012). A3H is the 
most genetically diverse of all of the A3s. In humans, at least 7 haplotypes are known and 
the differences between haplotypes manifest in varying degrees of protein stability. Two 
phenotypic groupings have been assigned to the haplotypes based on prior 
overexpression analyses, with one group (haplotypes II, V, VII) capable of robust stable 
expression and the other (haplotypes I, II, IV, VI) either expressed weakly or not at all 
(OhAinle et al., 2008; Wang et al., 2011). How these haplotype differences affect 
endogenous A3H protein expression and what impact this genetic diversity has on its 
HIV restriction activity remain under studied. 
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 To better understand how endogenous A3H haplotypes dictate protein stability 
and anti-HIV activity, we performed a series of primary cell experiments and ex vivo 
spreading infections using cells isolated from healthy donors with different A3H 
haplotypes. Using novel antibodies to detect endogenous A3H for the first time, alleles of 
haplotypes II and V were readily detected by immunoblot. Haplotypes I, III, and IV 
however, were either weakly detected or undetectable. These results were consistent with 
prior overexpression studies and demonstrated that humans differentially express A3H. 
To avoid the confounding and possibly dominant effects of the expression of A3D, A3F, 
and A3G in primary CD4+ lymphocytes, naturally occurring A3H-specific Vif 
separation-of-function variants were generated that had either increased capacity (hyper-
Vif) or decreased capacity (hypo-Vif) to neutralize A3H. Importantly, these molecular 
probes retained their ability to counteract A3D, A3F, and A3G. Using these viruses, a 
single stable allele of A3H was enough to encapsidate, restrict, and hypermutate a hypo-
Vif virus, demonstrating that stable A3H alleles are an endogenous barrier to infection by 
some HIV variants. These data also predict that an individual’s A3H haplotype may be 
used to predict the transmission efficiency of some circulating HIV variants. Large 
clinical datasets will be required to test this prediction. 
 But why would humans express an unstable A3H? Three possibilities relate to its 
function as a restriction factor. First, it’s tempting to hypothesize that populations 
encoding heterogeneity in a potent host restriction factor could limit the possibility of 
devastating viral sweeps. In other words, decreasing the selective pressure in certain 
subsets of the population only to reintroduce it upon infection to an individual or subset 
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of the population that encodes the active form of the restriction factor could be one 
strategy the slower evolving host immune system adopts to limit pathogen spread.  
 The second explanation is related to the role the A3 family plays in limiting 
endogenous retrovirus replication and retrotransposition (Esnault et al., 2005; MacDuff et 
al., 2009; Schumacher et al., 2005). These retroelements have been implicated in 
generating diversity, and adaptation within a species (Carmi et al., 2011; Kazazian, 
2004). By inactivating a large number of alleles in a population of a retroelement 
restriction factor, it may permit the slow accumulation of genetic variation driving 
evolution of a host’s genome. 
 The third explanation is that the ancient pathogenic agent that necessitated the 
evolution of an A3H deaminase has since been eradicated and the benefit of A3H 
expression is outweighed by the costs associated with its now unnecessary activity. If this 
were the case, the ancient pathogen would be very ancient indeed as an A3H-like (or 
A3Z3-like) single domain deaminase is encoded in every mammal sequenced to date 
(LaRue et al., 2009; LaRue et al., 2008; LaRue et al., 2010). This implies the original 
A3H target pathogen would likely be more than 100 million years old, the date around 
which mammals started to diverge into different clades. But while there is one A3Z3-like 
deaminase encoded in every mammalian genome, there is only one. Unlike the often 
duplicated A3Z1 and A3Z2 demainase domains that constitute human A3A-G, A3Z3 
(A3H) is only present in a single copy, suggesting that the dosage of this A3 is tightly 
regulated. Consistent with this idea, another A3 family member A3B, recently implicated 
in cancer mutagenesis by our laboratory and others, has a similar inactivating genotype in 
a subset of the human population (Burns et al., 2013; Kidd et al., 2007; Leonard et al., 
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2013; Nik-Zainal et al., 2012; Roberts et al., 2013). This raises the possibility that another 
A3 deaminase, A3H, may have pathological consequences when misregulated and is 
being selected against in spite of its innate immune functions. 
 Finally, consideration must be given to the question why primates including 
human encode 7 A3 proteins when many have similar functions. The most 
straightforward and likely reason is that immune systems favor redundancy. Multiple A3s 
(as with other arms of the innate and adaptive immune systems) with overlapping 
functions constitute a much more formidable barrier to the zoonotic transmissions that 
underlie the emergence of many of the most pathogenic agents (akin to an invading army 
encountering a castle it would like to overtake). The castle is far more likely to fend off 
the invasion if, in addition to its high walls, there is a moat and draw bridge, archers on 
the towers, and a catapult defending it. In addition, this redundancy may provide the A3 
defenses the flexibility required for an increased rate of evolutionary change, an 
important feature for any immunity factor challenged with keeping up with the 
extraordinary adaptation rates of viruses. Consistent with this idea is that many of the 
A3s are under positive selection either from individual challenges or shared pressures to 
maintain their overlapping functions (Duggal and Emerman, 2012). Thus, while the 
experiments we have performed here indicate a single A3 is sufficient to restrict Vif-
deficient HIV, this may not be the case for other pathogens, contemporary or ancient. 
 It is easy to forget that HIV-1, while a formidable pathogenic agent, is a very 
recent addition to the long list of pathogens humans have encountered. It is very likely 
the root causes of the primate expansion of the A3 locus some 95 million years ago, was 
initiated by threats long since extinct. The challenges facing humans today are very 
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different, reflecting the dispersal of our species and the mobility of modern societies. Our 
immune defenses are up to this task. Taken together, my research highlights the 
expression and HIV-restrictive capacity of 4 members- A3D, A3F, A3G, and A3H- of a 
unique family of DNA cytosine deaminases. I present evidence that one of member, 
A3H, may in fact constitute a contemporary HIV-1 restriction factor, and its differential 
protein stability phenotypes may represent the latest move in an ongoing evolutionary 
conflict. These enzymes, capable of directly inhibiting HIV replication, represent one of 
the most promising avenues for the development of targeted innate immune therapies.  
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